zidovudine has been researched along with didanosine in 957 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (0.52) | 18.7374 |
| 1990's | 693 (72.41) | 18.2507 |
| 2000's | 200 (20.90) | 29.6817 |
| 2010's | 56 (5.85) | 24.3611 |
| 2020's | 3 (0.31) | 2.80 |
| Authors | Studies |
|---|---|
| Gumus, F; Ishaq, KS; Iyer, N; Kucera, LS; Marasco, CJ; Meyer, KL; Morris-Natschke, SL; Piantadosi, C; Surles, JR; Wallen, CA | 1 |
| Breslin, HJ; De Clercq, E; Diamond, CJ; Grous, PP; Ho, CY; Kukla, MJ; Miranda, M; Pauwels, R; Rodgers, JD; Sherrill, RG | 1 |
| Andries, K; Breslin, HJ; Fedde, CL; Kukla, MJ; Miranda, M; Pauwels, R; Raeymaekers, A; Scott, MK; Sherrill, RG; Van Gelder, J | 1 |
| Aoki, S; Driscoll, JS; Ford, H; Kelley, JA; Kojima, E; Mitsuya, H; Murakami, K; Shirasaka, T; Yoshioka, H | 1 |
| Aoki, S; Barchi, JJ; Driscoll, JS; Ford, H; Kelley, JA; Marquez, VE; Mitsuya, H; Shirasaka, T | 1 |
| Antonenko, SV; Chentsova, NP; Kukhar, VP; Luik, AI; Poda, GI; Tetko, IV | 1 |
| abu Sheikha, G; Cappellacci, L; de Montis, A; Franchetti, P; Grifantini, M; La Colla, P; Loi, AG; Messini, L; Spiga, MG; Tramontano, E | 1 |
| Driscoll, JS; Ford, H; Kelley, JA; Marquez, VE; Mitsuya, H; Shirasaka, T; Siddiqui, MA | 1 |
| Andrei, G; Balzarini, J; Blache, Y; Chapat, JP; Chavignon, O; De Clercq, E; Debouzy, JC; Elhakmaoui, A; Essassi, EM; Gueiffier, A; Kerbal, A; Lhassani, M; Snoeck, R; Teulade, JC; Witvrouw, M | 1 |
| Gam, J; Kim, DK; Kim, HT; Kim, KH; Kim, YW; Lim, J | 1 |
| Cha, SH; Endou, H; Kanai, Y; Kimura, M; Sekine, T; Tsuda, M; Wada, S | 1 |
| Bader, JP; Cragg, GM; Newman, DJ; Yang, SS | 1 |
| Alam, N; Hong, J; Im, KS; Jung, JH; Lee, CK; Li, F; Liu, Y; Wang, W | 1 |
| Chen, IS; Ishikawa, T; Nishigaya, K; Takami, K; Tsai, IL; Uchikoshi, H | 1 |
| Jolivette, LJ; Ward, KW | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lund, KC; Peterson, LL; Wallace, KB | 1 |
| Ainsworth, J; Booth, C; Bradshaw, D; Geretti, AM; Malik, S; Pattery, T; Van Houtte, M; Waters, A | 1 |
| Anderson, DJ; Gottlieb, GS; Preston, BD; Pyrak, CL; Smith, RA | 1 |
| Beadle, JR; Bradley, M; Farasati, NA; Hostetler, KY; Huang, Y; Meier, C; Randhawa, P; Sauerbrei, A; Zemlicka, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Haas, RH; Naviaux, RK; Saitoh, A; Salva, NG; Spector, SA; Wong, JK | 1 |
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Bachmann, MH; Fessel, WJ; Kagan, RM; Mitsuya, Y; Shafer, RW; Shahriar, R; Varghese, V | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Amblard, F; Bassit, L; Bondada, L; Coats, SJ; Detorio, M; Grier, J; Hernandez-Santiago, BI; Koontz, D; Mellors, JW; Rapp, KL; Schinazi, RF; Sluis-Cremer, N | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Almond, MR; Buckheit, RW; Hartman, T; Keilholz, L; Lampert, BM; Lanier, ER; Mankowski, MK; Osterling, MC; Painter, GR; Ptak, RG | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Azas, N; Casano, G; Dumètre, A; Hutter, S; Pannecouque, C; Robin, M | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, W; Chen, X; De Clercq, E; Li, D; Li, X; Liu, X; Pannecouque, C; Tian, Y; Zhan, P | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Balzarini, J; Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Pannecouque, C; Wu, HQ; Yan, ZH | 1 |
| Balzarini, J; Chen, X; De Clercq, E; Li, Z; Liu, H; Liu, X; Pannecouque, C; Xie, Z; Zhan, P; Zhang, L; Zhao, T | 1 |
| Costa, J; Dumontet, V; Leyssen, P; Litaudon, M; Neyts, J; Nothias-Scaglia, LF; Pannecouque, C; Paolini, J; Retailleau, P; Roussi, F | 1 |
| Chen, W; De Clercq, E; Liu, X; Liu, Z; Pannecouque, C; Zhan, P | 1 |
| Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Pannecouque, C; Wu, HQ; Yao, J | 1 |
| Balzarini, J; Chen, W; De Clercq, E; Fu, L; Huang, B; Li, C; Liu, H; Liu, T; Liu, X; Pannecouque, C; Sun, Y; Yu, M; Zhan, P | 1 |
| Ashok, P; Balzarini, J; Chander, S; Murugesan, S; Pannecouque, C | 1 |
| Chen, W; De Clercq, E; Fu, L; Huang, B; Li, C; Li, X; Liang, X; Liu, H; Liu, T; Liu, X; Pannecouque, C; Sun, Y; Zhan, P | 1 |
| Girard-Valenciennes, E; Grondin, I; Leyssen, P; Litaudon, M; Neyts, J; Olivon, F; Palenzuela, H; Pannecouque, C; Roussi, F | 1 |
| Arumugam, SR; Badri, KR; He, JJ; Visalli, RJ; Zhang, X; Zhao, H; Ziobrowski, H | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, X; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Li, W; Liu, X; Meng, Q; Pannecouque, C; Zhan, P | 1 |
| Bhatt, HG; Pannecouque, C; Patel, BD; Patel, SB | 1 |
| Chizhov, AO; Geisman, AN; Khandazhinskaya, AL; Kochetkov, SN; Naesens, L; Novikov, MS; Ozerov, AA; Pannecouque, C; Seley-Radtke, KL; Valuev-Elliston, VT | 1 |
| Bingöl Özakpınar, Ö; De Clercq, E; Küçükgüzel, İ; Kulabaş, N; Özsavcı, D; Pannecouque, C; Tatar, E | 1 |
| Buckheit, RW; Cushman, M; Hartman, TL; Hoshi, A; Okazaki, M; Pannecouque, C; Sakamoto, T; Takayama, J; Xuan, M | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Camarasa, MJ; de Castro, S | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Gao, Q; Gu, Z; Li, X; Parniak, MA; Wainberg, MA | 1 |
| Ayehunie, S; Britton, S; Sönnerborg, A; Strannegård, O; Wondimu, Z | 1 |
| Fauci, AS | 1 |
| Caliò, R; Perno, CF | 1 |
| Brett, CM; Giacomini, KM; Hui, AC; Wu, X; Yuan, G | 1 |
| Johnson, VA | 2 |
| Kahn, J | 1 |
| Balzarini, J; Bergamini, A; Calio, R; De Clercq, E; Milanese, G; Pauwels, R; Perno, CF; Rocchi, G; Yarchoan, R | 1 |
| Husson, RN; Pizzo, PA | 1 |
| Hammer, SM; McLeod, GX | 2 |
| Saag, MS | 2 |
| Skowron, G | 1 |
| Watson, AJ; Wilburn, LM | 1 |
| Garfunkel, AA; Glick, M | 1 |
| Boon, GD; Chan, TC; Redmond, R; Shaffer, L | 1 |
| Blakeslee, JR; Mathes, LE; Olsen, RG; Tanabe-Tochikura, A; Tochikura, TS | 1 |
| Bawdon, RE; Dax, J; Sobhi, S | 1 |
| Foerster, M; Kastner, U; Neubert, R | 1 |
| Bjornson, DC; Cortese, M | 1 |
| Lynn, LA | 1 |
| Morse, GD; O'Donnell, AM; Shelton, MJ | 1 |
| Beall, G; Brown, M; Cross, A; Crumpacker, CS; Kahn, JO; Lagakos, SW; Liou, SH; Pettinelli, C; Richman, DD; Volberding, PA | 1 |
| Lane, HC | 1 |
| Aboulker, JP; Darbyshire, JH | 1 |
| Martin, ES; Rathbun, RC | 1 |
| Barsanti, L; Batoni, G; Ceccherini Nelli, L; Chirianni, A; Liuzzi, G; Piazza, M; Santoro, G; Tullio Cataldo, P | 1 |
| Cooper, DA; Danner, SA; Lange, JM | 1 |
| Broder, S; Caliò, R; Cooney, DA; Foli, A; Gao, WY; Hao, Z; Hartman, NR; Johns, DG; Perno, CF; Yarchoan, R | 1 |
| Cameron, JM; Cammack, N; Coates, JA; Jenkinson, HJ; Jowett, AJ; Jowett, MI; Pearson, BA; Penn, CR; Rouse, PL; Viner, KC | 1 |
| Agrawal, KC; Gogu, SR; Malter, JS | 1 |
| Blais, FX | 1 |
| Friedmann, PD; Roberts, MS; Saitz, R | 1 |
| Venes, DJ | 1 |
| Behrman, RE; Feigal, DW; Kammerman, LA | 1 |
| Butler, KM; Husson, RN; Lewis, LL; Patronas, N; Pizzo, PA; Saini, R | 1 |
| Allan, JD; Beltangady, M; Canetta, R; Cooley, TP; Dolin, R; Kelley, S; Lambert, J; Liebman, HA; Rozencweig, M; Schacter, LP | 1 |
| Benson, CA; Kessler, HA; Pottage, JC; Sha, BE; Urbanski, P | 1 |
| Grieco, MH; Hargrove, D; McHugh, T; McKinley, GF; Reddy, MM; Winger, EE | 1 |
| Heinzl, S | 1 |
| Hsiung, GD; Medina, DJ; Mellors, JW | 1 |
| Hammer, SM; Ladd, EA; McGrath, JM; McLeod, GX | 1 |
| Erickson, J; Kageyama, S; Kempf, DJ; Mitsuya, H; Norbeck, DW; Plattner, JJ; Shirasaka, T; Weinstein, JN | 1 |
| Canipari, R; Coluzzi, ML; Cossu, G; Cusella De Angelis, MG; Floridia, M; Mezzogiorno, A; Sieh, E; Vella, S | 1 |
| Albert, J; Cox, SW; Uhlén, M; Wahlberg, J; Wahren, B | 1 |
| Finco, TS; Gallo, JM; Mehta, MU; Qian, M; Swagler, AR; Viswanathan, CT | 1 |
| Armstrong, JA; Asuncion, C; Gueverra, L; Ho, M; O'Marro, SD | 1 |
| DiJohn, D; Karpatkin, M; Kaul, A; Krasinski, K; Lawrence, R; Leibovitz, E; Nardi, M; Pollack, H; Quee, CS; Rigaud, M | 1 |
| Gupta, I; Kocher, J; Miller, AJ; Perz, J; Scully, M; Weisholtz, SJ | 1 |
| Batash, S; Falkenstein, D; Hollander, D; Katz, K; Ma, T; Raicht, R; Weinshel, E | 1 |
| Gao, Q; Gu, Z; Parniak, MA; Wainberg, MA | 1 |
| Cohen, JB; Derish, PA; Hernandez, SR; Hirozawa, AM; Lemp, GF; McKinney, KC | 1 |
| Au, JL; Wientjes, MG | 1 |
| Groopman, JE; Molina, JM | 1 |
| Keilbaugh, SA; Prusoff, WH; Simpson, MV | 1 |
| Rousseau, F; Sereni, D | 1 |
| Goldsmith, MF | 1 |
| Fischl, MA | 1 |
| Allan, JD; Canetta, R; Connolly, KJ; Fitch, H; Groopman, JE; Jackson-Pope, L; McLaren, C | 2 |
| Butler, K; Husson, R; Marshall, D; Pizzo, PA; Roilides, E; Venzon, D | 1 |
| Ayisi, NK; Gupta, SV; Qualtiere, LF | 1 |
| Cao, W; Fuchs, BA; Germolec, DR; Luster, MI; Munson, AE; Prejean, JD; Rosenthal, GJ; Shopp, G; Thompson, MB; Tomaszewski, JE | 1 |
| LeBourdais, E | 1 |
| Coplan, PM; Nolan, LL | 1 |
| Pinching, AJ | 2 |
| Gallo, JM; Qian, MX; Swagler, AR | 1 |
| Andries, K; Breslin, HJ; Desmyter, J; Heykants, J; Kukla, MJ; Pauwels, R; Raeymaeckers, A; Schols, D; Van Gelder, J; Woestenborghs, R | 1 |
| Hirsch, MS | 2 |
| Horgan, J | 1 |
| Ashorn, P; Berger, EA; Chaudhary, VK; FitzGerald, DJ; Moss, B; Pastan, I; Weinstein, JN | 1 |
| Chatis, PA; Crumpacker, CS; Eigenrauch, HA; Japour, AJ | 1 |
| Averett, DR; Burns, CL; Dornsife, RE; Huang, AT; Koszalka, GW; Panella, TJ; St Clair, MH | 1 |
| Broder, S; Kageyama, S; Mitsuya, H; Yarchoan, R | 1 |
| Broder, S; Mitsuya, H; Perno, CF; Pluda, JM; Yarchoan, R | 1 |
| Byington, RE; Chou, TC; D'Aquila, RT; Eron, JJ; Hirsch, MS; Johnson, VA; Merrill, DP; Videler, JA | 1 |
| Bach, MC; Kellam, P; Kemp, SD; King, DM; Larder, BA; Martin, JL; St Clair, MH; Tudor-Williams, G; Vavro, CL | 1 |
| Mitsuya, H | 2 |
| Fernández-Cruz, E | 1 |
| Cersosimo, RJ; Matthews, SJ; Spivack, ML | 1 |
| Gao, Q; Gu, ZX; Li, XG; Parniak, MA; Wainberg, MA | 1 |
| Belfort, R; Butler, KM; Caruso, R; de Smet, MD; Husson, RN; Lopez, JS; Nussenblatt, RB; Pizzo, PA; Rubin, B; Whitcup, SM | 1 |
| Back, DJ; Eagling, VA; Macleod, R; Sim, SM | 1 |
| Healy, B | 1 |
| Beall, G; Boyar, A | 1 |
| Grieco, MH; McKinley, GF; Reddy, MM | 1 |
| McCune, JM; Péault, B; Rabin, L; Streeter, PR | 1 |
| Merigan, TC | 1 |
| Chen, CH; Cheng, YC; Vazquez-Padua, M | 1 |
| Kaneshima, H; Machado, SG; McCune, JM; Namikawa, R; Outzen, H; Rabin, L; Shih, CC | 1 |
| Crumpacker, C; Finberg, RW; Heagy, W; Lopez, PA | 1 |
| Jost, J; Lüthy, R | 1 |
| Goldspiel, BR | 1 |
| Connor, E | 1 |
| Back, DJ; Breckenridge, AM; Sim, SM | 1 |
| Hirschel, B; Vanhems, P | 1 |
| Aoki-Sei, S; Broder, S; Cooney, DA; Ford, H; Fujii, H; Gilbert, DA; Johns, DG; Mitsuya, H; O'Brien, MC | 1 |
| Foth, H; Frijus-Plessen, N; Kahl, GF; Michaelis, HC | 1 |
| Broder, S; Brouwers, P; Hartman, N; Johns, DG; Mitsuya, H; Pluda, JM; Thomas, RV; Wyvill, KM; Yarchoan, R | 1 |
| Bach, MC | 1 |
| Cooper, EC | 2 |
| Hoth, D | 1 |
| Pizzo, PA; Roilides, E; Rubin, M; Venzon, D | 1 |
| Marwick, C | 1 |
| McGourty, C | 1 |
| de Noronha, F; Postie, L; Roneker, C; Tavares, L | 1 |
| González-Lahoz, J; Soriano, V | 1 |
| Portegies, P | 1 |
| Gallicchio, VS; Hughes, NK | 2 |
| Cauda, R; Donelli, G; Landay, AL; Lucia, MB; Malorni, W; Ortona, L | 1 |
| Carr, A; Cooper, DA; Loewenthal, M | 1 |
| Mitsuya, H; Shirasaka, T | 1 |
| Akagi, K; Okuyama, N | 1 |
| Kurimura, T; Sakamoto, T; Tsuchie, H | 1 |
| Koerber, KL; Pagano, JS; Smith, MS | 1 |
| Allen, LB; Buckheit, RW; Chirigos, MA; Germany-Decker, J; Hollingshead, MG; Janssen, PA; Shannon, WM | 1 |
| Bozzette, SA; Hay, J; Parker, R | 1 |
| Balfour, HH; Erice, A | 1 |
| Neuzil, KM | 1 |
| Cameron, J; Fang, H; Gao, Q; Goldberg, E; Gu, Z; Parniak, MA; Salomon, H; Wainberg, MA | 1 |
| Connell, EV; Hsu, MC; Richman, DD | 1 |
| Efron, B; Katzenstein, DA; Kozal, MJ; Kroodsma, K; Merigan, TC; Shafer, RW; Winters, MA | 1 |
| Caliendo, AM; Hirsch, MS | 1 |
| Auclair, C; Beaulieu, R; Boulerice, F; Gill, J; Montaner, JS; Phillips, P; Rachlis, A; Schindzielorz, A; Schlech, W; Smaldone, L | 1 |
| Britton, S; Julander, I | 1 |
| Au, JL; Mathes, LE; Mukherji, E | 1 |
| Biteau, N; Doignon, F; Fleury, HJ; Masquelier, B; Michelet, C; Morlat, P; Pellegrin, I; Ragnaud, JM; Ruffault, A | 1 |
| Andries, K; Breslin, HJ; De Clercq, E; Debyser, Z; Desmyter, J; Janssen, MA; Kukla, MJ; Pauwels, R; Schols, D; Woestenborghs, R | 1 |
| Besemer, D; Eastman, PS; Kolberg, J; Stempien, M; Urdea, M | 1 |
| Aguiniga, E; Iversen, AK; Katzenstein, DA; Merigan, TC; Shafer, RW; Winters, MA | 1 |
| Brennan, TM; Bridges, CG; Leyda, JP; Taylor, DL; Tyms, AS | 1 |
| Barry, DW; Pennington, KN; Rooney, J; St Clair, MH | 1 |
| Farr, SS; Kammerman, LA; Kazempour, K | 1 |
| Stephenson, J | 1 |
| Choo, V | 1 |
| Dillner, L | 1 |
| Dalakas, MC; Lewis, W | 1 |
| Stretcher, BN | 1 |
| Flexner, C; Ginsberg, R; Hamzeh, FM; Haubrich, RH; Hirsch, M; Lederman, MM; Lietman, P; Pettinelli, CP; Richman, DD; Spector, SA | 1 |
| Demeter, LM; Dexter, A; Dolin, R; Gerondelis, P; Morse, G; Nawaz, T; Reichman, RC | 1 |
| Bartlett, JA; Cohen, OJ; Graziosi, C; Holodniy, M; Lalezari, J; Niu, M; Pantaleo, G; Pavlakis, GN; Schnittman, S; Steigbigel, RT | 1 |
| Domanski, MJ; Egan, D; Follmann, DA; Pizzo, PA; Scalise, PP; Sloas, MM; Tucker, EE | 1 |
| Darbyshire, J | 1 |
| Gunnarsson, G; Hammer, SM | 1 |
| Arasteh, K; Haase, W; Jablonowski, H; Ruf, B; Schomaker, U; Schrappe, M; Staszewski, S; Stellbrink, HJ; Stoehr, A; von Eisenhart Rothe, B | 1 |
| Hoernle, EH; Reid, TE | 1 |
| Cameron, W; Gallicano, K; Garber, G; Pakuts, A; Sahai, J | 1 |
| Brouwers, P; Crowley, JS; Heyes, MP; Katz, DA; Kleiner, DE; Pizzo, PA; Saito, K; Sei, S; Stewart, SK | 1 |
| Aperia, K; Cox, S; Palmer, S; Wahren, B | 1 |
| Chokekuchai, S; Gao, WY; Johns, DG; Mitsuya, H | 1 |
| Back, D; Barry, M; Giaquinto, C; Gibb, D; Nokes, L; Ormesher, S; Seefried, M | 1 |
| Beaulieu, R; Cameron, B; Dunkle, L; Gill, J; Montaner, JS; Raboud, J; Rachlis, A; Salomon, H; Schechter, MT; Smaldone, L; Tsoukas, C; Wainberg, MA | 1 |
| Bechtel, LJ; Chow, YK; D'Aquila, RT; Eron, JJ; Hirsch, MS; Kaplan, JC; Merrill, DP | 1 |
| Rennie, J | 1 |
| Kamali, F | 1 |
| Campbell, TB; D'Aquila, RT; Eron, JJ; Kuritzkes, DR; Tarpley, WG; Young, RK | 1 |
| Cohen, J | 1 |
| Byrnes, VW; Condra, JH; Emini, EA; Gotlib, L; Graham, DJ; Schleif, WA | 1 |
| Albert, J; Cox, SW; Ljungdahl-Ståhle, E; Wahren, B | 1 |
| Hansen, JE; Mathiesen, LR; Nielsen, C; Nielsen, JO; Sørensen, AM | 1 |
| Caliendo, AM; Chow, YK; Cooley, TP; D'Aquila, RT; Devore, KM; Eron, JJ; Hirsch, MS; Kaplan, JC; Liebman, HA; Videler, J | 1 |
| Kellam, P; Kemp, SD; Larder, BA | 1 |
| Allen, LB; Buckheit, RW; Decker, WD; Germany-Decker, J; Hollingshead, MG; McMahon, JB; Ross, LJ; Shannon, WM; Westbrook, L; White, EL | 1 |
| Besemer, D; Fong, SJ; Hoo, B; Irvine, B; Kern, DG; Pachl, C; Sheridan, PJ; Stempien, M; Todd, JA; Yeghiazarian, T | 1 |
| Bagnarelli, P; Clementi, M; Manzin, A; Menzo, S; Paolucci, S; Petroni, S; Sampaolesi, R; Scalise, G; Valenza, A; Varaldo, PE | 1 |
| Anderson, BD; Kojima, E; Mitsuya, H; Shirasaka, T; Yarchoan, R | 1 |
| Atwood, SM; Cummins, TJ; Dewhurst, S; Frenkel, LM; Wagner, LE | 1 |
| Aboulker, JP; Darbyshire, JH; Debré, M; Giaquinto, C; Gibb, DM; Martinez, M; Tudor-Williams, G | 1 |
| Baseler, MW; Foli, A; Saville, MW; Yarchoan, R | 1 |
| Baughman, WL; Nosbisch, C; Pereira, CM; Unadkat, JD | 1 |
| Amato, DA; Beltangady, M; Brown, MJ; Cross, AP; Dolin, R; Fischl, MA; Hardy, WD; Hirsch, MS; Liou, SH; Pettinelli, C | 1 |
| Amato, DA; DeGruttola, V; Eyster, ME; Gjerset, GF; Ho, M; Kessler, CM; LoFaro, ML; Parenti, DM; Ragni, MV; Van Der Horst, C | 1 |
| Lissen, E | 1 |
| Boyer, E; Dong, H; Eastman, S; Holodniy, M; Kolberg, J; Margolis, D; Mole, L; Moss, J; Urdea, M | 1 |
| Anderson, BD; Broder, S; Chokekijchai, S; Kojima, E; Mitsuya, H; Shirasaka, T; Steinberg, SM; Yarchoan, R | 1 |
| Broder, S; Mitsuya, H; Nguyen, BY; Pluda, JM; Venzon, DJ; Wyvill, KM; Yarchoan, R | 1 |
| Brown, T; Dancis, J; Esterman, AL; Rosenberg, C | 1 |
| Faye, M; Michel, P; Sarthou, JL; Toure Balde, A | 1 |
| Khoo, SH; Wilkins, EG | 1 |
| Kitamura, T; Kunisada, T; Müller, WE; Ushijima, H | 1 |
| Hsieh, YH; Velasco-Hernandez, JX | 1 |
| Capparelli, EV; Connor, JD; Wu, LR | 1 |
| Carroll, R; Holodniy, M; Margolis, D; Mole, L; Todd, J | 1 |
| Birch, NJ; Gaines, H; Gallicchio, VS; Hughes, NK; Kirk, PR; Scott, KW; Tse, KF | 1 |
| Hamby, RL; Henderson, GI; Perez, AB; Schenken, RS; Schenker, S; Yang, Y | 1 |
| Back, DJ; Barry, MG; Veal, GJ; Wild, MJ | 1 |
| Krasinski, K | 1 |
| Spector, SA | 1 |
| Abrams, DI | 1 |
| Dormont, J | 1 |
| Coombs, RW; DeGruttola, V; Fiscus, SA; Gupta, P; Katzenstein, DA; Katzman, M; LoFaro, ML; Meyer, WA; Ragni, MV; Reichelderfer, PS | 1 |
| Machado, SG; Robinson, GA | 1 |
| Coombs, RW; Crumpacker, CS; D'Aquila, RT; DeGruttola, V; Japour, AJ; Johnson, VA; Kahn, JO; Kuritzkes, DR; Reichelderfer, PS; Richman, DD; Welles, SL | 1 |
| Dudley, MN | 1 |
| Rowe, PM | 1 |
| Baumberger, C; Hirschel, B; Kaiser, L; Perrin, LH; Yerly, S | 1 |
| Albert, J; Apéria, K; Cox, SW; Wahren, B | 1 |
| Debaisieux, L; Delforge, ML; Farber, CM; Liesnard, C; Tchetcheroff, M; Van Vooren, JP | 1 |
| Carpenter, CC; Cobbs, CG; Holmes, KK; Sande, MA; Sanford, JP | 1 |
| Houston, SC; Ostashewski, PM; Robertson, JA | 1 |
| Klein, HG; Kumar, P; Merritt, S; Sacher, R; Sloand, E | 1 |
| Agbaria, R; Brawley, OW; Lietzau, JA; Mitsuya, H; Nguyen, BY; Pluda, JM; Saville, MW; Steinberg, SM; Wyvill, KM; Yarchoan, R | 1 |
| Lancaster, DJ; Lancaster, LL | 1 |
| Bernstein, BM; Berry, A; Brand, J; Brown, MJ; Crane, L; Cross, A; Dunkle, LM; Frank, I; Green, SL; Gugliotti, R; Ingraham, P; MacArthur, RD; Morey, GE; Pachucki, CT; Patterson, TF; Pavia, AT; Peterson, D; Peterson, EA; Pollard, R; Ramirez-Ronda, CH; Remick, SC; Rios, A; Schindzielorz, AH; Smaldone, L; Spruance, SL; Sweet, DE; Thompson, M | 1 |
| Bubp, J; Israelski, D; Katzenstein, DA; Merigan, TC; Winger, E; Winters, M | 1 |
| Abrams, DI; Crane, LR; Goldman, AI; Grodesky, M; Kornegay, S; Korvick, JA; Launer, C; Muth, K; Neaton, JD; Wakefield, S | 1 |
| Balis, FM; Brouwers, P; Farley, M; Goldsmith, JC; Husson, RN; Kovacs, A; Lewis, LL; Mueller, BU; Ono, J; Woods, L | 1 |
| Bagnarelli, P; Clementi, M; Manzin, A; Menzo, S; Scalise, G; Valenza, A; Varaldo, PE | 1 |
| Grange, JM; Hamedi-Sangsari, F; Malley, SD; Vila, JR | 2 |
| Frost, SD; McLean, AR | 1 |
| Arts, EJ; Wainberg, MA | 1 |
| Baldwin, RW; Byers, VS; Levin, AS; Malvino, A; Robins, RA; Waites, L | 1 |
| Danner, SA; de Jong, MD; Enting, RH; Goudsmit, J; Lange, JM; Portegies, P; Reiss, P | 1 |
| Stretcher, B | 1 |
| Picard, O | 1 |
| Craib, KJ; Hogg, RS; Montaner, JS; O'Shaughnessy, MV; Schechter, MT; Strathdee, SA | 1 |
| Hirschel, B | 1 |
| Bush, CE; Cohen, F; Donovan, RM; Moore, E; Saravolatz, LD; Smereck, SM | 1 |
| Gao, WY; Johns, DG; Mitsuya, H | 1 |
| Cara, A; Gallo, RC; Lisziewicz, J; Lori, F; Malykh, A; Sun, D; Weinstein, JN | 1 |
| Albert, J; Aperia, K; Fenyö, EM; Karlsson, A; Parsmyr, K; Sandström, E | 1 |
| Lüthy, R | 1 |
| Gao, Q; Gu, Z; Nagai, K; Parniak, MA; Salomon, H; Wainberg, MA | 1 |
| Morris, DJ | 1 |
| Fleckenstein, B; Stamminger, T | 1 |
| Brouwers, P; Church, JA; Farley, M; Goldsmith, J; Husson, RN; Kovacs, A; Mueller, BU; Ono, J; Pizzo, PA; Woods, L | 1 |
| Fonseca, VA; Martin, RE; Munshi, MN | 1 |
| Portet-Brunet, L | 1 |
| Gobert, JM; North, TW; Remington, KM; Zhu, YQ | 1 |
| Beekmann, SE; Henderson, DK | 1 |
| Back, DJ; Barry, M; Beeching, N; Bergin, C; Breckenridge, AM; Howe, JL; Mulcahy, F; Nye, F; Ormesher, S | 1 |
| Brenner, BJ; Mercure, L; Phaneuf, D; Tsoukas, C; Wainberg, MA | 1 |
| Bincsik, A; Lane, J; Mayers, D; Otto, MJ; Scarnati, H; Winslow, DL | 1 |
| Volberding, PD | 1 |
| Hayashi, T; Imai, M; Ito, A; Kondo, M; Nagao, T; Saito, T; Watanabe, S | 1 |
| Gazzard, BG; Moyle, GJ; Nelson, MR | 1 |
| Chandiok, S; Higgins, S; Woolley, PD | 1 |
| Holodniy, M; Katzenstein, D; Kozal, M; Merigan, TC; Montoya, J; Ragni, M; Shafer, R; Winters, M | 1 |
| Bush, CE; Donovan, RM; Markowitz, N; Saravolatz, LD; Smereck, SM; Strang, D | 1 |
| Blumberg, B; Bonnez, W; Dolin, R; Epstein, L; Lambert, JL; Reichman, RC; Strussenberg, J; Tejani, N | 1 |
| Lagakos, S; Pettinelli, C; Stein, D | 1 |
| Broder, S; Jaffe, ES; Karp, JE; Lietzau, J; Nelson, DL; Pluda, JM; Tosato, G; Venzon, DJ; Wyvill, K; Yarchoan, R | 1 |
| Coombs, R; Gupta, P; Iversen, AK; Katzenstein, DA; Kozal, MJ; Meyer, WA; Ragni, MV; Rasheed, S; Shafer, RW; Winters, MA | 1 |
| Bergé, P; Mildvan, D; Salgo, M; St Clair, M; Starrett, S | 1 |
| Blanes, N; Coutellier, A; Fenouillet, E; Gluckman, JC | 1 |
| Volberding, PA | 1 |
| al-Habet, S; Ravasco, RJ; Tuntland, T; Unadkat, JD | 1 |
| Magnuson, T; Mourton, T; Toltzis, P | 1 |
| Agbaria, R; Driscoll, JS; Gao, WY; Mitsuya, H | 1 |
| Dalakas, MC; Jay, C; Ropka, M | 1 |
| Cinatl, J; Doerr, HW; Kornhuber, B; Mainke, M; Rabenau, H; Weber, B; Weissflog, A | 1 |
| Katz, MH | 1 |
| Arduino, JM; Chung, R; Crumpacker, CS; Hammer, SM; Japour, AJ; Lane, J; Mayers, DL; McLeod, GX; Reichman, R; Wagner, KF | 1 |
| Armbrecht, C; Hengels, KJ; Jablonowski, H; Manegold, C; Mauss, S; Szelenyi, H | 1 |
| Ennen, J; Kühne, FW; Kurth, R; Werner, K | 1 |
| Drusano, GL | 1 |
| Kahn, JO; Liou, SH; Richardson, D | 1 |
| Dubin, DT; Farnham, AE; Fitzgibbon, JE; Kim, H; Sperber, SJ | 1 |
| Chow, FP; Hamburger, AW; Ordóñez, JV; Sutton, PA | 1 |
| Maayan, S; Rahav, G | 1 |
| Yamada, K | 2 |
| Takamatsu, J | 1 |
| Mayaud, C | 1 |
| Sommadossi, JP | 1 |
| Brun-Vezinet, F; Pépin, JM; Simon, F | 1 |
| Jäger, H | 1 |
| Wong, RJ | 1 |
| Hirschel, B; Pechère, M; Samii, K | 1 |
| Boutin, P; Collier, AC; Coombs, RW; Corey, L; Davis, LG; Fischl, MA; Henrard, DR; Hooper, CJ; Kaplan, LD; Northfelt, D; Skolnik, PR; Volberding, PA; Weller, S | 1 |
| Anderson, BD; Broder, S; Husson, RN; Kojima, E; Mitsuya, H; O'Brien, MC; Shimada, T; Shirasaka, T; Yarchoan, R | 1 |
| Carr, A; Penny, R | 1 |
| Baird, BF; Davey, RT; deSmet, MD; Falloon, J; Kovacs, JA; Masur, H; Mellow, S; Nussenblatt, RB; Palestine, AG; Polis, MA | 1 |
| Lang, W; Moss, A; Osmond, D; Page-Bodkin, K; Winkelstein, W | 1 |
| Bucher, GG | 1 |
| Gazzard, BG; Hawkins, D; Moyle, GJ; Nelson, MR | 1 |
| Broder, S; Gao, WY; Johns, DG; Mitsuya, H; Shirasaka, T | 1 |
| D'Aquila, RT; Hirsch, MS | 1 |
| Ratner, L; Vander Heyden, N | 1 |
| Butler, KM; Husson, RN; Mitsuya, H; Pizzo, PA; Shirasaka, T | 1 |
| Brawley, O; Broder, S; Cohen, RB; Nguyen, BY; Pluda, JM; Shay, LE; Venzon, DJ; Whitcup, SM; Wyvill, KM; Yarchoan, R | 1 |
| Clumeck, N | 2 |
| Cvetkovich, TA; Frenkel, LM | 1 |
| Bray, DH; Johnson, MA; Kawana, A; Poulter, LW; Squire, SB | 1 |
| Allan, JD; Beltangady, M; Cooley, TP; Dolin, R; McLaren, C; Nicaise, C; Rozencweig, M; Seidlin, M; Smaldone, LF; Yarchoan, R | 1 |
| Liu, YQ; Lor, E | 1 |
| Demonty, J | 1 |
| Hamed, KA; Holodniy, M; Katzenstein, DA; Merigan, TC; Winters, MA | 1 |
| Robinson, EN | 1 |
| Gallicchio, VS; Hughes, NK; Tse, KF | 1 |
| Howard, EJ; Naides, SJ; Stapleton, JT; Swack, NS; True, CA | 1 |
| Benowitz, NB; Coleman, R; Delahunty, T; Harb, GE; Jacobson, MA; Mandema, JW; Sheiner, LB | 1 |
| Chien, YW; Kim, DD | 2 |
| Bartos, L; DeRemer, M; Ho, M; Morse, GD; Ragni, M; Shelton, MJ | 1 |
| Cooper, DA; Emery, S | 1 |
| Chesebro, B; Iversen, AK; Merigan, TC; Mullins, JI; Shafer, RW; Wehrly, K; Winters, MA | 1 |
| Arts, EJ; Gu, Z; Le Grice, SF; Marois, JP; Wainberg, MA | 1 |
| Auten, J; Bonyhadi, ML; Kaneshima, H; McCune, JM; Su, L | 1 |
| Brenner, B; Lalonde, R; Mercure, L; Phaneuf, D; Wainberg, MA | 1 |
| Bissuel, F; Cotte, L; Leriche, K; Rougier, P; Schlienger, I; Trabaud, MA; Trepo, C | 1 |
| Cox, S; Palmer, S | 1 |
| López, M; Mayol, N; Vázquez-Padua, MA | 1 |
| Chokekijchai, S; Mitsuya, H; Shirasaka, T; Weinstein, JN | 1 |
| Jablonowski, H | 1 |
| Beijnen, JH; Burger, DM; Hoetelmans, RM; Koks, CH; Kraayeveld, CL; Meenhorst, PL; Mulder, JW | 1 |
| Adams, O; Jablonowski, H; Mauss, S; Willers, R | 1 |
| LaCasse, RA; North, TW; Remington, KM | 1 |
| Cotton, D; Dolin, R; Feinberg, J; Finkelstein, DM; Kahn, J; Molenberghs, G; Powderly, WG; Williams, PL | 1 |
| Montaner, JS; Raboud, JM; Schechter, MT; Singer, J; Thorne, A | 1 |
| Chambers, DE; Cooper, DA; Crowe, S | 1 |
| Basgoz, N; D'Aquila, RT; Fischl, MA; Hirsch, MS; Hughes, MD; Johnson, VA; Liou, SH; Myers, M; Niu, M; Sommadossi, JP; Timpone, J | 1 |
| Detels, R; Graham, NM; Hoover, DR; Mellors, JW; Park, LP; Phair, JP; Saah, AJ; Stein, DS | 1 |
| Besley, D; Graham, NM; Jacobson, LP; Muñoz, A; Murphy, R; Park, LP; Zucconi, S | 1 |
| Cooper, DA; Harrigan, PR; Kinghorn, I; Lange, JM; Larder, BA; Lavelle, J; Lefkowitz, L; McKinnis, R; Moore, M; Mulder, JW; Pennington, KN; Ramirez-Ronda, C; Rooney, JF; Schooley, RT; St Clair, M; Steel, H | 1 |
| Weller, IV; Williams, I | 1 |
| Bergamini, A; Capozzi, M; Cappannoli, L; Faggioli, E; Mancino, G; Placido, R; Rocchi, G; Salanitro, A; Stoler, A; Ventura, L | 1 |
| Ballester Belda, E; de Lelis, FP; Gil Egea, M; Herrera Ballester, A; López de Medrano, V; Martín Herrera, A; Ortega González, E; Ronda Gasulla, FA | 1 |
| Hu, P; Sinko, PJ | 1 |
| Antunes, F; Clotet, B; Doroana, M; Gatell, JM; Gil-Aguado, A; González-Lahoz, J; Jou, A; Kasparova, L; Miro, JM; Podzamczer, D; Saballs, P; Santamaria, JM; Thomis, J; Verdejo, J | 1 |
| Arseneau, R; Gill, J; McLean, BD; Montaner, JS; Raboud, J; Ruedy, J; Schechter, MT; Singer, J | 1 |
| Chaisson, RE; Fortgang, I; Keruly, J; Moore, RD | 1 |
| de Mendonça, JS | 1 |
| Arredondo-Garcia, JL; Flores-Rivera, E; Gorbea-Robles, MC; Paredes-Vivas, Y; Villegas-Castrejon, H | 1 |
| Costes, O; Lafeuillade, A; Poggi, C; Profizi, N; Tamalet, C | 1 |
| Jellinger, RM; Merigan, TC; Shafer, RW; Winters, MA | 1 |
| Bloor, S; Harrigan, PR; Kemp, SD; Kohli, A; Lange, JM; Larder, BA; Pennington, KN; Schooley, RT; St Clair, MH | 1 |
| Childress, JF; DeMets, DL; Ellenberg, SS; Fleming, TR; Foulkes, M; Mayer, KH; O'Fallon, J; Pollard, RB; Rahal, JJ; Whitley, RJ | 1 |
| Baruch, A; Bassett, R; Collier, AC; Coombs, RW; Corey, L; Schoenfeld, DA | 1 |
| Pollard, RB | 1 |
| Ahmed, PS; Brennan, TM; Bridges, CG; Casara, P; Hornsperger, JM; Navé, JF; Taylor, DL; Tyms, AS | 1 |
| Cox, S; Harmenberg, J; Palmer, S | 1 |
| Mofenson, LM | 1 |
| Abraham, T; Nusbaum, NJ | 1 |
| Dally, LG; De Rienzo, B; Dianzani, F; Floridia, M; Fragola, V; Mazzotta, F; Milazzo, F; Moroni, M; Ortona, L; Pastore, G; Scalise, G; Sinicco, A; Tomino, C; Vella, S; Weimer, LE | 1 |
| Boulton, A | 1 |
| Bruun, L; Gerstoft, J; Mathiesen, LR; Nielsen, C; Pedersen, C | 1 |
| Leal, M; Lissen, E; Medrano, FJ; Rey, C; Sánchez-Quijano, A; Torres, Y | 1 |
| André, E; Bez, G; Bourdillon, F; Delfraissy, JF; Nadal, JM | 1 |
| Amatea, MA; Bechtel, C; Kovacs, JA; Metcalf, JA; Piscitelli, SC; Vogel, S | 1 |
| Bélec, L; Chrétien, F; de Truchis, P; Dubreuil-Lemaire, ML; Gray, F; Levy, Y | 1 |
| Baba, M; Fujiwara, M; Ijichi, K; Konno, K; Machida, H; Mori, K; Morozumi, M; Shigeta, S; Yokota, T | 1 |
| Anderson, B; Farley, M; Fox, C; Luzuriaga, K; Mueller, BU; Pizzo, PA; Schwartzentruber, DJ; Sei, S; Sullivan, JL; Tudor-Williams, G; Venzon, DJ | 1 |
| Ho, DD | 1 |
| Costes, O; Djediouane, A; Lafeuillade, A; Poggi, C; Profizi, N; Tamalet, C | 1 |
| Chatis, PA; Crumpacker, CS; Dogon, AL; Mayers, DL; McCutchan, FE; Page, C; Sharma, PL | 1 |
| Boyle, J; Chaitt, DG; Coleman, S; Cox, SR; Daenzer, CL; Davey, RT; Eastman, PS; Falloon, J; Freimuth, WW; Herpin, BR; Kovacs, JA; Lane, HC; Masur, H; Metcalf, JA; Polis, MA; Reed, GF; Walker, RE; Wathen, L | 1 |
| Chikami, GK; Piazza-Hepp, TD; Styrt, BA | 1 |
| Gundacker, H; Hammer, SM; Haubrich, RH; Henry, WK; Hirsch, MS; Hughes, MD; Katzenstein, DA; Lederman, MM; Merigan, TC; Niu, M; Phair, JP; Schooley, RT | 1 |
| Elbeik, T; Fiscus, S; Gundacker, H; Hammer, SM; Hirsch, MS; Hughes, MD; Jackson, JB; Japour, A; Katzenstein, DA; Merigan, TC; Rasheed, S; Reichman, R | 1 |
| Abrams, D; Collins, G; Crane, L; Hodges, JS; Loveless, MO; Markowitz, N; Pettinelli, C; Reves, R; Saravolatz, LD; Stein, DS; Thompson, M; Winslow, DL | 1 |
| Corey, L; Holmes, KK | 1 |
| Lane, HC; Masur, H; Spooner, KM | 1 |
| Holodniy, M; Katzenstein, D; Merigan, T; Mole, L; Winters, M | 1 |
| Arezzo, JC; Bregman, CL; Comereski, CR; Davidson, TJ; Durham, SK; Frantz, JD; Kaul, S; Knupp, CA; Warner, WA; Wasserman, AJ | 1 |
| Medlin, HK; North, TW; Phillips, TR; Remington, KM; Zhu, YQ | 1 |
| Datema, R; Hincenbergs, M; Linquist, V; McCune, JM; Moreno, MB; Rabin, L; Rosenwirth, B; Seifert, J; Warren, S | 1 |
| Charpiot, B; Datema, R; Hincenbergs, M; Kaneshima, H; Linquist, V; McCune, JM; Moreno, MB; Rabin, L; Seifert, J; Warren, S | 1 |
| Hasegawa, T; Juni, K; Kawaguchi, T; Saneyoshi, M | 1 |
| Carlo, DJ; Daigle, AE; Ferre, F; Jensen, FC; Levine, A; Moss, RB; Richieri, SP; Salk, J; Trauger, RJ; Truckenbrod, A; Turner, J | 1 |
| Canivet, M; Molina, JM; Peries, J; Santillana-Hayat, M; Valla, J | 1 |
| Fuchs, D; Gisslen, M; Hagberg, L; Norkrans, G; Svennerholm, B; Wachter, H | 1 |
| Domachowske, JB | 1 |
| Cohen, LG; Noormohamed, SE | 1 |
| Brichacek, B; Janoff, EN; Pirruccello, S; Stevenson, M; Swindells, S | 1 |
| Carr, A; Cooper, DA; Emery, S; Kelleher, A; Law, M | 1 |
| Ambetima, N; Blanquet, D; Hallard, M; Mathé, G; Morette, C; Orbach-Arbouys, S; Pontiggia, P; Triana, K | 1 |
| Barber, CG; Hogg, R; Montaner, JS; Murphy, C; O'Shaughnessy, M; Phillips, P; Schechter, MT; Srour, LF | 1 |
| Iezzi, A; Pizzigallo, E; Sisto, A | 1 |
| Baba, M; Hashimoto, KI; Okamoto, M; Shigeta, S; Tsunoda, R | 1 |
| Zaretsky, MD | 1 |
| Lafeuillade, A; Pellegrino, P; Poggi, C; Profizi, N; Sayada, C | 1 |
| Millard, PS | 1 |
| Belohradsky, BH; Eberle, J; Gürtler, L; Notheis, G; Sölder, B; Wintergerst, U | 1 |
| Bechtel, LM; Starich, GH; Whitfield, RM | 1 |
| Berrios, L; Cox, S; Demeter, LM; Dexter, A; Freimuth, W; Gerondelis, P; Meehan, PM; Morse, G; Reichman, RC | 1 |
| Gatell, JM; Guerra, L; Pérez-Elías, MJ; Santamaría, JM | 1 |
| Antela, A; Parras, F; Podzamczer, D; Ruiz, I | 1 |
| Aguirrebengoa, K; Mallolas, J; Torres Tortosa, M; Uriz, J | 1 |
| Bascuñana, A; Laguna, F; Ocaña, I; Pulido, F | 1 |
| Albrecht, H; Greten, H; Stellbrink, HJ | 1 |
| Gatell-Artigas, JM | 1 |
| Augenbraun, M; Minkoff, H | 1 |
| Cui, L; Locatelli, L; Sommadossi, JP; Xie, MY | 1 |
| Caruz, A; Leal, M; Lissen, E; Rey, C | 1 |
| Cohen, MS; Dyer, JR; Eron, JJ; Fiscus, SA; Gilliam, BL; Vernazza, PL | 1 |
| Gingeras, T; Jellinger, RA; Mamtora, G; Merigan, TC; Shafer, RW; Winters, MA | 1 |
| Agrofoglio, L; Bernhard, S; Duchin, KL; Kirk, M; Pan-Zhou, XR; Sommadossi, JP; Squires, K; Zhou, XJ | 1 |
| Wei, LJ; Zackin, R | 1 |
| Hirschel, B; Rutschmann, O | 1 |
| Sugiyama, Y; Suzuki, H; Takasawa, K; Terasaki, T | 1 |
| Aiuti, F; Angarano, G; Arlotti, M; d'Arminio Monforte, A; Galli, M; Gritti, F; La Regina, A; Lazzarin, A; Mazzotta, F; Milazzo, F; Moroni, M; Musicco, M; Paga, C; Visco, G | 1 |
| Chong, KT; Pagano, PJ | 1 |
| Gates, GA; Longstreth, WT; Marra, CM; Rees, TS; Syapin, CL; Wechkin, HA | 1 |
| Griffy, KG | 1 |
| Broder, S; Brouwers, P; Hendricks, M; Lietzau, JA; Mitsuya, H; Pluda, JM; Yarchoan, R | 1 |
| Izopet, J; Lafeuillade, A; Pellegrino, P; Poggi, C; Tamalet, C; Tourres, C | 1 |
| Hirschel, B; Jenni, R; Joller-Jemelka, HI; Lüthy, R; Opravil, M; Pechère, M; Russi, EW; Speich, R | 1 |
| Aromin, I; Elliot, B; Flanigan, T; Gold, R; Mileno, M | 1 |
| Heins, JR | 1 |
| Iversen, AK; Merigan, TC; Shafer, RW; Winters, MA | 1 |
| Costes, O; Lafeuillade, A; Poggi, C; Profizi, N; Tamalet, C; Tourres, C | 1 |
| al-Mulla, W; Church, D; Gill, MJ | 1 |
| Bryson, Y; Cort, S; Krogstad, P; Lamson, M; Luzuriaga, K; Robinson, J; Stechenberg, B; Sullivan, JL | 1 |
| Brewster, F; Chatis, PA; Chung, PH; Greene, RA; Japour, AJ; Joseph, RA; Kasila, PA | 1 |
| Lagakos, SW; Li, QH | 1 |
| Ammi-Saïd, M; Barlovatz-Meimon, G; Benbrik, E; Bonavaud, S; Chariot, P; Frisdal, E; Gherardi, R; Rey, C | 1 |
| Brizzi, M; Ceccherini-Nelli, L; Forastieri, G; Iuliano, R; Mazzotta, F; Mecocci, L | 1 |
| Bonsel, GJ; Danner, SA; Lange, JM; Reiss, P; van Leeuwen, R | 1 |
| Berglund, O; Bruun, JN; Gerstoft, J; Głtzsche, PC; Mathiesen, L; Melander, H; Norrby, SR; Pedersen, C; Skinhłj, P | 1 |
| Abrams, EJ; Baker, CJ; Englund, JA; Fowler, MG; Gershon, A; McKinney, RE; McSherry, GD; Pearson, D; Petrie, B; Raskino, C; Schliozberg, J; Sullivan, JL | 1 |
| Basgoz, N; Bremer, JW; D'Aquila, RT; Elbeik, T; Erice, A; Fischl, MA; Hirsch, MS; Hughes, MD; Johnson, VA; Kuritzkes, DR; Scott, WA; Spector, SA | 1 |
| Eisen, JA; Katzenstein, DA; Merigan, TC; Shafer, RW | 1 |
| Fantini, J; Lafeuillade, A; Poggi, C; Tamalet, C; Yahi, N | 1 |
| Clifford, DB; Dafni, U; Hall, C; Kieburtz, K; Price, RW; Sidtis, JJ; Slasor, P; Tucker, T | 1 |
| Alberici, F; Bassetti, D; Cargnel, A; Carosi, G; Chiodo, F; Concia, E; Cremoni, L; Dianzani, F; Floridia, M; Fragola, V; Giannini, V; Gritti, FM; Mazzotta, F; Milazzo, F; Moroni, M; Ranieri, S; Ricciardulli, D; Seeber, AC; Sinicco, A; Tomino, C; Vella, S; Weimer, LE | 1 |
| Gisslén, M; Hagberg, L; Norkrans, G; Svennerholm, B | 1 |
| Errante, D; Nasti, G; Tirelli, U | 1 |
| Böhler, T; Debatin, KM; Geiss, M; Haas, J; Herr, I | 1 |
| Collins, DO; Sakamoto, A | 1 |
| Comar, M; De Paoli, P; Giacca, M; Simonelli, C; Tirelli, U; Zanussi, S | 1 |
| Lillo, FB; Maillard, M; Saracco, A; Varnier, OE | 1 |
| Roca, B; Simón, E | 1 |
| Lafeuillade, A; Poggi, C; Profizi, N; Tamalet, C | 1 |
| Delmas, B; Janbon, F; Montes, B; Reynes, J; Segondy, M; Vendrell, JP | 1 |
| Ooie, T; Sugiyama, Y; Suzuki, H; Takasawa, K; Terasaki, T | 1 |
| Boucher, C; Brun-Vézinet, F; Descamps, D; Fauveau, V; Izopet, J; Jeffries, D; Kaye, S; Krzyanowski, C; Loveday, C; Nunn, A; Schuurman, R; Seigneurin, JM; Tamalet, C; Tedder, R; Weber, J; Weverling, GJ | 1 |
| Sugiyama, Y; Suzuki, H; Takasawa, K | 1 |
| Amado, RG; Chen, IS; Jamieson, BD; Kaplan, AH; Koka, PS; Withers-Ward, ES; Zack, JA | 1 |
| Back, DJ; Barry, MG; Hoggard, PG; Kewn, S; Veal, GJ | 1 |
| Cretton-Scott, E; Duchin, K; Pan-Zhou, XR; Rahmani, R; Schinazi, RF; Sommadossi, JP; Xie, MY; Zhou, XJ | 1 |
| Freedman, AR; Gibson, FM; Gill, V; Gordon-Smith, EC; Griffin, GE; Hayes, P; Scopes, J; Shattock, RJ | 1 |
| Bakker, M; Boucher, CA; Danner, SA; de Jong, MD; de Wolf, F; Lange, JM; Loeliger, AE; Notermans, DW; Ran, LJ; Reiss, P; Schuitemaker, H; van Leeuwen, R; van't Wout, AB | 1 |
| Accorinti, M; Aiuti, F; Ciapparoni, V; Pivetti-Pezzi, P; Vullo, V | 1 |
| Izopet, J; Marchou, B; Massip, P; Pasquier, C; Puel, J; Sandres, K; Tamalet, C | 1 |
| Comar, M; De Paoli, P; Giacca, M; Simonelli, C; Tirelli, U; Vaccher, E; Zanussi, S | 1 |
| Alaeus, A; Albert, J; Cox, S; Palmer, S | 1 |
| Edelstein, RE; Frenkel, LM; Manns-Arcuino, LA; Nickerson, DA; Tobe, VO | 1 |
| Feigley, CE; Gu, J; Khajotia, RR; Lee, E | 1 |
| Bagnarelli, P; Butini, L; Montroni, M; Munoz, C; Silvestri, G | 1 |
| Kavlick, MF; Kosalaraksa, P; Mitsuya, H; Yusa, K | 1 |
| Oka, S | 1 |
| Aker, D; Balis, FM; Brouwers, P; Edgerly, M; Heath-Chiozzi, M; Higham, C; Hsu, A; Jarosinski, P; Katz, TT; Mueller, BU; Nelson, RP; Pizzo, PA; Pizzuti, D; Saulis, R; Sei, S; Serchuck, L; Sleasman, J; Steinberg, SM; Whitcup, SM; Wood, LV; Zeichner, S; Zuckerman, J | 1 |
| Beaumanoir, A; Burkhard, P; Burquier, V; Hirschel, B; Jallon, P; Koralnik, IJ; Mayer, E; Vibert, D | 1 |
| Back, DJ; Barry, MG; Hoggard, PG; Manion, V | 1 |
| Casserella, S; Cimoch, PJ; Griffy, KG; Jung, D; Lavelle, J; Pollard, R; Tarnowski, TL; Wong, R | 1 |
| Barton, S; Blaxhult, A; Clotet, B; Goebel, FD; Hirschel, B; Katlama, C; Lundgren, JD; Pedersen, C; Phillips, AN; Vella, S | 1 |
| Adrados, M; Alvar, J; González-Lahoz, JM; Jiménez, MI; Laguna, F; Martínez, ML; Martínez, P; Moreno, V; Polo, R; Soriano, V; Valencia, ME; Verdejo, J | 1 |
| Byington, R; Elbeik, T; Fiscus, SA; Griffith, BP; Hammer, SM; Hughes, MD; Jackson, B; Japour, A; Katzenstein, DA; Lathey, JL; Pi, T; Rasheed, S; Reichman, R; Scott, W | 1 |
| Barnett, T; Eidelberg, D; Frank, Y; Hyman, RA; Lu, D; Pavlakis, SG; Wiznia, A | 1 |
| Brettle, RP; Gore, S; Hutchinson, S; Leen, CL; Lewis, S; Morgan, R; Morris, S; Povey, S; Wilson, A | 1 |
| Arranz, ME; Balzarini, J; De Clercq, E; Declercq, R; Desmyter, J; Diaz, JA; Esnouf, R; Ingate, ST; Jonckheere, H; Pannecouque, C; Schmit, JC; Van Meervelt, L; Vandamme, AM; Vega, S; Witvrouw, M | 1 |
| Conway, B; Hogg, RS; Montaner, JS; O'Shaughnessy, MV; Rhone, SA; Schechter, MT; Sherlock, C; Yip, B | 1 |
| Arbeit, RD; Hadad, DJ; Lewi, DS; Martins, MC; Pignatari, AC; Vitti Júnior, W | 1 |
| DeMasi, R; Hill, AM; Montaner, JS | 1 |
| Conway, B; Cooper, D; Hall, D; Harris, M; Lange, JM; Montaner, JS; Myers, M; Reiss, P; Robinson, P; Smith, D; Vella, S; Wainberg, MA | 1 |
| Bethel, J; Landay, AL; Schnittman, S | 1 |
| García-Lerma, G; Gómez-Cano, M; González-Lahoz, J; Soriano, V | 1 |
| Adrados, M; Calvo, F; Casas, E; García-Lerma, G; Gómez-Cano, M; Soriano, V | 1 |
| Maeda, Y; Mitsuya, H; Venzon, DJ | 1 |
| Fox, CH; Hirschel, B; Marchal, F; Pantaleo, G; Perrin, L; Schockmel, GA; Yerly, S | 1 |
| Kavlick, MF; Mitsuya, H; Wyvill, K; Yarchoan, R | 1 |
| Bethel, J; Mayers, D; Schnittman, S; Wainberg, MA; Weislow, O | 1 |
| Conway, B; Cooper, D; Dohnanyi, C; Hall, DB; Lange, J; Montaner, JG; Myers, M; Reiss, P; Vella, S | 1 |
| Blanchard, G; Blum, L; Calvo, F; Danne, O; Lebbé, C; Morel, P; Pellet, C; Vérola, O | 1 |
| Bloor, S; de Béthune, MP; Gröschel, B; Harrigan, PR; Hertogs, K; Kemp, SD; Larder, BA; Miller, V; Pauwels, R; Staszewski, S; Stürmer, M | 1 |
| Bloch, J; Chavance, M | 1 |
| Bridges, EG; Cheng, YC; Dutschman, GE; Gullen, E; Guo, X; Kukhanova, M; Liu, SH | 1 |
| Clotet, B; Gómez-Cano, M; Leal, M; Pérez-Olmeda, M; Pineda, JA; Puig, T; Rubio, A; Ruiz, L; Soriano, V; Xaus, N; Zamora, L | 1 |
| Foli, A; Gallo, RC; Lisziewicz, J; Lori, F; Maserati, R; Minoli, L; Wainberg, MA | 1 |
| Baldeweg, T; Catalan, J; Gazzard, BG | 1 |
| Clotet, B; De Clercq, E; Desmyter, J; Puig, T; Rossau, R; Ruiz, L; Schmit, JC; Stuyver, L; Van Laethem, K; Vandamme, AM; Vanderlinden, I | 1 |
| Font, E; Lasanta, S; Rodríguez, JF; Rosario, O | 1 |
| Bouscarat, F; Brun-Vézinet, F; Girard, PM; Landman, R; Levacher, M; Muffat-Joly, M; Saimot, AG; Sinet, M | 1 |
| Harrigan, PR; Harris, M; Mo, T; Montaner, JS | 1 |
| Boucher, CA; Bruisten, SM; Huisman, JG; Loeliger, AE; Reiss, P; Schuurman, R; van Swieten, P; Weverling, GJ | 1 |
| Berenguer, J; Cano, J; Fernández Alvarez, JM; Gimeno, M; Gonzalo Lafuente, JC; Vázquez-Piñeiro, T | 1 |
| Clotet, B; Cruceta, A; García, F; Gatell, JM; Leal, M; Mallolas, J; Miró, JM; Pumarola, T; Ruiz, L; Tortajada, C; Vidal, C | 1 |
| Bachmeyer, C; Blum, L | 1 |
| Ibrahim, JG; Kleinman, KP | 1 |
| Belec, L; Cotigny, S; Gilquin, J; Gutmann, L; Kazatchkine, M; Matta, M; Piketty, C; Si Mohamed, A; Weiss, L | 1 |
| Koopmans, PP; van Ginneken, EE | 1 |
| Conway, B; Cooper, D; Hall, D; Harris, M; Lange, J; Montaner, JS; Myers, M; Raboud, JM; Rae, S; Reiss, P; Robinson, P; Vella, S; Wainberg, MA | 2 |
| Heald, AE; Pieper, CF; Schiffman, SS | 1 |
| Kempf-Durepaire, G; Krantz, V; Lang, JM; Nicolle, M; Partisani, M; Rey, D; Schmitt, AC; Schmitt, MP | 1 |
| Caballero, B; Henderson, RA; Hutton, N; Talusan, K; Yolken, RH | 1 |
| Saag, MS; Schooley, RT | 1 |
| Brouwers, P; Johnson, GM; Keller, A; McKinney, RE; McNamara, J; Mitchell, WG; Mofenson, L; O'Donnell, KJ; Spector, SA; Stanley, K; Wara, DW; Wiznia, A; Yogev, R; Yong, FH | 1 |
| Ishizaka, K; Kageyama, Y; Kihara, K; Nagai, H; Oshima, H; Tosaka, A; Tsujii, T | 1 |
| Dimitrov, DS; Heath-Chiozzi, M; Kuznetsov, VA; Mueller, BU; Pizzo, PA; Zeichner, SL | 1 |
| Chan, KC; Ho, TT; Lee, SS; Wong, KH | 1 |
| Arnedo, A; Mínguez, C; Olmos, P; Roca, B; Sáez-Royuela, A; Segarra, M; Simón, E; Teruel, C; Usó, J | 1 |
| Coolley, KL; Girard, YA; Hamdan, H; Katzenstein, DA; Levee, DJ; Merigan, TC; Shafer, RW; Winters, MA | 1 |
| Balfour, HH; Erice, A; Fischl, MA; Henry, K; Hirsch, MS; Kahn, JO; Kenton, A; Kmack, A; Liou, SH; Martinez, A; Phair, J; Tierney, C | 1 |
| Ippolito, G; Puro, V | 1 |
| Gitterman, SR; Pratt, RD; Struble, KA | 1 |
| Vittecocq, D | 1 |
| Blaschke, TF; Girard, P; Kastrissios, H; Katzenstein, D; Sheiner, LB; Suárez, JR | 1 |
| Blaschke, TF; Hammer, S; Kastrissios, H; Katzenstein, D; Suárez, JR | 1 |
| D'Aquila, RT; Fischl, MA; Hirsch, MS; Hughes, MD; Johnson, VA; Myers, M; Sheiner, LB; Sommadossi, JP; Zhou, XJ | 1 |
| Esposito, S; Gabiano, C; Galli, L; Gattinara, GC; Marchisio, P; Orlandi, P; Principi, N; Rossi, P; Zuccotti, GV | 1 |
| Moyle, GJ; Sadler, M | 1 |
| Clay, PG; Rathbun, RC; Slater, LN | 1 |
| Haubrich, R; Richman, D | 1 |
| Fleury, S; Miedema, F; Otto, SA; Reiss, P; ten Kate, RW; van der Zee, AG; Wisman, GB; Wolthers, KC | 1 |
| Alberici, F; Andreotti, M; Bucciardini, R; Cargnel, A; De Rienzo, B; Fiaccadori, F; Floridia, M; Fragola, V; Francisci, D; Galluzzo, CM; Giannini, G; Grillone, W; Leoncini, F; Nigra, E; Ortona, L; Piazza, M; Pirillo, MF; Ricciardulli, D; Scalzini, A; Tomino, C; Tumietto, F; Vella, S; Weimer, LE | 1 |
| Bortolin, MT; Comar, M; De Paoli, P; Giacca, M; Lucenti, A; Sandri, S; Simonelli, C; Talamini, R; Tirelli, U; Zanussi, S | 1 |
| Baker, CJ; Englund, JA; Fiscus, S; Pahwa, S; Palumbo, PE; Raskino, C; Schutzbank, T; Spector, SA | 1 |
| Bortolin, MT; Comar, M; D'Andrea, M; De Paoli, P; Giacca, M; Simonelli, C; Tirelli, U; Zanussi, S | 1 |
| Phillips, L | 1 |
| Flandre, P | 1 |
| Claessen, FA; Hall, D; Hamann, D; Kauffmann, RH; Koopmans, PP; Kroon, ED; Kroon, FP; Lange, JM; Miedema, F; Montaner, JS; Otto, SA; Pakker, NG; Reiss, P; Roos, MT; Schellekens, PT; Sprenger, HG; ten Napel, CH; van der Ende, ME; Weigel, HM; Wit, FW | 1 |
| Le Hello, C | 1 |
| Abramson, SL; Douglas, SD; Fenton, T; Kline, MW; Shearer, WT; Starr, SE | 1 |
| Baseler, M; Goodenow, MM; Hutson, A; Mueller, BU; Nelson, RP; Pizzo, PA; Sleasman, JW; Wilfret, D; Zuckerman, J | 1 |
| Dhillon, AP; Lee, CA; Mistry, PK; Nitu, IC | 1 |
| Armitage, P | 2 |
| Karchmer, S; Mayón González, J; Paredes Vivas, Y; Villegas Castrejón, H | 1 |
| Kavlick, MF; Kosalaraksa, P; Le, R; Maroun, V; Mitsuya, H | 1 |
| Aboulker, JP; Boumsell, L; Capitant, C; Carriere, I; Delfraissy, JF; Gastaut, JA; Gomard, E; Goujard, C; Guillet, JG; Houhou, S; Levy, Y; Oksenhendler, E; Rabian, C; Seligmann, M; Viard, JP; Weiss, L | 1 |
| Djomand, G; Lackritz, EM; Mbidde, E; Weidle, PJ | 1 |
| Back, DJ; Barry, MG; Henry-Mowatt, JS; Hoggard, PG; Kewn, S; Sales, SD; Veal, GJ | 1 |
| Chêne, G; Cotte, L; Debord, T; Decazes, JM; Ferchal, F; Journot, V; Madelaine, I; Molina, JM; Pellegrin, I; Rancinan, C; Sombardier, MN | 1 |
| Bassett, R; Bell, D; Eron, JJ; Fife, K; Fischl, MA; Johnson, VA; Kuritzkes, DR; Maenza, J; Marschner, I; Murphy, RL; Pettinelli, C; Rosandich, ME; Sommadossi, JP; Wood, K | 1 |
| Finkelstein, DM; Schoenfeld, DA | 1 |
| Amado, RG; Cole, SW; Cortado, R; Jamieson, BD; Zack, JA | 1 |
| Chennebault, JM; Gouello, JP; Pennison-Besnier, I; Roy, PM | 1 |
| Bassett, R; Connick, E; Demeter, L; Fischl, M; Freimuth, W; Friedland, GH; Griffith, B; Hirsch, M; Hughes, M; Morse, G; Nevin, T; Pollard, R | 1 |
| Brouwers, P; Cox, JH; Jarosinski, P; Kumagai, M; Loomis-Price, LD; Moss, RB; Pizzo, PA; Ratto-Kim, S; Robb, ML; Sandelli, SL; Sei, S; Theofan, G; Venzon, DJ; Walsek, CM; Wood, LV; Xu, J | 1 |
| Ahmad, M; Brennan, JM; Caliendo, AM; Fiske, WD; Flanigan, TP; Gormley, JM; Tashima, KT | 1 |
| Cross, A; Dunkle, L; Kelleher, T | 1 |
| Baker, CJ; Brouwers, P; Englund, JA; Jimenez, E; Lifschitz, MH; McKinney, RE; Mintz, M; Nozyce, M; O'Donnell, K; Pearson, DA; Raskino, C | 1 |
| Brown, AJ; D'Aquila, RT; Günthard, HF; Johnson, VA; Kuritzkes, DR; Richman, DD; Wong, JK | 1 |
| Cauda, R; Gastaldi, R; La Verde, G; Lucia, MB; Marasca, G; Petrucci, MT; Rutella, S | 1 |
| Artlip, M; Brazinski, S; Kaloss, M; Lyons, R; McGarrity, GJ; Otto, E; Powell, SK | 1 |
| Aleman, S; Loré, K; Sönnerborg, A; Visco-Comandini, U | 1 |
| Ross, L; St Clair, M; Vavro, C; Zimmermann, A | 1 |
| Ahrens, P; Funk, MB; Hoffmann, F; Kornhuber, B; Kreuz, W; Linde, R; Notheis, G; Schuster, T; Wintergerst, U | 1 |
| Denayrolles, M; Fleury, H; Izopet, J; Massip, P; Montes, B; Pellegrin, I; Pellegrin, JL; Puel, J; Reynes, J; Segondy, M | 1 |
| Murakami, J; Nagai, N; Ohama, K; Shigemasa, K | 1 |
| Bicart-See, A; Bonnet, E; Izopet, J; Marchou, B; Massip, P; Pasquier, C; Puel, J; Sandres, K | 1 |
| DiCarlo, M; Escobar, P; Freyssenet, D; Grey, J; Hood, DA; Schneider, J | 1 |
| Martin, EM; Mullane, KM; Novak, RM; Pitrak, DL; Pursell, KJ | 1 |
| Alesse, E; Boschini, A; Cifone, MG; De Simone, C; Di Marzio, L; Famularo, G; Marcellini, S; Moretti, S; Parroni, R; Zazzeroni, F | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Arlotto, C; Bernard, A; Bernard-Pomier, G; Breittmayer, JP; Dellamonica, P; Pradier, C; Pugliese, P; Roger, PM | 1 |
| Arrizabalaga, J; Clotet, BG; Cruceta, A; Dalmau, D; Gallart, T; García, F; Gatell, JM; Gomez-Sirvent, JL; Grau, I; Knobel, H; Miró, JM; O'Brien, WA; Podzamczer, D; Pumarola, T; Romeu, J; Sambeat, MA | 1 |
| Flepp, M; Jost, J; Ledergerber, B; Opravil, M; Paris, D; Ruef, C; Weber, R; Zimmerli, S | 1 |
| Gendelman, HE; Lanier, ER; Limoges, J; McClernon, DR; Persidsky, Y; Poluektova, L; Rasmussen, J; Ratanasuwan, W; Zelivyanskaya, M | 1 |
| Clotet, B; Gómez-Cano, M; Leal, M; Pérez-Olmeda, M; Puig, T; Rey, C; Rubio, A; Ruiz, L; Soriano, V; Xaus, N; Zamora, L | 1 |
| Bagnarelli, P; Chirianni, A; Clementi, M; Liuzzi, G; Piazza, M | 1 |
| Briones, C; Soriano, V | 1 |
| Giorgi, JV; Killian, S; Kitchen, SG; Zack, JA | 1 |
| Campi, G; Casorati, G; Corey, L; Demarest, JF; Kaufmann, D; Lazzarin, A; Lenge, C; Pantaleo, G; Rizzardi, GP; Soudeyns, H; Tambussi, G | 1 |
| Coakley, EP; Gillis, JM; Hammer, SM | 1 |
| Andreotti, M; Bricalli, D; Clerici, M; Dally, LG; Di Fabio, S; Ferrante, P; Pirillo, M; Principi, N; Saresella, M; Vanzulli, A; Vella, S; Vigano, A | 1 |
| Brown, AJ; D'Aquila, RT; Hanna, GJ; Hazelwood, JD; Johnson, VA; Kuritzkes, DR; Richman, DD; Savara, AV | 1 |
| Cauda, R; Citton, R; Donati, KG; Leone, F; Spanu, T; Tacconelli, E; Tumbarello, M | 1 |
| Bucciardini, R; Fragola, V; Harrigan, PR; Montaner, JS; Raboud, JM; Rae, S; Ricciardulli, D; Vella, S | 1 |
| Clotet, B; De Clercq, E; Desmyter, J; Evans, C; Hermans, P; Muyldermans, G; Ruiz, L; Schmit, JC; Schneider, F; Simons, P; Stuyver, L; Van Laethem, K; Van Vaerenbergh, K; Van Wanzeele, F; Van Wijngaerden, E; Vandamme, AM; Verhofstede, C | 1 |
| Angel, JB; Badley, AD; Cameron, DW; Cassol, S; Chambers, KA; Gallicano, K; Hawley-Foss, N; Kravcik, S; Mandy, F; Parato, K; Phenix, BN | 1 |
| Babiker, A; Collins, R; Darbyshire, J; Duncan, W; Foulkes, M; Hughes, M; Peto, R; Peto, T; Walker, A | 2 |
| Miyakuni, T; Sato, H; Shibamura, K; Shiino, T; Takebe, Y; Tomita, Y | 1 |
| Booss, J; Marra, CM | 1 |
| Allende, MC; Belloso, WH; Benetucci, JA; Cahn, PE; Davey, RT; Emery, S; Lane, HC; Lasala, MC; Law, MG; Lopardo, G; Losso, MH; Nelson, E; Salomon, H; Saracco, M | 1 |
| Beylot, J; Dabis, F; Dequae-Merchadou, L; Marimoutou, C; Mercié, P; Morlat, P; Neau, D; Pellegrin, I | 1 |
| Boschini, A; Calista, D | 1 |
| Bray, D; Clerici, M; Colombo, F; Dix, LP; Fusi, ML; Milazzo, F; Piconi, S; Rizzardini, G; Trabattoni, D | 1 |
| Fitzmaurice, GM; Ibrahim, J; Lipsitz, SR; Molenberghs, G | 1 |
| Carr, A; Chuah, J; Cooper, DA; Emery, S; French, M; Hoy, J; Hudson, J; Law, M; Sayer, D | 1 |
| Baker, CJ; Barroga, CF; Englund, JA; Fangon, MC; Palumbo, PE; Raskino, C; Spector, SA | 1 |
| James, IR; John, M; Mallal, SA; McKinnon, EJ; Moore, CB | 1 |
| Fujinaga, M; Holodniy, M; Schulte, M | 1 |
| Ahmed, PS; Bedard, J; Bowlin, TL; Chambers, P; Clarke, J; Kelly, LA; Rando, RF; Taylor, DL; Tyms, AS; Wood, LJ | 1 |
| Barzilai, A; Soen-Grisaru, G | 1 |
| Angarano, G; Bagnarelli, P; Balotta, C; Berlusconi, A; Clementi, M; Facchi, G; Galli, M; Lippi, M; Monno, L; Moroni, M; Riva, C; Rusconi, S; Violin, M | 1 |
| Andreotti, M; Binelli, A; Bucciardini, R; Floridia, M; Fragola, V; Galluzzo, MC; Giannini, G; Pirillo, MF; Ricciardulli, D; Tomino, C; Vella, S; Weimer, LE | 1 |
| Bellos, N; Eron, JJ; Esinhart, J; Grosso, R; Jemsek, J; Murphy, RL; Parenti, DM; Peterson, D; Pottage, J; Rashbaum, BC; Schoellkopf, N; Sepulveda, G; Stevens, M; Swindells, S | 1 |
| Badia, X; Benavides, A; Coma, A; López Lavid, C; Pinto, JL | 1 |
| García-Lerma, JG; Gerrish, PJ; Heneine, W; Qari, SH; Wright, AC | 1 |
| Cotton, DJ; Currier, JS; Grimes, J; Hammer, SM; Hughes, MD; Katzenstein, DA; Spino, C; Wofsy, CB | 1 |
| Albrecht, MA; Balfour, HH; Hammer, SM; Hughes, MD; Katzenstein, DA; Liou, SH; Murphy, R; Para, MF; Valdez, H | 1 |
| Belec, L; Costagliola, D; Kazatchkine, MD; Ledeine, JM; Mohammed, AS; Troccaz, M; Van, PN | 1 |
| Antiochos, BB; Meng, Q; Olivero, OA; Poirier, MC; Shi, X; Walker, DM; Walker, VE | 1 |
| Boers, PH; Gruters, RA; Guillon, C; Ly, TD; Osterhaus, AD; Schutten, M; van der Ende, ME | 1 |
| Cotton, MF; Pijnenburg, MW | 1 |
| Gates, ME; Gu, ML; Langford, G; Lockey, C; Long, Z; Otto, E; Powell, SK | 1 |
| Birch, C; Cunningham, AL; Dwyer, DE; Haddad, DN; Middleton, T; Saksena, NK | 1 |
| La Seta Catamancio, S; Parker, D; Rusconi, S; Sheridan, F | 1 |
| Baker, CJ; Brouwers, P; Englund, JA; Lifschitz, MC; McGrath, NM; Nichols, SL; Nozyce, M; Pearson, DA; Raskino, C | 1 |
| Andreotti, M; Bucciardini, R; Floridia, M; Fragola, V; Galluzzo, CM; Giannini, G; Marzi, M; Massella, M; Mirra, M; Pirillo, MF; Ricciardulli, D; Tomino, C; Vella, S; Weimer, LE; Wu, AW | 1 |
| Agy, M; Anderson, D; Bui, T; Finn, E; Herz, AM; Ho, RJ; Larsen, K; Morton, WR; Nosbisch, C; Schmidt, A; Sherbert, C; Unadkat, JD; Wang, XY | 1 |
| Fiore, TC; Tashima, KT | 1 |
| Davis, C; Heredia, A; Redfield, R | 1 |
| Fukuda, Y; Hayakawa, T; Hayashi, K; Katano, Y; Nakano, I; Takamatsu, J; Toyoda, H; Yokozaki, S | 1 |
| Fleury, H; Garrigue, I; Izopet, J; Massip, P; Montes, B; Pellegrin, I; Pellegrin, JL; Puel, J; Reynes, J; Segondy, M | 1 |
| Brown, T; Feingold, AR; Meislich, D; Rudy, BJ; Rutstein, RM | 1 |
| Alejo, A; García, ML; Palomares, JC; Perea, EJ; Romero, J; Terrero, E; Torres, MJ | 1 |
| Albrecht, M; Balfour, H; Hammer, S; Hughes, MD; Katzenstein, DA; Liou, SH; Murphy, R; Para, M | 1 |
| Bamberger, JD; Chambers, D; Chesney, M; Coates, TJ; Franses, K; Kahn, JO; Katz, MH; Martin, JN; Roland, ME | 1 |
| Amsden, G; Flaherty, J; Luke, D | 1 |
| Autran, B; Carcelain, G; Damond, F; Dehée, A; Delphin, N; Girard, PM; Jacomet, C; Mariot, P; Nicolas, JC; Rozenbaum, W; Saimot, AG; Schneider, V | 1 |
| Genka, I; Kikuchi, Y; Oka, S; Tachikawa, N; Teruya, K; Yamamoto, Y; Yasuoka, A; Yasuoka, C | 1 |
| Arendt, G; Hefter, H; Theisen, A; von Giesen, HJ | 1 |
| Arazo, P; Manero, FJ; Sesma, J | 1 |
| Mendelow, BV; Sanne, I; Smego, RA | 1 |
| Angelosante, W; Carneiro, M; Maneiro, P; Pérez, C; Sanchéz, A; Valleé, M | 1 |
| Chaisson, RE; Keruly, JC; Moore, RD | 1 |
| Caruz, A; Falgueras, T; Gatell, JM; Jiménez de Anta, MT; Leal, M; Lissen, E; Mallolas, J; Padró, S; Parra, R; Pumarola, T; Rey, C; Sánchez-Quijano, A; Soriano, E; Torres, Y; Vidal, C | 1 |
| Denereaz, N; Hirschel, B; Mermillod, B; Perrin, L; Yerly, S | 1 |
| Berry, S; Bozzette, SA; Duan, N; Kanouse, DE; Richman, DD | 1 |
| Hirsch, MS; Yeni, P | 1 |
| Foli, A; Lisziewicz, J; Lori, F; Maserati, R; Minoli, L; Tinelli, C | 1 |
| Caselli, D; Gabiano, C; Galli, L; Gattinara, GC; La Regina, A; Marchisio, P; Paga, C; Principi, N; Zuccotti, G | 1 |
| Charvier, A; Figueras, G; Hirschel, B; Perrin, L; Schockmel, GA; Yerly, S | 1 |
| Gazzard, BG; Moyle, GJ | 1 |
| Beltangady, M; Cross, A; Dolin, R; Dunkle, L; Gatell, J; Hammer, SM; Hughes, MD; Kahn, J; Katzenstein, DA; Montaner, JS; Pavia, A; Raboud, JM; Rae, S; Smaldone, L | 1 |
| Carr, A; Mallon, P; Morey, A; Thorburn, DR; Williams, D | 1 |
| Farley, J; Vink, P | 1 |
| Haas, GJ | 1 |
| Gilden, D | 1 |
| Parks, VE | 1 |
| Glick, ME | 1 |
| Poscher, M | 2 |
| Japour, AJ | 1 |
| Vella, S | 1 |
| James, JS | 7 |
| Levin, J | 1 |
| King, E | 1 |
| Torres, G | 3 |
| Smart, T | 4 |
| Mascolini, M | 3 |
| Bray, JM | 1 |
| Coombs, R; Cotton, D; Hammer, S; Saag, M; van der Horst, C | 1 |
| Cheng, B | 2 |
| Alcorn, K | 1 |
| Folkers, G | 1 |
| Grubman, S | 1 |
| Smart, T; Torres, G | 1 |
| Randall, P | 1 |
| Bowersox, J | 2 |
| Elperin, A; Sax, P | 1 |
| Falkenberg, J; Gilden, D; Torres, G | 1 |
| Doepel, L; Folkers, G | 1 |
| Boonprakong, L | 1 |
| MacDougall, DS | 1 |
| Cadman, J | 2 |
| Amaro, J; Bienvenu, L; Burel, F; Hofman, P; Hofman, V; Itchaï, C | 1 |
| Buranapraditkun, S; Cooper, DA; Kroon, ED; Kunanusont, C; Lange, JM; Pakker, N; Phanuphak, P; Ruxrungtham, K; Sonjai, A; Suwanagool, S; Tiengrim, S; Ubolyam, S; Ungsedhapand, C; Yimsuan, N | 1 |
| Beijnen, JH; Cooper, DA; Hall, D; Hoetelmans, RM; Lange, JM; Montaner, JS; Reiss, P; Veldkamp, AI; Vella, S; Weverling, GJ | 1 |
| Conway, B; Cooper, D; Curry, R; Hall, D; Harris, M; Lange, JM; Montaner, JS; Reiss, P; Robinson, P; Vella, S; Wainberg, MA | 1 |
| Corzo, JE; Gómez-Mateos , J; Lozano, F; Ramayo, E | 1 |
| Aiello, F; Armaroli, S; Bergamini, A; Bolacchi, F; Bongiovanni, B; Caccia, S; Campiani, G; Capozzi, M; Coletta, M; Fabbrini, M; Garofalo, A; Greco, G; Guiso, G; Maga, G; Marini, S; Morelli, E; Nacci, V; Novellino, E; Ramunno, A; Spadari, S; Ventura, L | 1 |
| Airoldi, M; Bertelli, D; Carosi, G; Moretti, F; Quiros-Roldan, E; Signorini, S; Torti, C | 1 |
| Angelini, E; Chêne, G; Clavel, F; Ferchal, F; Maillard, A; Molina, JM; Picard, V; Race, E | 1 |
| Cain, D; Clarke, JR; Erlwein, O; Frater, AJ; Grigg, AR; Hill, CL; McClure, MO; Patton, G; Rosenblum, LL | 1 |
| Bouchenafa, K; Burgard, M; Capitant, C; Delfraissy, JF; Gougeon, ML; Levy, Y; Liberman, I; Rouzioux, C; Taoufik, Y; Viard, JP | 1 |
| Chadapaud, S; Halfon, P; Hittinger, G; Khiri, H; Lafeuillade, A; Poggi, C | 1 |
| Kolata, G | 1 |
| Bernasconi, E; Boggian, K; Boubaker, K; Chave, JP; Egger, M; Flepp, M; Francioli, P; Furrer, H; Haensel, A; Hirschel, B; Opravil, M; Rickenbach, M; Sudre, P; Telenti, A | 1 |
| Blumoff, K; Garcia-Lerma, JG; Heneine, W; Nidtha, S; Weinstock, H | 1 |
| Altisent, C; Briones, C; Domingo, E; Mas, A; Pérez-Olmeda, M; Soriano, V | 1 |
| Borchard, C; Esser, S; Goos, M; Hengge, UR; Mirmohammadsadegh, A; Schröder, M | 1 |
| Alfaro-Martínez, J; Mellor-Pita, S; Suárez, E; Yebra-Bango, M | 1 |
| Delaporte, E; Malonga-Mouellet, G; Mansaray, H; Mavoungou, R; Mistoul, I; Peeters, M; Vergne, L | 1 |
| Bettendorf, D; Bucy, RP; Chan, E; Evans, T; Gonzalez, CJ; Landay, AL; Phair, JP; Schmitz, JL; Schnizlein-Bick, CT; Spritzler, J; Squires, KE | 1 |
| Blanquet, D; Hage, F; Hallard, M; Mathe, G; Morette, C; Pontiggia, P | 1 |
| Birkus, G; Cihlar, T; Greenwalt, DE; Hitchcock, MJ | 1 |
| Babiker, A; Darbyshire, J; Dunn, D; Hooker, M | 1 |
| Klinowska-Skupniewska, J; Prandota-Schoepp, A | 1 |
| Böckenholt, S; Evers, S; Frese, A; Frohne, L; Heese, C; Husstedt, IW; Rahmann, A; Reichelt, D | 1 |
| Baldwin, SA; Cass, CE; Loewen, SK; Ng, AM; Yao, SY; Young, JD | 1 |
| Brůcková, M; Linka, M; Reinis, M; Stanková, M; Vandasová, J | 1 |
| Meng, Q; O'Neill, JP; Su, T; Walker, VE | 1 |
| Domínguez Castellanos, A; Justo Alpañés, E; Orbea Ríos, L | 1 |
| Perronne, C | 1 |
| Flexner, C; Gandhi, R | 1 |
| Alesse, E; Boschini, A; De Simone, C; Famularo, G; Lucci, L; Marcellini, S; Moretti, S; Santini, G; Trinchieri, V | 1 |
| Aldamiz-Etxebarría, M; Andonegui Navarro, J | 1 |
| Brandi, G; Casabianca, A; Cerasi, A; Chiarantini, L; Fraternale, A; Magnani, M; Orlandi, C | 1 |
| Fan, B; Stewart, JT | 1 |
| Brandi, G; Casabianca, A; Chiarantini, L; Fraternale, A; Magnani, M; Orlandi, C; Silvestri, G | 1 |
| Bettendorf, DM; Christopherson, C; D'Aquila, RT; Hammer, SM; Katzenstein, DA; Lathey, JL; Tierney, C | 1 |
| Baldanti, F; Galloni, D; Gerna, G; Lilleri, D; Piccinini, G; Seminari, E | 1 |
| Graziadei, IW; Koch, RO; Maier, H; Romani, N; Vogel, W; Zangerle, R | 1 |
| Campos, SB; de Araujo, M; Magaldi, AJ; Rienzo, M; Seguro, AC; Seguro, FS | 1 |
| Aboulker, JP; Brun-Vézinet, F; Descamps, D; Flandre, P; Izopet, J; Joly, V; Meiffrédy, V; Tamalet, C | 1 |
| Oka, S; Teruya, K | 1 |
| Bacheler, L; Erickson-Viitanen, S; Gallagher, K; Garber, S; Geleziunas, R; Otto, MJ; Schinazi, RF; Shi, G; Wu, JT; Zhang, H | 1 |
| Andron, L; Asmuth, DM; Grady, JJ; Green, S; McKinsey, DS; Pollard, RB; Rossero, R | 1 |
| Harada, S; Kavlick, MF; Kosalaraksa, P; Matsumi, S; Mitsuya, H; Tsang, H | 1 |
| Bachiller Luque, P; de Luis Román, DA; Eiros Bouza, JM; Ortega Lafont, M; Ortiz de Lejarazu, R | 1 |
| Das, P | 1 |
| Lin, DY; Ying, Z | 1 |
| Chuenyam, T; Cooper, D; Emery, S; Lange, J; Phanuphak, P; Ruxrungtham, K; Sirivichayakul, S; Techasathit, W; Ubolyam, S; Ungsedhapand, C | 1 |
| Daniels, MJ; Robins, JM; Scharfstein, DO | 1 |
| Barber, RE; Lonergan, JT; Mathews, WC | 1 |
| Becker, MI; D'Aquila, RT; De Gruttola, V; Delapenha, R; Dubé, MP; Fischl, MA; Gedeon, L; Hirsch, MS; Merigan, TC; Murphy, RL; Pettinelli, C; Pollard, RB; Robbins, GK; Shafer, RW; Smeaton, LM; Snyder, SW; van der Horst, C; Vella, S | 1 |
| D'Aquila, RT; De Gruttola, V; Gripshover, BM; Haubrich, R; Hirsch, MS; Johnson, VA; Kaul, P; Martinez, AI; McCarty, SD; Merigan, TC; Morse, GD; Nokta, MA; Robbins, GK; Shafer, RW; Smeaton, LM; Snyder, SW; Swingle, M; Vella, S | 1 |
| Albert, J; Antonsson, L; Fenyö, EM; Karlsson, A; Karlsson, I; Leitner, T; Olde, B; Owman, C; Shi, Y | 1 |
| Casula, M; de Ronde, A; Goudsmit, J; Lange, JM; Reiss, P; Weverling, GJ | 1 |
| Baker, CJ; Colgrove, RC; Englund, JA; McKinney, R; Nikolic-Djokic, D; Palumbo, P; Raskino, C; Ross, LL; Vavro, C | 1 |
| Bishop, JB; Tice, RR; Witt, KL; Wolfe, GW | 2 |
| Agher, R; Ait-Mohand, H; Bricaire, F; Calvez, V; Costagliola, D; Duvivier, C; Ghosn, J; Katlama, C; Marcelin, AG; Myrto, A; Peytavin, G; Schneider, L | 1 |
| Boyle, BA | 1 |
| Burzykowski, T; Geys, H; Molenberghs, G; Tibaldi, F | 1 |
| Babiker, AG; Dunn, DT; Goodall, RL | 1 |
| Cardiello, P; Cooper, DA; Emery, S; Juengprasert, N; Kroon, ED; Lange, JM; Phanuphak, P; Ratanasuwan, W; Ruxrungtham, K; Siangphoe, U; Srasuebkul, P; Tongtalung, M; Ubolyam, S; Ungsedhapand, C | 1 |
| Beland, FA; Bishop, ME; Dobrovolsky, VN; Heflich, RH; Shaddock, JG; Von Tungeln, LS | 1 |
| Bates, M; Chappey, C; Clair, MS; Fisher, R; Lanier, ER; Parkin, N; Ross, L; Tisdale, M | 1 |
| Rosa, U; Sepkowitz, D; Smith, PR; Tripuraneni, NS; Weedon, J | 1 |
| Artuch, R; Fortuny, C; Jimenez, R; Muñoz-Almagro, C; Noguera, A; Pou, J; Sanchez, E; Vilaseca, MA | 1 |
| Auclair, M; Capeau, J; Caron, M; Kornprobst, M; Lagathu, C; Lombès, A; Walker, UA | 1 |
| Aarnoutse, RE; Burger, DM; Verweij-van Wissen, CP | 1 |
| Ambu, S; Bartolozzi, D; Boddi, V; Farese, A; Giuntini, R; Leoncini, F; Martinelli, C | 1 |
| Fahey, JL; Grossberg, SE; Johnston, DM; Kagan, J; Mildvan, D; Schock, BR; Spritzler, J | 1 |
| Cossarizza, A; Ferraresi, R; Galluzzi, L; Mussini, C; Nasi, M; Pinti, M; Prada, N; Salomoni, P; Troiano, L | 1 |
| Abraira, V; Antela, A; Casado, JL; Dronda, F; Gutiérrez, C; López, D; Moreno, A; Moreno, S; Pérez-Elías, MJ; Rodríguez, MA | 1 |
| Baker, SG; Fitzmaurice, GM; Freedman, LS; Kramer, BS | 1 |
| Britto, P; Capparelli, E; Cowles, MK; Fowler, MG; Husson, RN; Kovacs, A; McIntosh, K; Moye, J; Pitt, J; Rathore, MH | 1 |
| Götte, M; Kuritzkes, DR; Liang, F; Miranda, LR | 1 |
| Chêuc, G; Cotte, L; Debord, T; Decazes, JM; Ferchal, F; Journot, V; Madelaine, I; Molina, JM; Pellegrin, I; Rancinan, C; Sombardier, MN | 1 |
| Campanini, A; Cancellieri, C; Marani, M; Mastroianni, A; Vicini, C | 1 |
| Lewis, W | 1 |
| Alston-Smith, BL; Dubé, MP; Kitch, DW; Mulligan, K; Parker, RA | 1 |
| Alhassoon, OM; Brown, GG; Ellis, RJ; Gonzalez, R; Grant, I; Letendre, S; McCutchan, JA; Patterson, TL; Schweinsburg, BC; Taylor, MJ; Videen, JS | 1 |
| Engels, JW; Lazrek, HB; Rochdi, A; Taourirte, M; Vasseur, JJ | 1 |
| Bautista-Arredondo, S; Bertozzi, SM; Mane, A | 1 |
| Ballardin, M; Barale, R; Kotwal, GJ; Scarpato, R | 1 |
| Abrams, EJ; Gvetadze, R; Kline, MW; Rivadeneira, E; Weidle, PJ | 1 |
| Bampi, C; Bibillo, A; Darlix, JL; Divita, G; Gorelick, RJ; Le Grice, SF; Wendeler, M | 1 |
| Collier, AC; Lockhart, DW; Marra, CM; Rees, TS; Schouten, JT | 1 |
| Kiseleva, IaIu; Pliasunova, OA; Pokrovskaia, NV; Pokrovskiĭ, AG | 1 |
| Barberá Farré, JR; Beato Pérez, JL; Cuadra García-Tenorio, F; Geijo Martínez, MP; Maciá Martínez, MA; Marcos Sánchez, F; Martínez Alfaro, E; Moreno Mendaña, JM; Rodríguez Zapata, M; Sanz Moreno, J; Sanz Sanz, J; Solera Santos, J | 1 |
| Balestre, E; Boucher, S; Capdepont, S; Dabis, F; Dupon, M; Fleury, H; Masquelier, B; Thiébaut, R | 1 |
| Gray, G; Jivkov, B; Ledeine, JM; McIntyre, J; Reynolds, L; Schnittman, S; Violari, A | 1 |
| Bacheler, L; Koontz, D; Mellors, JW; Parikh, UM | 1 |
| Alvarez, ML; Cihlar, T; Cordobilla, B; Domingo, JC; Domingo, P; Giralt, M; Guallar, J; López-Dupla, M; Sánchez de la Rosa, R; Saumoy, M; Torres, F; Vidal, F; Villarroya, F | 1 |
| Engchanil, C; Kosalaraksa, P; Lulitanond, V; Lumbiganon, P; Pongjunyakul, P; Suwan-apichon, O; Thuennadee, R; Tungsawad, S | 1 |
| Kilby, M; McDonald, JM; Pan, G | 1 |
| Amellal, B; Calvez, V; Castro, ND; Chêne, G; Cotte, L; Gourlain, K; Journot, V; Molina, JM; Palmer, P; Pédrono, G; Rancinan, C | 1 |
| López, G; Omiste, T; Ramos, C; Ruiz, M | 1 |
| Teruya, K | 1 |
| Dubé, MP; Grinspoon, SK; Mulligan, K; Parker, RA; Robbins, GK; Roubenoff, R; Tebas, P | 1 |
| Johnston, E; Kassaye, SG; Katzenstein, DA; Shulman, NS; Winters, MA | 1 |
| Abdoulaye, D; André, C; André, E; Bernard, L; Sandrine, PF; Sylvie, A | 1 |
| Dubé, MP; Grinspoon, SK; Komarow, L; Mulligan, K; Parker, RA; Robbins, GK; Roubenoff, R; Tebas, P | 1 |
| Bussmann, H; DeGruttola, V; Essex, M; Gaseitsiwe, S; Marlink, RG; Moyo, S; Musonda, R; Novitsky, V; Thomas, A; Van Widenfelt, E; Wester, CW | 1 |
| Enejosa, J; Hinkle, J; Kearney, BP; Ramanathan, S; Shen, G | 1 |
| Doerries, R; Drechsler, H; Gass, A; Hardmeier, M; Kuhle, J; Mehling, M; Ruegg, S | 1 |
| de Andrade, HH; de Castro Pereira, K; Guimarães, NN; Lehmann, M; Silva Cunha, K | 1 |
| Arenas-Pinto, A; Bhaskaran, K; Dunn, D; Weller, IV | 1 |
| Basseila, GB; Bokilo, AD; Dokekias, AE; Galiba, FO; Malanda, F; Nsitou, MB; Ntsimba, P | 1 |
| Ahmadou Ahidjo, B; Becker, P; Dusé, AG; Marais, E; Veale, R | 1 |
| Cao, YL; Guo, Y | 1 |
| Braude, J; Galambos, MR; Joelson, D; Johnson, M; Rubin, RA; Saifee, S; Sellers, M; Shrestha, R | 1 |
| Bentata, M; Chêne, G; Collin, F; Garré, M; Goujard, C; Lafaurie, M; Leport, C; Levy, Y; Molina, JM | 1 |
| Angels Ribas, M; Asensi, V; Berenguer, J; Domingo, P; Gimeno, JL; González, J; Miralles, P; Pedrol, E; Pérez-Molina, JA; Ribera, E; Santamaría, JM; Santos, J; Terrón, JA | 1 |
| Berrisford, AE; Boulle, AM; Jaspan, HB | 1 |
| Antonelli, A; Casabianca, A; Fraternale, A; Magnani, M; Orlandi, C; Paoletti, MF; Pierigè, F; Rossi, L; Schiavano, GF; Serafini, S; Sfara, C | 1 |
| Ishikawa, H; Kaneko, S; Katayama, M; Matsuda, Y; Miyaji, K; Suzuki, K; Takamatsu, K | 1 |
| Afonso, AO; Cunha, SM; Lemey, P; Machado, ES; Nissley, DV; Oliveira, RH; Soares, MA | 1 |
| Bouic, PJ; Pretorius, E | 1 |
| Bussmann, H; Degruttola, V; Essex, M; Gaolathe, T; Makhema, J; Marlink, RG; Mawoko, N; Mine, M; Moffat, H; Moyo, S; Musonda, R; Muzenda, T; Ndwapi, N; Novitsky, V; Okezie, R; Thomas, A; Wester, CW; Widenfelt, E | 1 |
| Carter, MM; Hardy, AW; Kajon, AE; McCash, CL; Olivero, OA; Poirier, MC; Shearer, GM; Swenberg, JA; Torres, SM; Upton, PB; Walker, DM; Walker, VE | 1 |
| Heckl-Ostreicher, B; Lebrecht, D; Reuss, FU; Venhoff, AC; Venhoff, N; Walker, UA; Wehr, R | 1 |
| Fox, MP; Ive, P; Long, L; Maskew, M; Sanne, I | 1 |
| Cooper, V; Fisher, M; Gellaitry, G; Horne, R; Lange, AC; Vrijens, B; White, D | 1 |
| Achalapong, J; Ariyadej, S; Chotivanich, N; Collins, IJ; Cressey, TR; Frenkel, LM; Hemvuttiphan, J; Jarupanich, T; Jourdain, G; Kanchana, S; Kanjanasing, A; Kengsakul, K; Koetsawang, S; Lallemant, M; Le Coeur, S; Liampongsabuddhi, P; McIntosh, K; Ngo-Giang-Huong, N; Pornkitprasarn, W; Ratanakosol, J; Sabsanong, P; Sittipiyasakul, V; Sukhumanant, T; Traisaithit, P; Van Dyke, RB; Wannapira, W; Winiyakul, N | 1 |
| Cotton, MF; Rabie, H; van Zyl, GU | 1 |
| Fitzmaurice, GM; Ibrahim, JG; Lipsitz, SR; Molenberghs, G; Sinha, D; Troxel, AB | 1 |
| Aguiar, CV; Braga Neto, MB; Brito, GA; Guerrant, RL; Lima, AA; Maciel, JG; Oliveira, BM; Oriá, RB; Sevilleja, JE; Warren, CA | 1 |
| Cook, A; Divi, RL; Einem, TL; Fletcher, SL; Harbaugh, JW; Harbaugh, SW; Kuo, MM; Nagashima, K; Poirier, MC; Shockley, ME; St Claire, MC | 1 |
| Feng, Y; Huang, J; Huang, Y; Liao, L; Liu, S; Ma, L; Qu, S; Shao, Y; Sun, J; Xing, H; Yu, X; Yuan, L | 1 |
| Dhlomo, S; Emery, S; Grandits, G; Khabo, P; Khanyile, T; Komati, S; Magongoa, D; Naidoo, LC; Neaton, JD; Polis, M; Qolohle, D; Ratsela, A | 1 |
| Delaporte, E; Diouf, A; Etard, JF; Girard, PM; Landman, R; Laurent, C; Molinari, N; Ndoye, I; Ngom Guèye, NF; Sow, PS; Tchatchueng Mbougua, JB | 1 |
| Du, L; Jin, Y; Li, M; Tong, L; Xin, R | 1 |
| Arenas-Pinto, A; Bolhaar, M; Bradman, N; Ekong, R; Grant, A; Ingram, C; Karstaedt, A; Reiss, P; Telisinghe, L; Weber, R; Weller, I | 1 |
| Aschacher, T; Bergmann, M; Bernhard, D; Holzmann, K; Käser, L; Sampl, S; Spittler, A | 1 |
| Lovett, ST; Seier, T; Zeiger, DM; Zilberberg, G | 1 |
| Côté, HC; Hukezalie, KR; Thumati, NR; Wong, JM | 1 |
| Cunha, KS; de Andrade, HH; Dihl, RR; Guimarães, NN; Lehmann, M; Silva, CJ | 1 |
| Gabrielian, A; Holland, GN; Kukuyev, A; MacCumber, MM; Mitsuyasu, R; Sarraf, D | 1 |
| Campbell, GR; Pallack, ZT; Spector, SA | 1 |
| Chen, D; Chen, X; Ding, W; Gao, Z; Jin, R; Qiao, L; Song, F; Yang, S; Zhang, Y | 1 |
| Gibbons, AT; Liu, Y; Mitchell, JB; Nguyen, P; Poirier, MC; Shim, E | 1 |
| Berendes, S; Campbell, TB; Cardoso, SW; Christian, P; Gupta, A; Gupte, N; Kanyama, C; Lama, JR; Mwelase, N; Pillay, S; Riviere, C; Samaneka, W; Semba, RD; Shivakoti, R; Sugandhavesa, P; Tang, AM; Yang, WT | 1 |
| Gilks, CF; Kikaire, B; Kiwuwa-Muyingo, S; Levin, JB; Mambule, I; Musana, H; Musoro, G; Walker, AS | 1 |
| Brul, S; de Boer, R; De Vos, WH; Manders, EM; Smith, RL; van der Spek, H | 1 |
| Chen, D; Chen, J; Guo, H; Liang, Q; Qiao, L; Wang, B; Wu, J; Xu, B; Yang, S; Zhang, H; Zhang, Y | 1 |
| Avi, R; Huik, K; Jõgeda, EL; Kallas, E; Karki, T; Lutsar, I; Margus, T; Pauskar, M | 1 |
| Arnold, E; Das, K; Martinez, SE | 1 |
| Abad-Carrillo, MA; Álvarez-Ríos, AI; Bernal-Morell, E; Genebat, M; González-García, J; Herrero-Fernández, I; Leal, M; Montero, M; Pacheco, YM; Pulido, F; Rosado-Sánchez, I; Ruiz-Mateos, E; Vidal, F | 1 |
| Blanche, S; Clavel, J; Dollfus, C; Faye, A; Goujon, S; Hleyhel, M; Mandelbrot, L; Sibiude, J; Tubiana, R; Warszawski, J | 1 |
| Clifford, M; Czaplewski, L; Dowson, CG; Garner, RC; Hind, CK; Jackson, T; Sutton, JM | 1 |
| Fernández, S; Ferrero, M; Martín-Nieves, V; Sanghvi, YS | 1 |
| Ge, Z; Mashiach, D; Miller, JH; Shin, J; Singh, S; Yaramada, L | 1 |
103 review(s) available for zidovudine and didanosine
| Article | Year |
|---|---|
Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.
Topics: Amino Acid Sequence; Anti-HIV Agents; HIV-1; Models, Biological; Models, Chemical; Molecular Sequence Data; National Institutes of Health (U.S.); Retrospective Studies; United States; Virus Replication | 2001 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Polypharmacology in HIV inhibition: can a drug with simultaneous action against two relevant targets be an alternative to combination therapy?
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; HIV; Humans; Microbial Sensitivity Tests; Molecular Structure; Polypharmacology | 2018 |
[New therapeutic trends in AIDS].
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Deoxyadenosines; Didanosine; Dideoxynucleosides; Humans; Poly I-C; Poly U; Randomized Controlled Trials as Topic; Ribavirin; RNA, Double-Stranded; Zalcitabine; Zidovudine | 1992 |
New developments in antiretroviral drug therapy for HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Combinations; Drug Therapy, Combination; Gene Products, tat; HIV Infections; HIV-1; Humans; Protease Inhibitors; tat Gene Products, Human Immunodeficiency Virus; Zalcitabine; Zidovudine | 1992 |
Anti-human immunodeficiency virus therapeutics: now and the future.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Dideoxynucleosides; HIV; HIV-1; Humans; Trichosanthin; Zalcitabine; Zidovudine | 1992 |
The use of nucleoside analogues in the treatment of HIV-infected children.
Topics: Child; Child, Preschool; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Infant; Infant, Newborn; Zalcitabine; Zidovudine | 1992 |
Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: combination therapy.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Evaluation; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Zalcitabine; Zidovudine | 1992 |
Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: adverse effects.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Zalcitabine; Zidovudine | 1992 |
Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: monotherapy.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Time Factors; Zalcitabine; Zidovudine | 1992 |
HIV disease: therapy, related systemic and oral conditions--an update.
Topics: Acquired Immunodeficiency Syndrome; Bacterial Infections; Didanosine; HIV Infections; Humans; Mouth Diseases; Mycoses; Sarcoma, Kaposi; Virus Diseases; Zalcitabine; Zidovudine | 1992 |
Primary care for HIV infection.
Topics: CD4-Positive T-Lymphocytes; Clinical Protocols; Clinical Trials as Topic; Didanosine; Drug Monitoring; HIV Infections; HIV-1; Humans; Immunization; Leukocyte Count; Pneumonia, Pneumocystis; Primary Health Care; Sex Counseling; Zidovudine | 1992 |
Didanosine.
Topics: Acquired Immunodeficiency Syndrome; Adult; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Clinical Trials as Topic; Didanosine; Drug Evaluation; Drug Interactions; Female; Humans; Leukocyte Count; Male; Time Factors; Zidovudine | 1992 |
Current status of therapy for human immunodeficiency virus type 1.
Topics: CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Didanosine; Drug Resistance; HIV Infections; HIV Seropositivity; HIV-1; Humans; T-Lymphocytes, Helper-Inducer; Zalcitabine; Zidovudine | 1992 |
[Anti-HIV treatment, today and in the near future].
Topics: Antiviral Agents; Didanosine; Dideoxynucleosides; DNA, Viral; Drug Therapy, Combination; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Stavudine; Transcription, Genetic; Zalcitabine; Zidovudine | 1992 |
[Treatments of human immunodeficiency virus infection. Current developments].
Topics: Acquired Immunodeficiency Syndrome; Didanosine; HIV; HIV Infections; Humans; Zalcitabine; Zidovudine | 1991 |
New developments in dideoxynucleoside antiretroviral therapy for HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Dideoxynucleosides; HIV Infections; Humans; Zalcitabine; Zidovudine | 1991 |
HIV/AIDS pathogenesis and treatment: new twists and turns.
Topics: Acquired Immunodeficiency Syndrome; CD4-Positive T-Lymphocytes; Didanosine; Humans; Lymphocyte Depletion; Trichosanthin; Zalcitabine; Zidovudine | 1991 |
Chemotherapy of human immunodeficiency virus infections: current practice and future prospects.
Topics: Animals; Antiviral Agents; Didanosine; DNA Nucleotidyltransferases; DNA Replication; Drug Therapy, Combination; Endopeptidases; HIV Infections; HIV-1; Humans; Integrases; RNA-Directed DNA Polymerase; Virus Replication; Zalcitabine; Zidovudine | 1990 |
Targeted therapy of human immunodeficiency virus-related disease.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Antiviral Agents; CD4 Antigens; Didanosine; Dideoxynucleosides; Dipyridamole; Drug Synergism; Gene Expression Regulation, Viral; Genes, nef; Genes, rev; Genes, tat; HIV; HIV Protease; Interferon Type I; Organophosphonates; RNA-Directed DNA Polymerase; Stavudine; Transcription, Genetic; Zalcitabine; Zidovudine | 1991 |
Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Resistance; HIV; HIV Infections; Humans; Lymphoma, Non-Hodgkin; Retroviridae; Reverse Transcriptase Inhibitors; T-Lymphocytes, Helper-Inducer; Virus Replication; Zalcitabine; Zidovudine | 1991 |
Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Child; Didanosine; Female; Foscarnet; HIV Infections; Humans; Phosphonoacetic Acid; Pregnancy; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1991 |
Preclinical evaluation of human hematolymphoid function in the SCID-hu mouse.
Topics: Acquired Immunodeficiency Syndrome; Animals; Bone Marrow Transplantation; Didanosine; Hematopoiesis; HIV; Humans; Liver Transplantation; Lymph Nodes; Mice; Mice, SCID; Models, Biological; Thymus Gland; Transplantation, Heterologous; Zidovudine | 1991 |
Treatment of AIDS with combinations of antiretroviral agents.
Topics: Acquired Immunodeficiency Syndrome; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Interferon Type I; Recombinant Proteins; Zalcitabine; Zidovudine | 1991 |
Update on reverse transcriptase inhibitors in HIV disease.
Topics: Acquired Immunodeficiency Syndrome; Clinical Trials as Topic; Didanosine; Humans; Prognosis; Reverse Transcriptase Inhibitors; Risk Factors; Zalcitabine; Zidovudine | 1993 |
[Reverse transcriptase inhibitors as anti-HIV agents].
Topics: Amino Acid Sequence; Antiviral Agents; Didanosine; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Protein Conformation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 1993 |
Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review.
Topics: Antiviral Agents; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1994 |
Pharmacologic therapy for human immunodeficiency virus infection: a review.
Topics: Antiviral Agents; Didanosine; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; Humans; Reverse Transcriptase Inhibitors; Stavudine; Structure-Activity Relationship; Zidovudine | 1994 |
Combination therapy for infection due to human immunodeficiency virus type 1.
Topics: Acyclovir; Antiviral Agents; CD4 Antigens; Clinical Trials as Topic; Combined Modality Therapy; Didanosine; Drug Therapy, Combination; Foscarnet; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1994 |
Survival effects of ZDV, ddI, and ddC in patients with CD4 < or = 50 cells/mm3.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Didanosine; Double-Blind Method; HIV Infections; Humans; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Zalcitabine; Zidovudine | 1995 |
Mitochondrial toxicity of antiviral drugs.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antiviral Agents; Arabinofuranosyluracil; Didanosine; DNA-Directed DNA Polymerase; DNA, Mitochondrial; Humans; Mitochondria; Zalcitabine; Zidovudine | 1995 |
Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.
Topics: Aging; Antineoplastic Agents; Antiviral Agents; Didanosine; Drug Interactions; Guidelines as Topic; HIV Infections; Humans; Phosphorylation; Racial Groups; Sex Characteristics; Stavudine; Zalcitabine; Zidovudine | 1995 |
An approach to antiretroviral treatment of HIV disease. Nucleoside monotherapy.
Topics: Antiviral Agents; Didanosine; HIV Infections; HIV-1; Humans; Lamivudine; Nucleosides; Stavudine; Zalcitabine; Zidovudine | 1995 |
Human immunodeficiency virus infection in children.
Topics: Adolescent; AIDS-Related Opportunistic Infections; Child; Child, Preschool; Dapsone; Didanosine; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Pentamidine; Pneumonia, Pneumocystis; Pregnancy; Pregnancy Complications, Infectious; Recurrence; Stavudine; Trimethoprim, Sulfamethoxazole Drug Combination; Zalcitabine; Zidovudine | 1995 |
Clinical pharmacology of zidovudine and other 2',3'-dideoxynucleoside analogues.
Topics: Acquired Immunodeficiency Syndrome; Adult; Child; Didanosine; Dideoxynucleosides; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Interferons; Needlestick Injuries; Sarcoma, Kaposi; Zalcitabine; Zidovudine | 1993 |
[Anti-HIV therapy (1987-1994): from nothing to confusion].
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Time Factors; Zalcitabine; Zidovudine | 1995 |
Controversies in anti-retroviral therapy of adults.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; AIDS-Related Complex; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Drug Tolerance; HIV Infections; HIV-1; Humans; Zalcitabine; Zidovudine | 1995 |
Therapy of pediatric AIDS.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Child; Didanosine; Humans; Immunization, Passive; Infectious Disease Transmission, Vertical; Vaccination; Zidovudine | 1995 |
Antiretroviral therapy for children.
Topics: Acquired Immunodeficiency Syndrome; Adult; Child; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Didanosine; DNA, Viral; Drug Resistance, Microbial; HIV-1; Humans; Immunity, Cellular; Virus Replication; Zalcitabine; Zidovudine | 1994 |
HIV therapy advances. Pediatric antiretroviral choices.
Topics: Body Weight; Clinical Trials as Topic; Didanosine; Female; Growth; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Treatment Failure; Zalcitabine; Zidovudine | 1994 |
Future treatment strategies in HIV infection.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Antiviral Agents; Biomarkers; CD4 Lymphocyte Count; Didanosine; Forecasting; HIV Infections; Humans; Zalcitabine; Zidovudine | 1994 |
Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1.
Topics: Clinical Trials as Topic; Didanosine; Dideoxynucleosides; Drug Resistance; HIV Infections; HIV-1; Humans; Zidovudine | 1995 |
Clinical pharmacokinetics of nucleoside antiretroviral agents.
Topics: Animals; Didanosine; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |
Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-Infected Patients.
Topics: Adult; CD4-Positive T-Lymphocytes; Clinical Trials as Topic; Didanosine; Dideoxynucleosides; Drug Resistance; Guidelines as Topic; HIV Infections; Humans; Leukocyte Count; Zalcitabine; Zidovudine | 1993 |
Management of antiretroviral drug therapy in human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; HIV-1; Humans; Retroviridae Infections; Zalcitabine; Zidovudine | 1994 |
Antiretroviral therapy for human immunodeficiency virus infection: hope and despair.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Humans; In Vitro Techniques; Zalcitabine; Zidovudine | 1994 |
[Antiretroviral therapy. Current status and perspectives].
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Stavudine; Zalcitabine; Zidovudine | 1994 |
Adverse effects and drug interactions of clinical importance with antiviral drugs.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Amantadine; Antiviral Agents; Didanosine; Drug Interactions; Foscarnet; Ganciclovir; Humans; Interferon-alpha; Ribavirin; Rimantadine; Vidarabine; Zalcitabine; Zidovudine | 1994 |
Managing occupational risks in the dental office: HIV and the dental professional.
Topics: Blood-Borne Pathogens; Dental Staff; Didanosine; HIV Infections; HIV Seropositivity; Humans; Needlestick Injuries; Occupational Exposure; Risk Factors; Universal Precautions; Zidovudine | 1994 |
Perspectives on the use of antiretroviral drugs in the treatment of HIV infection.
Topics: Didanosine; Dideoxynucleosides; Drug Administration Schedule; HIV Infections; Humans; Stavudine; Zalcitabine; Zidovudine | 1994 |
Effect of HIV treatment on cognition, behavior, and emotion.
Topics: Acquired Immunodeficiency Syndrome; Cognition Disorders; Cycloserine; Didanosine; Humans; Mental Disorders; Mood Disorders; Stavudine; Zidovudine | 1994 |
[Therapy of HIV infection with nucleoside analogs].
Topics: Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Nucleosides; Zalcitabine; Zidovudine | 1993 |
Pharmacodynamics of antiretroviral chemotherapy.
Topics: Antiviral Agents; Biological Availability; CD4 Antigens; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dextran Sulfate; Didanosine; HIV Core Protein p24; HIV Infections; Humans; T-Lymphocytes; Zidovudine | 1993 |
[Dideoxynucleoside therapy in acquired immunodeficiency syndrome].
Topics: Acquired Immunodeficiency Syndrome; Clinical Trials as Topic; Didanosine; Dideoxynucleosides; Humans; Zidovudine | 1993 |
[What is known about the cellular and molecular pharmacodynamics of nucleosides?].
Topics: Didanosine; Dideoxyadenosine; Dideoxynucleosides; DNA-Directed DNA Polymerase; Drug Resistance, Microbial; Hematopoietic Stem Cells; HIV-1; Humans; In Vitro Techniques; Zidovudine | 1993 |
[Is resistance of human immunodeficiency viruses (HIV) to nucleoside analogs an indication for their combined use?].
Topics: Acyclovir; Didanosine; Drug Synergism; Drug Therapy, Combination; Female; Foscarnet; HIV-1; Humans; In Vitro Techniques; Male; Ribavirin; Zalcitabine; Zidovudine | 1993 |
Roundtable discussion: management issues in didanosine therapy.
Topics: Didanosine; Dose-Response Relationship, Drug; Health Personnel; HIV Infections; Humans; Occupational Exposure; Pancreatitis; Peripheral Nervous System Diseases; Zidovudine | 1993 |
Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet).
Topics: Acquired Immunodeficiency Syndrome; Cohort Studies; Cytomegalovirus Infections; Didanosine; Drug Tolerance; Follow-Up Studies; Foscarnet; Ganciclovir; Humans; Infusions, Intravenous; Injections, Intravenous; Retinitis; Survival Rate; Time Factors; Zidovudine | 1993 |
Therapy for human immunodeficiency virus infection.
Topics: Didanosine; Drug Resistance; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Protease Inhibitors; Zalcitabine; Zidovudine | 1993 |
Current use of anti-HIV drugs in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1993 |
Current management of HIV infection in children.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Child; Child, Preschool; Didanosine; Drug Monitoring; HIV Infections; Humans; Infant; Infant, Newborn; Zidovudine | 1993 |
Arguments against the chemoprophylactic use of zidovudine following occupational exposure to the human immunodeficiency virus.
Topics: Didanosine; Health Personnel; HIV Infections; Humans; Occupational Exposure; Zidovudine | 1993 |
Antiretroviral therapy of human immunodeficiency virus type-1 (HIV-1) infection.
Topics: Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1995 |
Studies of zidovudine in combination with didanosine and zalcitabine.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Safety; Zalcitabine; Zidovudine | 1995 |
Managing HIV. Part 4: Primary therapy. 4.1 Antiretroviral therapies for HIV.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Multicenter Studies as Topic; Zalcitabine; Zidovudine | 1996 |
Ups and downs--and ups in the antiviral therapy of HIV infection.
Topics: AIDS-Related Complex; AIDS-Related Opportunistic Infections; Antiviral Agents; Didanosine; HIV Infections; Humans; Quality of Life; Randomized Controlled Trials as Topic; Zidovudine | 1996 |
The role of antiretroviral therapy in the management of HIV infection in women.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Treatment Outcome; Zidovudine | 1996 |
Clinical toxicity of antiretroviral nucleoside analogs.
Topics: Animals; Antiviral Agents; Didanosine; Humans; Lamivudine; Mitochondria; Nucleosides; Stavudine; Zalcitabine; Zidovudine | 1996 |
Guide to major clinical trials of antiretroviral therapy administered to patients infected with human immunodeficiency virus.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Meta-Analysis as Topic; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1996 |
Pediatric human immunodeficiency virus infection.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Central Nervous System Diseases; Child; Child, Preschool; Cytomegalovirus Infections; Didanosine; Disease Transmission, Infectious; Eye Diseases; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Herpes Simplex; Herpes Zoster; HIV Infections; Humans; Incidence; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Kidney Diseases; Male; Neoplasms; Pregnancy; Prevalence; Risk Factors; Sexual Behavior; Skin Diseases; Transfusion Reaction; Zidovudine | 1996 |
Pediatric HIV infection: a primer for pharmacists.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Didanosine; Female; HIV Infections; Humans; Infant; Infant, Newborn; Male; Pharmacists; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
[Initial anti-retroviral treatment (therapeutic approach to patients without previous treatment)].
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1996 |
[Anti-retroviral treatment. Approach to previously treated patients].
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1996 |
[Nucleoside analogs inhibiting reverse transcriptase: use in adult patient with HIV infection].
Topics: Adult; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1996 |
[Anti-retroviral treatment. Treatment modification: toxicity management].
Topics: Anti-HIV Agents; Didanosine; Drug Eruptions; Drug Therapy, Combination; Gastrointestinal Diseases; Hematologic Diseases; HIV Infections; Humans; Muscular Diseases; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
[Antiretroviral treatment. Present and future of the combinations].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; HIV-1; Humans; Zalcitabine; Zidovudine | 1996 |
Antiretroviral therapy for pregnant women.
Topics: Anti-HIV Agents; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Saquinavir; Zalcitabine; Zidovudine | 1997 |
Antiretroviral therapy: a guide to the most important trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1997 |
[Infectious diseases that require world-wide control--HIV infections].
Topics: Anti-HIV Agents; Communicable Disease Control; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; International Cooperation; Protease Inhibitors; Reverse Transcriptase Inhibitors; Zidovudine | 1997 |
[Antiretroviral treatment in human immunodeficiency virus infection].
Topics: Antiviral Agents; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Ritonavir; Saquinavir; Stavudine; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1997 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Toxicity of antiretroviral agents.
Topics: Anti-HIV Agents; Didanosine; Health Personnel; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Occupational Exposure; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1997 |
Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management.
Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Peripheral Nervous System Diseases; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1998 |
[Vasculitis associated with antiviral vaccines and antiviral agents].
Topics: Acyclovir; Antiviral Agents; Didanosine; Hepatitis B Vaccines; Humans; Interferons; Vasculitis; Viral Vaccines; Zidovudine | 1999 |
[Response of fetal macrophages in the placenta of pregnant HIV-positive patients with and without antiretroviral treatment].
Topics: Antiviral Agents; Didanosine; Female; HIV Infections; HIV Seropositivity; Humans; Macrophages; Pregnancy; Pregnancy Complications, Infectious; Retroviridae; Zidovudine | 1999 |
Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Didanosine; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Randomized Controlled Trials as Topic; Survival Rate; Time Factors; Zalcitabine; Zidovudine | 1999 |
Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Child, Preschool; Data Collection; Didanosine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Polypharmacy; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Zalcitabine; Zidovudine | 1999 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
Stavudine plus a non-thymidine nucleoside reverse transcriptase inhibitor as a backbone for highly active antiretroviral therapy.
Topics: Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Retroviridae; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 1998 |
Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team.
Topics: Adult; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Multivariate Analysis; Nevirapine; Proportional Hazards Models; Viral Load; Zidovudine | 1999 |
Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 2000 |
Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 2000 |
Antiretroviral agents.
Topics: Acyclovir; Animals; Antiviral Agents; Carcinogens; Didanosine; Disease Models, Animal; Evidence-Based Medicine; Humans; Intestinal Absorption; Neoplasms; Risk Factors; Tissue Distribution; Zalcitabine; Zidovudine | 2000 |
Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem?
Topics: Africa; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; MEDLINE; Treatment Outcome; Viral Load; Zidovudine | 2001 |
The role of didanosine in the management of HIV-1 infection.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV-1; Humans; Zidovudine | 1997 |
Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals.
Topics: AIDS Dementia Complex; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; HIV Infections; Humans; Incidence; Randomized Controlled Trials as Topic; Zidovudine | 1997 |
Pediatric antiretroviral therapy: from research to practice.
Topics: Adolescent; Age Factors; Anti-HIV Agents; Child; Child, Preschool; Didanosine; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Viral Load; Virus Replication; Zidovudine | 1996 |
[Treatment of chronic hepatitis C in patients coinfected with HIV: tolerability, drug interactions, therapeutic indications].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Didanosine; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Life Style; Mitochondria; Monitoring, Physiologic; Multicenter Studies as Topic; Patient Selection; Randomized Controlled Trials as Topic; Retrospective Studies; Reverse Transcriptase Inhibitors; Ribavirin; Stavudine; Time Factors; Viral Load; Zidovudine | 2002 |
[Antiretrovirals].
Topics: Acidosis, Lactic; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Hemophilia A; Hemorrhage; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Indinavir; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2003 |
The continuing evolution of HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Monitoring; Emtricitabine; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Stavudine; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Prognostic factors in lactic acidosis syndrome caused by nucleoside reverse transcriptase inhibitors: report of eight cases and review of the literature.
Topics: Acidosis, Lactic; Adult; Didanosine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; New York; Reverse Transcriptase Inhibitors; Stavudine; Syndrome; Zidovudine | 2004 |
Nucleoside reverse transcriptase inhibitors, mitochondrial DNA and AIDS therapy.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; DNA Replication; DNA, Mitochondrial; Humans; Lamivudine; Mitochondria; Nucleosides; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2005 |
[Antiretrovirals].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Prescriptions; Drug Therapy, Combination; Humans; Lopinavir; Protease Inhibitors; Pyrimidinones; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2007 |
212 trial(s) available for zidovudine and didanosine
| Article | Year |
|---|---|
A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; CD4-Positive T-Lymphocytes; Didanosine; Double-Blind Method; Female; HIV Core Protein p24; HIV Infections; Humans; Leukocyte Count; Male; Patient Compliance; Survival Rate; Zidovudine | 1992 |
Didanosine for zidovudine-intolerant patients with HIV disease.
Topics: Didanosine; Europe; HIV Infections; HIV-1; Humans; Survival Rate; Zidovudine | 1992 |
Continued zidovudine or didanosine for human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Humans; Patient Dropouts; Zidovudine | 1992 |
Continued zidovudine or didanosine for human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Humans; Zidovudine | 1992 |
Effects of therapy with didanosine on hematologic parameters in patients with advanced human immunodeficiency virus disease.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Complex; CD4 Antigens; Didanosine; Female; Granulocytes; Hemoglobins; HIV Seropositivity; Humans; Leukocyte Count; Male; Platelet Count; T-Lymphocyte Subsets; Time Factors; Zidovudine | 1992 |
Nucleoside therapy for HIV infection--some answers, many questions.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Didanosine; HIV Infections; Humans; Zidovudine | 1992 |
Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; AIDS-Related Complex; Didanosine; Drug Evaluation; Female; Hemoglobins; Humans; Hypocalcemia; Male; Pancreatitis; Peripheral Nervous System Diseases; Zidovudine | 1991 |
Chemotherapy of human immunodeficiency virus infections: current practice and future prospects.
Topics: Animals; Antiviral Agents; Didanosine; DNA Nucleotidyltransferases; DNA Replication; Drug Therapy, Combination; Endopeptidases; HIV Infections; HIV-1; Humans; Integrases; RNA-Directed DNA Polymerase; Virus Replication; Zalcitabine; Zidovudine | 1990 |
Retinal toxicity in human immunodeficiency virus-infected children treated with 2',3'-dideoxyinosine.
Topics: Atrophy; Child; Child, Preschool; Didanosine; Drug Evaluation; Electrooculography; Electroretinography; Female; Follow-Up Studies; Fundus Oculi; HIV Infections; HIV-1; Humans; Male; Pigment Epithelium of Eye; Prospective Studies; Retina; Retinal Diseases; Zidovudine | 1992 |
HIV-seropositive thrombocytopenia: the action of zidovudine.
Topics: Adult; Didanosine; Female; HIV Seropositivity; Humans; Male; Middle Aged; Platelet Count; Platelet Glycoprotein GPIb-IX Complex; Platelet Membrane Glycoproteins; Thrombocytopenia; Zidovudine | 1991 |
Treatment of AIDS with combinations of antiretroviral agents.
Topics: Acquired Immunodeficiency Syndrome; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Interferon Type I; Recombinant Proteins; Zalcitabine; Zidovudine | 1991 |
New drugs being tested for better AIDS treatment.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Humans; Zidovudine | 1991 |
Effects of antiretroviral dideoxynucleosides on polymorphonuclear leukocyte function.
Topics: Cell Survival; Chemotaxis, Leukocyte; Didanosine; HIV Infections; HIV-1; Humans; Neutrophils; Phagocytosis; Superoxides; Zalcitabine; Zidovudine | 1990 |
Expanding AIDS drug availability.
Topics: Acquired Immunodeficiency Syndrome; Clinical Trials as Topic; Didanosine; Dideoxynucleosides; Humans; Zidovudine | 1989 |
AIDS treatment: 'parallel trick' for ddI.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Evaluation; Humans; Zidovudine | 1989 |
FDA expands testing of anti-AIDS drugs.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; AIDS-Related Complex; Antiviral Agents; Clinical Trials as Topic; Didanosine; Humans; Infant; Infant, Newborn; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1989 |
Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy.
Topics: Acquired Immunodeficiency Syndrome; Cloning, Molecular; Didanosine; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Polymerase Chain Reaction; RNA-Directed DNA Polymerase; Zidovudine | 1994 |
Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.
Topics: Amino Acid Sequence; Base Sequence; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Codon; Didanosine; DNA Primers; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Point Mutation; Polymerase Chain Reaction; RNA-Directed DNA Polymerase; RNA, Viral; Zidovudine | 1995 |
A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team.
Topics: Adult; Antiviral Agents; Benzodiazepines; CD4 Lymphocyte Count; Didanosine; Dose-Response Relationship, Drug; Female; Gene Products, tat; HIV Core Protein p24; HIV Infections; Humans; Male; Middle Aged; Pyrroles; tat Gene Products, Human Immunodeficiency Virus; Time Factors; Zidovudine | 1995 |
Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue.
Topics: Adult; Didanosine; DNA, Viral; Female; HIV Infections; HIV-1; Humans; Lymph Nodes; Lymphocytes; Male; Time Factors; Viremia; Zidovudine | 1995 |
A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; AIDS-Related Complex; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Evaluation; Drug Tolerance; Female; Humans; Male; Middle Aged; Pancreatitis; Survival Rate; Treatment Outcome; Zidovudine | 1995 |
Pharmacokinetics of simultaneously administered zidovudine and didanosine in HIV-seropositive male patients.
Topics: Adult; Cross-Over Studies; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Seropositivity; Humans; Male; Metabolic Clearance Rate; Zidovudine | 1995 |
Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Didanosine; Drug Interactions; Drug Therapy, Combination; Half-Life; HIV Infections; Humans; Male; Radioimmunoassay; Zidovudine | 1995 |
Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.
Topics: Adult; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Resistance, Microbial; Female; HIV Infections; Humans; Male; Prospective Studies; Zidovudine | 1995 |
Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Patient Compliance; Severity of Illness Index; Survival Analysis; Treatment Outcome; Zidovudine | 1995 |
Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. AIDS Clinical Trial Groups.
Topics: Adult; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Didanosine; Drug Therapy, Combination; Female; Hemophilia A; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Male; Safety; Treatment Outcome; Viremia; Zidovudine | 1995 |
Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.
Topics: Adult; Base Sequence; CD4 Lymphocyte Count; Codon; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genes, pol; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation; RNA, Viral; Viremia; Zidovudine | 1995 |
Five-year follow-up of a phase I study of didanosine in patients with advanced human immunodeficiency virus infection.
Topics: Adult; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Survival Rate; Zidovudine | 1995 |
Treatment options in zidovudine intolerance or failure.
Topics: Acquired Immunodeficiency Syndrome; Adult; Didanosine; Female; Follow-Up Studies; Humans; Male; Survival Rate; Time Factors; Treatment Failure; Zalcitabine; Zidovudine | 1994 |
Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial.
Topics: CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Treatment Outcome; Virus Cultivation; Zidovudine | 1995 |
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV-1; Humans; Male; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Zidovudine | 1995 |
Something better than zidovudine for children.
Topics: Adolescent; Child; Child, Preschool; Didanosine; Double-Blind Method; Drug Therapy, Combination; HIV Infections; Humans; Infant; Zidovudine | 1995 |
A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection.
Topics: Administration, Oral; Adolescent; Adult; AIDS-Related Opportunistic Infections; beta 2-Microglobulin; Body Weight; CD4-Positive T-Lymphocytes; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Core Protein p24; HIV Infections; Humans; Leukocyte Count; Male; Middle Aged; Pancreatitis; Pilot Projects; Zidovudine | 1994 |
Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; AIDS-Related Complex; CD4-Positive T-Lymphocytes; Didanosine; Double-Blind Method; Female; Humans; Leukocyte Count; Male; Middle Aged; Zidovudine | 1994 |
A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; CD4-Positive T-Lymphocytes; Didanosine; Female; Follow-Up Studies; HIV Infections; Humans; Leukocyte Count; Male; Risk; Zalcitabine; Zidovudine | 1994 |
Zidovudine and didanosine combination therapy in children with human immunodeficiency virus infection.
Topics: Adolescent; Adult; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Leukocyte Count; Male; Treatment Outcome; Zidovudine | 1994 |
A phase II study of effect of addition of trichosanthin to zidovudine in patients with HIV disease and failing antiretroviral agents.
Topics: Adolescent; Adult; Aged; CD4-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Leukocyte Count; Liver; Male; Middle Aged; Trichosanthin; Zidovudine | 1994 |
AIDS dementia complex and didanosine.
Topics: Acquired Immunodeficiency Syndrome; AIDS Dementia Complex; Didanosine; Double-Blind Method; Follow-Up Studies; HIV-1; Humans; Zidovudine | 1994 |
Antiretroviral therapy is associated with a decrease in unintegrated HIV-1 DNA in pediatric patients.
Topics: CD4 Lymphocyte Count; Child, Preschool; Didanosine; DNA, Viral; Drug Therapy, Combination; Female; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Infant; Leukocytes, Mononuclear; Male; Polymerase Chain Reaction; Viremia; Zidovudine | 1994 |
Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection.
Topics: Adolescent; Adult; Child; Child, Preschool; Didanosine; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Male; Zidovudine | 1994 |
Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Chromatography, High Pressure Liquid; Didanosine; Drug Interactions; Drug Therapy, Combination; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Zidovudine | 1994 |
Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.
Topics: Amino Acids; Base Sequence; Cells, Cultured; Codon; Didanosine; DNA Primers; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; Genes, pol; HIV Seropositivity; HIV-1; Humans; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Proviruses; RNA, Viral; Zidovudine | 1994 |
Uric acid and didanosine compliance in AIDS clinical trials: an analysis of AIDS Clinical Trials Group protocols 116A and 116B/117.
Topics: Adult; Clinical Protocols; Cohort Studies; Didanosine; Double-Blind Method; Female; HIV Infections; Humans; Male; Patient Compliance; Sensitivity and Specificity; Uric Acid; Zidovudine | 1993 |
Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection.
Topics: Adult; CD4 Antigens; Cell Count; Didanosine; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; RNA, Viral; Zidovudine | 1993 |
Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet).
Topics: Acquired Immunodeficiency Syndrome; Cohort Studies; Cytomegalovirus Infections; Didanosine; Drug Tolerance; Follow-Up Studies; Foscarnet; Ganciclovir; Humans; Infusions, Intravenous; Injections, Intravenous; Retinitis; Survival Rate; Time Factors; Zidovudine | 1993 |
Longitudinal analysis of responses to oral didanosine therapy following zidovudine therapy in advanced infection with human immunodeficiency virus.
Topics: Administration, Oral; Adult; Blood Cell Count; Didanosine; Female; Hemoglobins; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Zidovudine | 1993 |
Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine.
Topics: Administration, Oral; Adult; Didanosine; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Diseases; HIV Infections; Humans; Male; Middle Aged; Zidovudine | 1993 |
Detection of human immunodeficiency virus type 1 in semen: effects of disease stage and nucleoside therapy.
Topics: Anti-Bacterial Agents; Cross-Sectional Studies; Didanosine; DNA, Viral; Drug Therapy, Combination; HIV Seropositivity; HIV-1; Humans; Leukocyte Count; Longitudinal Studies; Male; RNA, Viral; Semen; T-Lymphocytes; Zidovudine | 1993 |
Pharmacokinetics of zidovudine and didanosine during combination therapy.
Topics: Adult; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Zidovudine | 1995 |
Tolerance of a triple combination therapy with zidovudine, didanosine and interferon-alpha in seven HIV-infected patients.
Topics: Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Interferon-alpha; Zidovudine | 1995 |
Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex.
Topics: Acquired Immunodeficiency Syndrome; AIDS Dementia Complex; Antiviral Agents; Didanosine; Humans; Individuality; Zidovudine | 1995 |
Combination therapy with ZDV + DDI versus ZDV + DDC in patients with progression of HIV-infection under treatment with ZDV.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Survival Analysis; Treatment Outcome; Zalcitabine; Zidovudine | 1996 |
Patterns of opportunistic infections in patients with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Cytomegalovirus Infections; Didanosine; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Mycobacterium avium-intracellulare Infection; Mycoses; Pneumonia, Pneumocystis; Prospective Studies; Retrospective Studies; Risk Factors; Survival Rate; Zidovudine | 1996 |
Impact of missing data due to dropouts on estimates of the treatment effect in a randomized trial of antiretroviral therapy for HIV-infected individuals. Canadian HIV Trials Network A002 Study Group.
Topics: Antiviral Agents; Bias; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Data Interpretation, Statistical; Didanosine; Double-Blind Method; HIV Infections; Humans; Patient Dropouts; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome; Zidovudine | 1996 |
Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protoco
Topics: Adult; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Erythema; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 1996 |
Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; HIV Seropositivity; Humans; Longitudinal Studies; Male; Proportional Hazards Models; Zalcitabine; Zidovudine | 1996 |
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Phenotype; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Complex; AIDS-Related Opportunistic Infections; Antiviral Agents; Body Weight; CD4 Lymphocyte Count; Didanosine; Disease Progression; Female; HIV-1; Humans; Male; Pancreatitis; Zidovudine | 1996 |
Double-blind placebo-controlled pilot trial of acemannan in advanced human immunodeficiency virus disease.
Topics: Administration, Oral; Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Therapy, Combination; Drug Tolerance; HIV Infections; Humans; Male; Mannans; Pilot Projects; Safety; Zidovudine | 1996 |
[Comparative study of the placenta from HIV+ mothers. Ultrastructural analysis].
Topics: Antiviral Agents; Didanosine; Female; HIV Infections; HIV Seropositivity; Humans; Infectious Disease Transmission, Vertical; Microscopy, Electron; Placenta; Pregnancy; Pregnancy Complications, Infectious; Zidovudine | 1996 |
Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
Topics: Antigens, CD; Antiviral Agents; CD4 Antigens; Coculture Techniques; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HeLa Cells; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Lymphocytes; Microbial Sensitivity Tests; Phenotype; Point Mutation; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 1996 |
Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.
Topics: Adolescent; Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Male; Survival Analysis; Zalcitabine; Zidovudine | 1996 |
Combination therapy with zidovudine, didanosine and saquinavir.
Topics: Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Quinolines; Saquinavir; Zidovudine | 1996 |
D4T nucleoside combinations for HIV.
Topics: Adult; Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Stavudine; Zidovudine | 1996 |
A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Didanosine; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Zidovudine | 1996 |
Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Didanosine; Drug Resistance; HIV Infections; HIV-1; Humans; Mutation; Zidovudine | 1996 |
Effects of cytokines on antiviral pharmacokinetics: an alternative approach to assessment of drug interactions using bioequivalence guidelines.
Topics: Adult; Antiviral Agents; Cytokines; Didanosine; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Interferon-alpha; Interleukin-2; Male; Reference Standards; Reference Values; Therapeutic Equivalency; Zidovudine | 1996 |
Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.
Topics: Adult; Anti-HIV Agents; Biological Availability; Delavirdine; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indoles; Male; Middle Aged; Piperazines; Reverse Transcriptase Inhibitors; Zidovudine | 1996 |
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Proportional Hazards Models; Treatment Outcome; Zidovudine | 1996 |
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Multivariate Analysis; Phenotype; Proportional Hazards Models; RNA, Viral; Treatment Outcome; Virus Replication; Zidovudine | 1996 |
Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Rese
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Male; Risk; Survival Analysis; Zalcitabine; Zidovudine | 1996 |
The Alpha trial: European/Australian randomized double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease. Alpha International Coordinating Committee.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Tolerance; Female; HIV Core Protein p24; HIV Infections; Humans; Male; Pancreatitis; Zidovudine | 1996 |
Viral load, CD4 percentage, and delayed-type hypersensitivity in subjects receiving the HIV-1 immunogen and antiviral drug therapy.
Topics: AIDS Vaccines; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Envelope Protein gp120; HIV Infections; Hypersensitivity, Delayed; Immunotherapy, Active; Viral Load; Zidovudine | 1996 |
Intrathecal immunoactivation in patients with HIV-1 infection is reduced by zidovudine but not by didanosine.
Topics: Adult; Aged; Anti-HIV Agents; Biopterins; Didanosine; HIV Infections; HIV-1; Humans; Immunoglobulin G; Middle Aged; Neopterin; Zidovudine | 1996 |
CD8+ lymphocyte responses to antiretroviral therapy of HIV infection.
Topics: Acetamides; Acetophenones; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Lamivudine; Lymphocyte Count; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zalcitabine; Zidovudine | 1996 |
AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine
Topics: Acquired Immunodeficiency Syndrome; Acriflavine; Adult; Anti-Infective Agents; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Ellipticines; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Zalcitabine; Zidovudine | 1996 |
Should we embrace new drugs with open arms? Experience from a community-based, open-arm, randomized clinical trial of combination antiretroviral therapy in advanced HIV disease.
Topics: Adult; Anti-HIV Agents; British Columbia; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Patient Selection; Practice Patterns, Physicians'; Prospective Studies; Zalcitabine; Zidovudine | 1996 |
[Effect of treatment with nucleoside analogues in subjects with primary genotypic resistance to zidovudine].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance; Drug Therapy, Combination; Genotype; HIV-1; Humans; Zalcitabine; Zidovudine | 1996 |
Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.
Topics: Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Resistance, Microbial; Genotype; HIV Infections; HIV Reverse Transcriptase; Humans; Mutation; Polymerase Chain Reaction; Recombinant Proteins; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 1997 |
Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Biological Availability; Didanosine; Dideoxynucleotides; HIV Infections; Humans; Infusions, Intravenous; Male; Zidovudine | 1997 |
Italian multicentre study of didanosine compassionate use in advanced HIV infection. Italian BMS-906 Study Group.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; AIDS Dementia Complex; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Resistance, Microbial; Female; HIV Infections; Humans; Immunocompromised Host; Italy; Male; Middle Aged; Multivariate Analysis; Pancreatitis; Treatment Outcome; Zidovudine | 1997 |
Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV disease: a comparison of simultaneous and alternating regimens.
Topics: Adult; AIDS Dementia Complex; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; Humans; Male; Neuropsychological Tests; Zidovudine | 1997 |
Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4-CD8 Ratio; Didanosine; DNA, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocytes; Male; Pilot Projects; Proviruses; RNA, Viral; Zidovudine | 1997 |
Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.
Topics: Administration, Oral; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Male; Nevirapine; Pyridines; RNA, Viral; Viral Load; Zidovudine | 1997 |
Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.
Topics: Acetamides; Acetophenones; Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Health Services; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1997 |
Additive or sequential nucleoside analogue therapy compared with continued zidovudine monotherapy in human immunodeficiency virus-infected patients with advanced disease does not prolong survival: an observational study.
Topics: Adult; Age Factors; Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Middle Aged; Prognosis; Proportional Hazards Models; Survival Rate; Treatment Outcome; Zalcitabine; Zidovudine | 1997 |
Alternating treatment with didanosine and zidovudine versus either drug alone for the treatment of advanced HIV infection. The Alter Study. Nordic HIV Therapy Group.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Zidovudine | 1997 |
Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; Female; HIV Core Protein p24; HIV Infections; Humans; Infant; Male; Treatment Outcome; Zidovudine | 1997 |
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Drug Therapy, Combination; HIV-1; Humans; Monitoring, Physiologic; Nevirapine; Phenotype; Prospective Studies; Pyridines; RNA, Viral; Viral Load; Zidovudine | 1997 |
A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Body Weight; CD4 Lymphocyte Count; Didanosine; Disease Progression; Female; HIV Core Protein p24; HIV Infections; Humans; Male; Risk; Zidovudine | 1997 |
No therapeutic advantage from didanosine (ddI) and hydroxyurea versus ddI alone in patients with HIV infection.
Topics: CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; RNA, Viral; Treatment Outcome; Viremia; Zidovudine | 1997 |
HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combination; Genes, pol; HIV Infections; HIV-1; Humans; Point Mutation; Prospective Studies; RNA, Viral; Viral Load; Zalcitabine; Zidovudine | 1997 |
Quantification of HIV-1 proviral DNA by a standardized colorimetric PCR-based assay.
Topics: Adult; Anti-HIV Agents; Colorimetry; Didanosine; DNA, Viral; Evaluation Studies as Topic; Female; HIV-1; Humans; Indinavir; Lamivudine; Male; Polymerase Chain Reaction; Proviruses; Ritonavir; RNA, Viral; Transcription, Genetic; Zalcitabine; Zidovudine | 1998 |
Interleukin-2 in combination with zidovudine and didanosine is able to maintain high levels of CD4 cells and undetectable HIV viraemia.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Interleukin-2; Leukocyte Common Antigens; Male; Pilot Projects; RNA, Viral; Viremia; Zidovudine | 1998 |
A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection.
Topics: Administration, Oral; Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Male; Ritonavir; Viral Load; Zidovudine | 1998 |
[Effect of antiretroviral treatment on early electroencephalographic and otoneurologic manifestations in HIV infection and prognostic importance of verified perturbations].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cross-Over Studies; Didanosine; Double-Blind Method; Electroencephalography; Follow-Up Studies; Hearing Tests; HIV-1; Humans; Male; Neurologic Examination; Prognosis; Reproducibility of Results; Zidovudine | 1997 |
Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Antiviral Agents; Area Under Curve; Didanosine; Drug Interactions; Female; Ganciclovir; Half-Life; HIV Infections; Humans; Male; Probenecid; Renal Agents; Zidovudine | 1998 |
Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team.
Topics: Adult; Anti-HIV Agents; Biomarkers; CD4 Lymphocyte Count; Didanosine; Dideoxynucleosides; Disease Progression; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Multivariate Analysis; Prognosis; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1998 |
Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Multivariate Analysis; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1998 |
The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
Topics: Acetamides; Acetophenones; Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; RNA, Viral; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1998 |
A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; RNA, Viral; Viral Load; Zidovudine | 1998 |
Phenotypic variability of lymphocyte populations in peripheral blood and lymph nodes from HIV-infected individuals and the impact of antiretroviral therapy. DATRI 003 Study Group. Division of AIDS Treatment Research Initiative.
Topics: Anti-HIV Agents; B-Lymphocytes; Didanosine; HIV Seropositivity; Humans; Immunophenotyping; Lymph Nodes; Lymphocyte Count; Lymphocyte Subsets; Prospective Studies; T-Lymphocytes; Zidovudine | 1998 |
[Efficacy of combining zidovudine plus didanosine in patients with and without previous exposure to zidovudine].
Topics: Adult; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Viral Load; Zidovudine | 1998 |
Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons.
Topics: Anti-HIV Agents; Base Sequence; Didanosine; DNA Primers; DNA, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Proviruses; Reverse Transcriptase Inhibitors; Viral Load; Zalcitabine; Zidovudine | 1998 |
Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.
Topics: Adult; Analysis of Variance; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; Giant Cells; HIV Infections; HIV-1; Humans; Linear Models; Male; Middle Aged; Multivariate Analysis; Phenotype; Probability; Reverse Transcriptase Inhibitors; Risk Factors; Time Factors; Viral Load; Zalcitabine; Zidovudine | 1998 |
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy.
Topics: Anti-HIV Agents; Australia; Canada; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Italy; Netherlands; Nevirapine; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 1998 |
A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
Topics: Adolescent; Anti-HIV Agents; CD4 Antigens; Child; Child, Preschool; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Neurodegenerative Diseases; Polymerase Chain Reaction; RNA, Viral; Survival Rate; Zidovudine | 1998 |
A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1998 |
Individual prognoses of long-term responses to antiretroviral treatment based on virological, immunological and pharmacological parameters measured during the first week under therapy.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Prognosis; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Viral Load; Zidovudine | 1998 |
A trial comparing nucleoside monotherapy with sequential therapy with 3 drugs in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Reverse Transcriptase Inhibitors; Treatment Outcome; Zalcitabine; Zidovudine | 1998 |
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study T
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV; Humans; Male; Nevirapine; Placebos; Reverse Transcriptase Inhibitors; RNA, Viral; Survival Rate; Time Factors; Zalcitabine; Zidovudine | 1998 |
Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Patient Compliance; Reverse Transcriptase Inhibitors; Time Factors; Zalcitabine; Zidovudine | 1998 |
The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Patient Compliance; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1998 |
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Models, Biological; Nevirapine; Zidovudine | 1999 |
Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.
Topics: Anti-HIV Agents; Base Sequence; Child; Codon; Didanosine; DNA Primers; Drug Therapy, Combination; Genotype; HIV Infections; HIV-1; Humans; Mutation; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nevirapine; Zidovudine | 1999 |
Virologic and immunologic response to nucleoside reverse-transcriptase inhibitor therapy among human immunodeficiency virus-infected infants and children.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; Humans; Infant; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Zidovudine | 1999 |
An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 1999 |
HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Predictive Value of Tests; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Viral Load; Zalcitabine; Zidovudine | 1999 |
Recombinant human gamma interferon in human immunodeficiency virus-infected children: safety, CD4(+)-lymphocyte count, viral load, and neutrophil function (AIDS Clinical Trials Group Protocol 211).
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Interferon-gamma; Male; Neutrophils; Recombinant Proteins; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 1999 |
Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages.
Topics: Adolescent; Anti-HIV Agents; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Immunophenotyping; Infant; Leukocyte Common Antigens; Lymphocyte Subsets; Ritonavir; Viral Load; Zidovudine | 1999 |
[Response of fetal macrophages in the placenta of pregnant HIV-positive patients with and without antiretroviral treatment].
Topics: Antiviral Agents; Didanosine; Female; HIV Infections; HIV Seropositivity; Humans; Macrophages; Pregnancy; Pregnancy Complications, Infectious; Retroviridae; Zidovudine | 1999 |
Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Didanosine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interleukin-2; Male; Time Factors; Zidovudine | 1999 |
The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Viremia; Zidovudine | 1999 |
Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Invest
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Viral Load; Zidovudine | 1999 |
Combining mortality and longitudinal measures in clinical trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Anti-Infective Agents; Antifungal Agents; Candidiasis; Child; Child, Preschool; Clinical Trials as Topic; Clotrimazole; Dapsone; Didanosine; Drug Therapy, Combination; Fluconazole; Head; Humans; Longitudinal Studies; Pentamidine; Pneumonia, Pneumocystis; Statistics, Nonparametric; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Zidovudine | 1999 |
Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Safety; Zidovudine | 1999 |
Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection.
Topics: Adolescent; AIDS Vaccines; Anti-HIV Agents; Child; Child, Preschool; Combined Modality Therapy; Didanosine; Dose-Response Relationship, Drug; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Infant; Male; RNA, Viral; Safety; Time Factors; Zidovudine | 1999 |
Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Viral Load; Zidovudine | 1999 |
Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Child, Preschool; Data Collection; Didanosine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Polypharmacy; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Zalcitabine; Zidovudine | 1999 |
Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team.
Topics: Adolescent; Analysis of Variance; Anti-HIV Agents; Brain; Central Nervous System Diseases; Child; Child, Preschool; Cognition; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Intelligence Tests; Male; Motor Skills; Reverse Transcriptase Inhibitors; Zidovudine | 1999 |
Sequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Amino Acid Sequence; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Evolution, Molecular; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Nevirapine; Sequence Alignment; Time Factors; Viral Load; Zidovudine | 1999 |
Long-term effects of antiretroviral combination therapy on HIV type 1 DNA levels.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Data Interpretation, Statistical; Didanosine; DNA, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Polymerase Chain Reaction; RNA, Viral; Stavudine; Time Factors; Zidovudine | 1999 |
Rapid detection of the HIV type 1 reverse transcriptase codon T215Y by reverse transcription-polymerase chain reaction with fluorogenic probes.
Topics: Anti-HIV Agents; Child; Child, Preschool; Codon; Didanosine; DNA Mutational Analysis; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluorescent Dyes; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Point Mutation; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Zidovudine | 1999 |
Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Nelfinavir; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Viral Load; Zidovudine | 1999 |
Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance; Drug Therapy, Combination; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mutation; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Zidovudine | 1999 |
Combined antiviral therapy reduces HIV-1 plasma load and improves CD4 counts but does not interfere with ongoing lymphocyte apoptosis.
Topics: Adult; Anti-HIV Agents; Apoptosis; Caspase 1; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Ceramides; Didanosine; Drug Therapy, Combination; fas Receptor; HIV Infections; HIV-1; Humans; Male; Mitochondria; Viral Load; Viremia; Zidovudine | 1999 |
A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Palatine Tonsil; Ritonavir; RNA, Viral; Spain; Stavudine; Viremia; Zalcitabine; Zidovudine | 1999 |
Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.
Topics: Acquired Immunodeficiency Syndrome; Codon; Didanosine; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nevirapine; Polymerase Chain Reaction; Zidovudine | 2000 |
Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team.
Topics: Adult; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Multivariate Analysis; Nevirapine; Proportional Hazards Models; Viral Load; Zidovudine | 1999 |
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Injections, Subcutaneous; Interleukin-2; Lamivudine; Lymphocyte Count; Male; Nelfinavir; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 2000 |
Dual nucleoside regimens in nonadvanced HIV infection: prospective follow-up of 130 patients, Aquitaine Cohort, 1996 to 1998. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Multivariate Analysis; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Zalcitabine; Zidovudine | 2000 |
Effect of two different combinations of antiretrovirals (AZT+ddI and AZT+3TC) on cytokine production and apoptosis in asymptomatic HIV infection.
Topics: Anti-HIV Agents; Apoptosis; CD4 Lymphocyte Count; CD4-CD8 Ratio; Cytokines; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Prospective Studies; Reverse Transcriptase Inhibitors; Th1 Cells; Viremia; Zidovudine | 2000 |
A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Australia; CD4 Lymphocyte Count; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Stavudine; Viral Load; Zidovudine | 2000 |
The CCR5Delta32 allele slows disease progression of human immunodeficiency virus-1-infected children receiving antiretroviral treatment.
Topics: Alleles; Anti-HIV Agents; Child, Preschool; Clinical Trials as Topic; Didanosine; Disease Progression; Disease-Free Survival; Ethnicity; Gene Frequency; HIV Infections; HIV-1; Humans; Racial Groups; Receptors, CCR5; Sequence Deletion; Zidovudine | 2000 |
Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Therapy, Combination; Giant Cells; HIV Infections; HIV-1; Humans; Nevirapine; RNA, Viral; Viral Load; Zidovudine | 2000 |
A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Reverse Transcriptase Inhibitors; Stavudine; Thymidine; Viral Load; Zidovudine | 2000 |
Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Female; HIV Infections; Humans; Liver; Male; Nucleosides; Prospective Studies; Sex Characteristics; Zalcitabine; Zidovudine | 2000 |
Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zalcitabine; Zidovudine | 2000 |
Didanosine dosed once daily is equivalent to twice daily dosing for patients on double or triple combination antiretroviral therapy. The AI454-147 Team.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Zidovudine | 2000 |
Predicting HIV disease progression in children using measures of neuropsychological and neurological functioning. Pediatric AIDS clinical trials 152 study team.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; AIDS Dementia Complex; Anti-HIV Agents; Brain; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV-1; Humans; Infant; Intelligence Tests; Male; Neurologic Examination; Neuropsychological Tests; Predictive Value of Tests; Radiography; Regression Analysis; RNA, Viral; Zidovudine | 2000 |
Quality of life outcomes of combination zidovudine- didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nevirapine; Quality of Life; Reverse Transcriptase Inhibitors; Treatment Outcome; Zidovudine | 2000 |
Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection.
Topics: Adult; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zidovudine | 2001 |
Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-HIV Agents; Azithromycin; Didanosine; Drug Interactions; Female; HIV Infections; Humans; Male; Middle Aged; Zidovudine | 2001 |
Therapeutic effects of nucleoside analogues on psychomotor slowing in HIV infection.
Topics: Adult; Anti-HIV Agents; Central Nervous System Diseases; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Motor Skills; Stavudine; Zalcitabine; Zidovudine | 2001 |
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.
Topics: Adult; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Patient Selection; Randomized Controlled Trials as Topic; Research Design; Ritonavir; Sample Size; Saquinavir; Stavudine; Zidovudine | 2001 |
A pilot case-control study of zidovudine compared with zidovudine plus didanosine in patients with advanced HIV-1 disease and no previous experience with antiretrovirals.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; Codon; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Multivariate Analysis; Mutation; Nausea; Neutropenia; Pilot Projects; RNA, Viral; Survival Analysis; Zidovudine | 1996 |
The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. AIDS Clinical Trials Group 116/117 Study Group.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Female; HIV Infections; Humans; Male; Severity of Illness Index; Sickness Impact Profile; Survival Analysis; Time Factors; Treatment Outcome; Zidovudine | 1996 |
Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Hydroxyurea; Male; Middle Aged; Zidovudine | 1997 |
Once versus twice daily administration of didanosine in children with symptomatic HIV-associated disease who were intolerant to or clinically deteriorated on zidovudine. The Italian Pediatric Collaborative Study Group on Didanosine.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Drug Administration Schedule; Female; HIV Infections; Humans; Infant; Male; Zidovudine | 1997 |
Research study of combination AIDS therapies underway.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Humans; Lamivudine; Nevirapine; Pyridines; Zidovudine | 1996 |
Final CESARE trial results show continued clinical and survival benefit.
Topics: Acetamides; Acetophenones; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Controlled Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Survival Rate; Zalcitabine; Zidovudine | 1997 |
Viramune triple combo reduces viral load below limit of detection.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Randomized Controlled Trials as Topic; Viral Load; Zidovudine | 1997 |
AZT: pediatric study changed after worse monotherapy survival.
Topics: Adolescent; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Infant; Survival Analysis; Zidovudine | 1995 |
Pediatrics clinical trial drops AZT-alone arm.
Topics: Adolescent; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; Humans; Infant; Treatment Failure; Zidovudine | 1995 |
Major study shows AZT monotherapy inferior.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1995 |
New double vs. triple antiviral combination study, CD4 200-500, no prior treatment.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1995 |
Antiretroviral combination treatment prolongs life in people with HIV/AIDS.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
CPCRA 007: preliminary results of combination antiretroviral study.
Topics: Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1996 |
Major pediatric study stopped early: combination treatment better.
Topics: Anti-HIV Agents; Child; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Zidovudine | 1997 |
Combination therapies improve outlook for children with HIV disease.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Infant; Lamivudine; Zidovudine | 1997 |
Maintaining a low viral load with Nevirapine?
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 1998 |
Virus sidesteps convergent therapy.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Pyridines; Zidovudine | 1995 |
A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Thailand; Treatment Outcome; Zidovudine | 2001 |
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.
Topics: Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Zidovudine | 2001 |
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.
Topics: Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Infections; HIV-1; Humans; Mutation; Nevirapine; Phenotype; Reverse Transcriptase Inhibitors; Zidovudine | 2001 |
Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
Topics: Adult; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Microbial Sensitivity Tests; Phenotype; Point Mutation; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2001 |
Potential adverse effects of structured therapeutic interruptions on the pool of HIV-infected cells.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Disease Progression; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Count; Morbidity; Prognosis; Ritonavir; RNA, Viral; Saquinavir; Viral Load; Zidovudine | 2001 |
Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; International Cooperation; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Survival Analysis; Treatment Outcome; Zalcitabine; Zidovudine | 2001 |
Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Cyclopropanes; Didanosine; Dideoxynucleosides; Double-Blind Method; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2002 |
Impact of highly active antiretroviral therapy on cognitive processing in HIV infection: cross-sectional and longitudinal studies of event-related potentials.
Topics: Adult; AIDS Dementia Complex; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cross-Sectional Studies; Didanosine; Drug Therapy, Combination; Evoked Potentials; Female; Humans; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Treatment Outcome; Zalcitabine; Zidovudine | 2002 |
L-carnitine reduces lymphocyte apoptosis and oxidant stress in HIV-1-infected subjects treated with zidovudine and didanosine.
Topics: Anti-HIV Agents; Apoptosis; Carnitine; Didanosine; Drug Therapy, Combination; fas Receptor; Flow Cytometry; HIV Infections; HIV-1; Humans; Hydrogen Peroxide; Male; Membrane Potentials; Mitochondria; Oxidants; Oxidative Stress; Phenotype; Reverse Transcriptase Inhibitors; Superoxides; T-Lymphocytes; Zidovudine | 2002 |
Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; DNA, Viral; HIV-1; Humans; Multivariate Analysis; Prognosis; RNA, Viral; Zalcitabine; Zidovudine | 2003 |
Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Predictive Value of Tests; Reverse Transcriptase Inhibitors; Selection, Genetic; Thymidine; Zalcitabine; Zidovudine | 2003 |
Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
Topics: Adult; Anti-HIV Agents; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Hydroxyurea; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Viral Load; Zidovudine | 2003 |
Feeding risk cut for HIV-infected women.
Topics: Anti-HIV Agents; Breast Feeding; Didanosine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Risk Factors; Rwanda; Uganda; Zidovudine | 2003 |
Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Multiple; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2003 |
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Oxazines; RNA, Viral; Stavudine; Time Factors; Treatment Failure; Zidovudine | 2003 |
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nelfinavir; Oxazines; Stavudine; Time Factors; Treatment Failure; Zidovudine | 2003 |
Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
Topics: Case-Control Studies; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant; Male; Mutation; Pharmacogenetics; Phenotype; Polymerase Chain Reaction; Probability; Prospective Studies; Reference Values; Reverse Transcriptase Inhibitors; RNA, Viral; Statistics, Nonparametric; Viral Load; Zidovudine | 2004 |
Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Dideoxynucleosides; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Retrospective Studies; RNA, Viral; Stavudine; Thailand; Time Factors; Zidovudine | 2004 |
High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Drug Resistance, Multiple, Viral; Female; Follow-Up Studies; HIV-1; Humans; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2005 |
Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Male; Mutation; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Zidovudine | 2005 |
Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
Topics: Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 1999 |
Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors.
Topics: Adult; Aspartic Acid; Brain; Cell Respiration; Didanosine; Female; HIV Infections; Humans; Lamivudine; Magnetic Resonance Spectroscopy; Male; Middle Aged; Mitochondria; Mitochondrial Diseases; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome; Zidovudine | 2005 |
A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people.
Topics: Adult; Aging; Anti-HIV Agents; Didanosine; Female; Hearing Loss; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Zidovudine | 2006 |
[Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral-naive treatment with advanced HIV infection].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Disease Progression; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Ritonavir; Stavudine; Zidovudine | 2006 |
Antiviral activity of nucleoside analogues during short-course monotherapy or dual therapy: its role in preventing HIV infection in infants.
Topics: Acidosis, Lactic; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Fatty Liver; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Mothers; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; RNA, Viral; South Africa; Stavudine; Viral Load; Zidovudine | 2006 |
Therapeutic potential of chloroquine added to zidovudine plus didanosine for HIV-1 infected children.
Topics: Anti-HIV Agents; Antimalarials; Child; Child, Preschool; Chloroquine; Didanosine; Female; HIV Infections; HIV-1; Humans; Male; Zidovudine | 2006 |
Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy.
Topics: Adult; Anti-HIV Agents; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Leukocytes, Mononuclear; Logistic Models; Male; Reverse Transcriptase Inhibitors; Stavudine; Surveys and Questionnaires; Time Factors; Zidovudine | 2007 |
Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Didanosine; Double-Blind Method; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Nelfinavir; Prospective Studies; Stavudine; Testosterone; Zidovudine | 2007 |
More on the treatment-tropism relationship: the impact of prior antiretroviral treatment on HIV coreceptor tropism among subjects entering AIDS clinical trials group 175.
Topics: Adult; Anti-Retroviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Middle Aged; Receptors, CCR5; Receptors, CXCR4; Zalcitabine; Zidovudine | 2007 |
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.
Topics: Absorptiometry, Photon; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Composition; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Prospective Studies; Stavudine; Time Factors; Treatment Outcome; United States; Zidovudine | 2007 |
The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial.
Topics: Adult; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Peripheral Nervous System Diseases; Reverse Transcriptase Inhibitors; Risk Factors; Time Factors; Zalcitabine; Zidovudine | 2008 |
Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Bacterial Infections; Benzoxazines; Blood Platelets; Cardiovascular Diseases; Cyclopropanes; Deoxycytidine; Didanosine; Emtricitabine; Female; Hemoglobins; HIV Infections; Humans; Leukocyte Count; Male; Middle Aged; Neutrophils; Pancytopenia; Platelet Count; Prevalence; Zidovudine | 2008 |
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Botswana; CD4 Lymphocyte Count; Didanosine; Drug Tolerance; Female; HIV Infections; HIV-1; Humans; Male; Patient Compliance; RNA, Viral; Survival Analysis; Time Factors; Viremia; Zidovudine | 2009 |
The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Culture; Cyclopropanes; Didanosine; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Surveys and Questionnaires; Zidovudine | 2010 |
A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; RNA, Viral; South Africa; Stavudine; Treatment Outcome; Zidovudine | 2010 |
Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Treatment Outcome; Viral Load; Zidovudine | 2011 |
Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Body Mass Index; C-Reactive Protein; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Didanosine; Disease Progression; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Multivariate Analysis; Oligopeptides; Prospective Studies; Pyridines; Risk Factors; Selenium; World Health Organization; Zidovudine | 2014 |
Prevalence, incidence and predictors of peripheral neuropathy in African adults with HIV infection within the DART trial.
Topics: Adolescent; Adult; Aged; Anti-Retroviral Agents; Antitubercular Agents; Didanosine; Female; HIV Infections; Humans; Incidence; Isoniazid; Male; Middle Aged; Peripheral Nervous System Diseases; Prevalence; Risk Factors; Stavudine; Uganda; Young Adult; Zidovudine; Zimbabwe | 2014 |
648 other study(ies) available for zidovudine and didanosine
| Article | Year |
|---|---|
Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity.
Topics: Antiviral Agents; Cell Line; Didanosine; Dideoxynucleotides; Ethers; HIV-1; Humans; Indicators and Reagents; Molecular Structure; Phospholipid Ethers; Structure-Activity Relationship; Virus Replication; Zidovudine | 1991 |
Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-on e (TIBO) derivatives. 2.
Topics: Antiviral Agents; Benzodiazepines; HIV-1; Imidazoles; Microbial Sensitivity Tests; Structure-Activity Relationship; Virus Replication | 1991 |
Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TIBO) derivatives.
Topics: Antiviral Agents; Benzodiazepinones; Chemical Phenomena; Chemistry; HIV; Structure-Activity Relationship; Virus Replication | 1991 |
Escherichia coli mediated biosynthesis and in vitro anti-HIV activity of lipophilic 6-halo-2',3'-dideoxypurine nucleosides.
Topics: Adenosine Deaminase; Cells, Cultured; Chemical Phenomena; Chemistry; Dideoxynucleosides; Escherichia coli; HIV; Kinetics; Prodrugs; Structure-Activity Relationship | 1991 |
Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs.
Topics: Adenosine Deaminase; Antiviral Agents; Cells, Cultured; Chemical Phenomena; Chemistry; Chromatography, High Pressure Liquid; Dideoxynucleosides; HIV; Kinetics; Prodrugs; Structure-Activity Relationship | 1991 |
HIV-1 reverse transcriptase inhibitor design using artificial neural networks.
Topics: Algorithms; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Structure; Neural Networks, Computer; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; T-Lymphocytes; Zidovudine | 1994 |
Synthesis and evaluation of the anti-HIV activity of aza and deaza analogues of isoddA and their phosphates as prodrugs.
Topics: Adenosine Triphosphate; Antiviral Agents; Aza Compounds; Dideoxyadenosine; Dideoxynucleotides; HIV Reverse Transcriptase; HIV-1; HIV-2; Molecular Structure; Phosphates; Recombinant Proteins; Reverse Transcriptase Inhibitors | 1994 |
Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 2. 6-Halo and 6-alkoxy prodrugs of 2'-beta-fluoro-2',3'-dideoxyinosine.
Topics: Adenosine Deaminase; Antiviral Agents; Cells, Cultured; Didanosine; HIV Infections; Humans; Hydrogen-Ion Concentration; In Vitro Techniques; Prodrugs; Solubility | 1995 |
Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; HeLa Cells; Humans; Nucleosides; Pyridines; Pyrimidines; Structure-Activity Relationship; Tumor Cells, Cultured; Vero Cells | 1996 |
Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6-(arylthio)uracils.
Topics: Animals; Anti-HIV Agents; HIV Reverse Transcriptase; HIV-1; Liver; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Rats; Rats, Sprague-Dawley; Spectrophotometry, Infrared; Structure-Activity Relationship; Uracil | 1997 |
Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs.
Topics: Acyclovir; Animals; Anion Transport Proteins; Antiviral Agents; Carrier Proteins; Didanosine; In Vitro Techniques; Lamivudine; Oocytes; Rats; Stavudine; Transfection; Trifluridine; Xenopus laevis; Zalcitabine; Zidovudine | 2000 |
New saponins from the starfish Certonardoa semiregularis.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Artemia; HeLa Cells; Humans; Korea; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Saponins; Starfish; Stereoisomerism; Steroids | 2002 |
Isolation of salicin derivatives from Homalium cochinchinensis and their antiviral activities.
Topics: Anti-HIV Agents; Antiviral Agents; Benzyl Alcohols; Glucosides; Medicine, Traditional; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Plant Bark; Plant Leaves; Plant Roots; Plants, Medicinal; Salicaceae | 2004 |
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.
Topics: Animals; Antimetabolites; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Didanosine; DNA, Mitochondrial; Dose-Response Relationship, Drug; Humans; Lactates; Liver Neoplasms; Mitochondria; Myocytes, Cardiac; Rats; Superoxides; Zalcitabine; Zidovudine | 2007 |
Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
Topics: Adenine; Amino Acid Substitution; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2007 |
Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.
Topics: Anti-HIV Agents; HeLa Cells; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Reverse Transcriptase Inhibitors; Zidovudine | 2008 |
Anti-BK virus activity of nucleoside analogs.
Topics: Adenine; BK Virus; Esters; Fatty Acids; Humans; Microbial Sensitivity Tests; Nucleosides; Organophosphonates; Virus Replication | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.
Topics: Cell Proliferation; Cells, Cultured; Dideoxynucleosides; DNA, Mitochondrial; Humans; Lamivudine; Muscle Fibers, Skeletal; Muscle, Skeletal; Myoblasts; Nucleosides; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Mitochondrial; Stavudine; Zidovudine | 2008 |
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Nucleosides; Phenotype; Reverse Transcriptase Inhibitors | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
Topics: Anti-HIV Agents; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Molecular Structure; Reverse Transcriptase Inhibitors | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
Topics: Adenine; Anti-HIV Agents; Cell Survival; Cells, Cultured; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Macrophages; Nucleosides; Nucleotides; Organophosphonates; Tenofovir | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Anti-HIV and antiplasmodial activity of original flavonoid derivatives.
Topics: Anti-HIV Agents; Antimalarials; Cell Line; Cell Survival; Flavonoids; HIV; HIV Infections; Humans; Malaria, Falciparum; Plasmodium falciparum | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazoles; Virus Replication | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
Topics: Binding Sites; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Pyrimidines; Pyrimidinones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2013 |
Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.
Topics: Aniline Compounds; Anti-HIV Agents; Drug Design; HIV-1; Humans; Models, Molecular; Piperidines; Structure-Activity Relationship | 2014 |
Jatrophane diterpenes as inhibitors of chikungunya virus replication: structure-activity relationship and discovery of a potent lead.
Topics: Alphavirus Infections; Antiviral Agents; Chikungunya Fever; Chikungunya virus; Diterpenes; Euphorbia; France; HIV-1; HIV-2; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Semliki forest virus; Sindbis Virus; Structure-Activity Relationship; Virus Replication | 2014 |
Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
Topics: Anti-HIV Agents; Catalytic Domain; Dose-Response Relationship, Drug; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Structure; Niacinamide; Protein Conformation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured | 2014 |
Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Topics: Anti-HIV Agents; Binding Sites; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2015 |
Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
Topics: Anti-HIV Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Nitrogen; Reverse Transcriptase Inhibitors; Solubility; Structure-Activity Relationship; Sulfones | 2015 |
Design, synthesis of new β-carboline derivatives and their selective anti-HIV-2 activity.
Topics: Carbolines; Drug Design; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Piperazines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2015 |
Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
Topics: Anti-HIV Agents; Chemistry Techniques, Synthetic; Computational Biology; Drug Design; HIV Reverse Transcriptase; HIV-1; Imidazoles; Molecular Docking Simulation; Protein Conformation; Pyrazines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2015 |
Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata.
Topics: Antiviral Agents; Chikungunya virus; Diterpenes; Euphorbiaceae; France; HCT116 Cells; HIV-1; HIV-2; Humans; Macrocyclic Compounds; MCF-7 Cells; Molecular Structure; Semliki forest virus; Sindbis Virus; Virus Replication | 2015 |
Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase.
Topics: Acyclovir; Animals; Antiviral Agents; Betulinic Acid; Chlorocebus aethiops; Herpesvirus 2, Human; HIV Reverse Transcriptase; HIV-1; Humans; Pentacyclic Triterpenes; Triterpenes; Vero Cells; Virus Replication | 2015 |
Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
Topics: Anti-HIV Agents; Binding Sites; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Virus Replication | 2016 |
Design, synthesis and anti-HIV activity of novel quinoxaline derivatives.
Topics: Animals; Anti-HIV Agents; Chlorocebus aethiops; Computer Simulation; Drug Design; HIV Integrase; Molecular Docking Simulation; Quantitative Structure-Activity Relationship; Quinoxalines; Vero Cells | 2016 |
1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
Topics: Animals; Antiviral Agents; Cells, Cultured; Dogs; Dose-Response Relationship, Drug; HIV-1; Influenza A Virus, H1N1 Subtype; Madin Darby Canine Kidney Cells; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Uracil | 2016 |
Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells.
Topics: Acetamides; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; Membrane Potential, Mitochondrial; Structure-Activity Relationship; Triazoles | 2016 |
Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
Topics: Anti-HIV Agents; Drug Stability; Esters; HIV-1; Humans; Inhibitory Concentration 50; Methane; Models, Molecular; Reverse Transcriptase Inhibitors | 2016 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.
Topics: Acquired Immunodeficiency Syndrome; Base Sequence; Cell Line; Cloning, Molecular; Didanosine; Drug Resistance, Microbial; Genetic Variation; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutation; Oligodeoxyribonucleotides; Polymerase Chain Reaction; Restriction Mapping; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 1992 |
Response of Ethiopian human immunodeficiency virus type 1 isolates to antiviral compounds.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Ethiopia; HIV Core Protein p24; HIV-1; Humans; Interferon-alpha; Microbial Sensitivity Tests; Mutation; RNA-Directed DNA Polymerase; Sweden; Zidovudine | 1992 |
Combination therapy for HIV infection: getting closer.
Topics: Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1992 |
Trial of three drugs for HIV-infected patients.
Topics: Clinical Trials as Topic; Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1992 |
Sodium-dependent nucleoside transport in choroid plexus from rabbit. Evidence for a single transporter for purine and pyrimidine nucleosides.
Topics: Adenosine Triphosphate; Animals; Carrier Proteins; Choroid Plexus; Cytarabine; Didanosine; Membrane Proteins; Nucleoside Transport Proteins; Purine Nucleosides; Pyrimidine Nucleosides; Rabbits; Sodium; Substrate Specificity; Zalcitabine; Zidovudine | 1992 |
Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages.
Topics: Adenine; Antibodies, Viral; Antiviral Agents; Benzodiazepines; CD4 Antigens; Cytokines; Didanosine; Doxorubicin; Drug Interactions; HIV; HIV Infections; Humans; Imidazoles; Leukocytes, Mononuclear; Lymphocytes; Macrophages; Monocytes; Organ Specificity; Organophosphonates; Zalcitabine; Zidovudine | 1992 |
Treatment of HIV infection: the antiretroviral nucleoside analogues. Introduction.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Evaluation; HIV Infections; HIV-1; Humans; Nucleosides; Zalcitabine; Zidovudine | 1992 |
Inhibition of HIV infection of resting peripheral blood lymphocytes by nucleosides.
Topics: Base Sequence; Cells, Cultured; Didanosine; DNA, Viral; HIV; Humans; Lymphocyte Activation; Molecular Sequence Data; Polymerase Chain Reaction; Proviruses; T-Lymphocytes; Virus Replication; Zalcitabine; Zidovudine | 1992 |
Antiviral nucleoside toxicity in canine bone marrow progenitor cells and its relationship to drug permeation.
Topics: Animals; Biological Transport, Active; Colony-Forming Units Assay; Didanosine; Dipyridamole; Dogs; Dose-Response Relationship, Drug; Erythrocytes; Female; Granulocytes; Hematopoietic Stem Cells; In Vitro Techniques; Macrophages; Zalcitabine; Zidovudine | 1992 |
Anti-human immunodeficiency virus (HIV) agents are also potent and selective inhibitors of feline immunodeficiency virus (FIV)-induced cytopathic effect: development of a new method for screening of anti-FIV substances in vitro.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antiviral Agents; Cats; Cell Fusion; Cells, Cultured; Cytopathogenic Effect, Viral; Dextran Sulfate; Didanosine; Drug Evaluation, Preclinical; Heparin; HIV; Humans; Immunodeficiency Virus, Feline; Virus Replication; Zidovudine | 1992 |
The transfer of anti-human immunodeficiency virus nucleoside compounds by the term human placenta.
Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Didanosine; Female; HIV Infections; Humans; Maternal-Fetal Exchange; Osmolar Concentration; Placenta; Pregnancy; Zalcitabine; Zidovudine | 1992 |
Effect of six virustatic nucleoside analogues on the development of fetal rat thymus in organ culture.
Topics: Animals; Antiviral Agents; Cell Differentiation; Cell Division; Cells, Cultured; Didanosine; Female; Flow Cytometry; Ganciclovir; Immunity, Cellular; Male; Nucleotides; Organ Culture Techniques; Pregnancy; Rats; Rats, Wistar; Thymus Gland; Vidarabine; Zalcitabine; Zidovudine | 1992 |
Criteria for use of didanosine in adult and pediatric patients.
Topics: Adult; Child, Preschool; Didanosine; HIV Infections; Humans; Infant; Leukocyte Count; Zidovudine | 1992 |
Testing an anti-HIV trio.
Topics: Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1992 |
Didanosine therapy in patients intolerant of or failing zidovudine therapy.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; CD4-Positive T-Lymphocytes; Didanosine; Female; HIV Core Protein p24; Humans; Leukocyte Count; Male; Peripheral Nervous System Diseases; Retrospective Studies; Time Factors; Treatment Failure; Zidovudine | 1992 |
[HIV-1 proviral DNA sequences in the saliva of patients with HIV infection].
Topics: Base Sequence; CD4-Positive T-Lymphocytes; Didanosine; DNA, Viral; Genes, env; HIV Infections; HIV-1; Humans; Leukocyte Count; Molecular Sequence Data; Polymerase Chain Reaction; Proviruses; Saliva; Zidovudine | 1992 |
[AIDS. 3rd European conference on the clinical aspects and treatment of HIV infection. Paris, 12-13 March 1992. 4th German AIDS congress. Wiesbaden, 25-28 March 1992. 8th International AIDS Conference. Amsterdam, 19-24 July 1992].
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zidovudine | 1992 |
Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages.
Topics: Antiviral Agents; Bone Marrow; Cells, Cultured; Cytokines; Didanosine; Dideoxynucleosides; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; HIV; Humans; Macrophage Colony-Stimulating Factor; Macrophages; Monocytes; Virus Replication; Zalcitabine; Zidovudine | 1992 |
(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro.
Topics: Cell Death; Cells, Cultured; Didanosine; Giant Cells; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Lamivudine; RNA-Directed DNA Polymerase; Tritium; Virus Replication; Zalcitabine; Zidovudine | 1992 |
Children with AIDS benefit from two-drug regimen.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Child; Child, Preschool; Didanosine; Drug Synergism; Drug Therapy, Combination; Humans; Zidovudine | 1992 |
Zidovudine-induced blockade of the expression and function of the erythropoietin receptor.
Topics: Animals; Cell Differentiation; Colony-Forming Units Assay; Didanosine; Dose-Response Relationship, Drug; Down-Regulation; Hematopoietic Stem Cells; Male; Mice; Receptors, Erythropoietin; RNA, Messenger; Signal Transduction; Zidovudine | 1992 |
Starting therapy for an HIV-infected patient.
Topics: Didanosine; HIV Infections; Humans; Zidovudine | 1992 |
Continued zidovudine or didanosine for human immunodeficiency virus infection.
Topics: Didanosine; HIV Infections; Humans; Zidovudine | 1992 |
Cerebral artery aneurysms in children infected with human immunodeficiency virus.
Topics: Brain; Cerebral Angiography; Child; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Intracranial Aneurysm; Magnetic Resonance Imaging; Male; Zidovudine | 1992 |
Approval for broader use of DDI.
Topics: Didanosine; Drug Approval; HIV Infections; HIV-1; Humans; United States; United States Food and Drug Administration; Zidovudine | 1992 |
DDI more effective than AZT.
Topics: Didanosine; HIV Infections; Zidovudine | 1992 |
Treatment of patients with advanced HIV infection and zidovudine intolerance with dideoxyinosine.
Topics: Adult; Didanosine; Drug Tolerance; HIV Infections; Humans; Male; Middle Aged; Zidovudine | 1992 |
An improved method for monitoring efficacy of anti-retroviral therapy in HIV-infected individuals: a highly sensitive HIV p24 antigen assay.
Topics: Biomarkers; Didanosine; Enzyme-Linked Immunosorbent Assay; Evaluation Studies as Topic; HIV Core Protein p24; HIV Infections; Humans; Sensitivity and Specificity; Zidovudine | 1992 |
[AIDS from the CIA?].
Topics: Didanosine; Government Agencies; HIV Infections; HIV-1; HIV-2; Humans; Mass Media; Zidovudine | 1992 |
Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro.
Topics: Didanosine; Drug Interactions; Ganciclovir; HIV-1; Zidovudine | 1992 |
Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay.
Topics: Didanosine; Drug Resistance, Microbial; HIV-1; Humans; In Vitro Techniques; Methods; Virus Replication; Zidovudine | 1992 |
In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations.
Topics: Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Protease Inhibitors; HIV-1; Humans; Virus Replication; Zidovudine | 1992 |
The effects of AZT and DDI on pre- and postimplantation mammalian embryos: an in vivo and in vitro study.
Topics: Animals; Blastocyst; Cells, Cultured; Didanosine; Electrophoresis, Polyacrylamide Gel; Embryonic and Fetal Development; Embryonic Development; Female; Fluorescent Antibody Technique; Humans; Kinetics; Mice; Microscopy, Electron, Scanning; Pregnancy; Zidovudine | 1992 |
Loss of synergistic response to combinations containing AZT in AZT-resistant HIV-1.
Topics: Antiviral Agents; Cells, Cultured; Didanosine; Drug Resistance, Microbial; Drug Synergism; HIV-1; Humans; Thymidine; Zidovudine | 1992 |
Pharmacokinetic evaluation of drug interactions with anti-HIV drugs, II: Effect of 2',3'-dideoxyinosine (ddI) on zidovudine kinetics in monkeys.
Topics: Animals; Data Interpretation, Statistical; Didanosine; Drug Interactions; Macaca fascicularis; Male; Zidovudine | 1992 |
The effect of combinations of ampligen and zidovudine or dideoxyinosine against human immunodeficiency viruses in vitro.
Topics: Antiviral Agents; Cell Line; Cytopathogenic Effect, Viral; Didanosine; Drug Synergism; HeLa Cells; HIV; Humans; Poly I-C; Poly U; Zidovudine | 1992 |
Thrombocytopenia in children infected with human immunodeficiency virus: long-term follow-up and therapeutic considerations.
Topics: Acquired Immunodeficiency Syndrome; Child; Child, Preschool; Didanosine; Follow-Up Studies; Humans; Immunoglobulins, Intravenous; Infant; Infant, Newborn; New York; Platelet Count; Thrombocytopenia; Zidovudine | 1992 |
Mycobacterium haemophilum osteomyelitis in an AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Adult; Diagnosis, Differential; Didanosine; Drug Therapy, Combination; Female; Humans; Minocycline; Mycobacterium Infections, Nontuberculous; Opportunistic Infections; Osteomyelitis; Tuberculosis, Osteoarticular; Zidovudine | 1992 |
Intestinal permeability in HIV infection: proper controls are necessary.
Topics: California; Congresses as Topic; Didanosine; HIV Infections; Humans; Intestinal Absorption; Research Design; Zidovudine | 1992 |
Generation of nucleoside-resistant variants of HIV-1 by in vitro selection in the presence of AZT or DDI but no by combinations.
Topics: Amino Acid Sequence; Didanosine; Drug Combinations; Drug Resistance, Microbial; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Recombinant Proteins; Zidovudine | 1992 |
Survival for women and men with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Age Factors; Didanosine; Female; Humans; Longevity; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Risk Factors; San Francisco; Sex Characteristics; Zidovudine | 1992 |
Lack of pharmacokinetic interaction between intravenous 2',3'-dideoxyinosine and 3'-azido-3'-deoxythymidine in rats.
Topics: Animals; Didanosine; Drug Interactions; Half-Life; Injections, Intravenous; Metabolic Clearance Rate; Rats; Zidovudine | 1992 |
The PC12 cell as a model for studies of the mechanism of induction of peripheral neuropathy by anti-HIV-1 dideoxynucleoside analogs.
Topics: Animals; Axons; Bone Marrow; Cell Division; Cell Line, Transformed; Didanosine; Dideoxynucleosides; Dose-Response Relationship, Drug; Peripheral Nervous System Diseases; Stavudine; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1991 |
Therapeutic options expand, take new directions.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Humans; United States; Zalcitabine; Zidovudine | 1991 |
Bacterial infections in human immunodeficiency virus type 1-infected children: the impact of central venous catheters and antiretroviral agents.
Topics: Adolescent; Antiviral Agents; Bacterial Infections; Catheterization, Central Venous; Child; Child, Preschool; Didanosine; Female; HIV Infections; HIV-1; Humans; Male; Retrospective Studies; Zalcitabine; Zidovudine | 1991 |
Modified tetrazolium-based colorimetric method for determining the activities of anti-HIV compounds.
Topics: Antiviral Agents; Cell Line; Colorimetry; Didanosine; Foscarnet; HIV-1; Humans; Phosphonoacetic Acid; Tetrazolium Salts; Thymidine; Zalcitabine; Zidovudine | 1991 |
Experimental studies of the hematologic and immune system toxicity of nucleoside derivatives used against HIV infection.
Topics: Animals; Bone Marrow; Didanosine; Dideoxyadenosine; Female; HIV Infections; Immune System; Immunoglobulin M; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Zalcitabine; Zidovudine | 1991 |
AIDS patients' concerns at centre stage during Vancouver conference.
Topics: Acquired Immunodeficiency Syndrome; Canada; Clinical Trials as Topic; Didanosine; Humans; Patient Participation; Risk Factors; Zidovudine | 1991 |
The selective toxicity of medications used in the treatment of AIDS on the CEM human leukemic CD4+ T-cell line.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4-Positive T-Lymphocytes; Didanosine; Humans; Leukemia; Tumor Cells, Cultured; Zidovudine | 1991 |
Pharmacokinetics of anti-HIV nucleosides in microswine.
Topics: Animals; Antiviral Agents; Chromatography, High Pressure Liquid; Didanosine; Half-Life; HIV; Male; Nucleosides; Swine; Swine, Miniature; Zalcitabine; Zidovudine | 1991 |
Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.
Topics: Animals; Antiviral Agents; Benzodiazepines; CD4-Positive T-Lymphocytes; Cell Line; Cytopathogenic Effect, Viral; Didanosine; Dogs; HIV-1; HIV-2; Humans; Imidazoles; Lymphocytes; Molecular Conformation; Molecular Structure; Reverse Transcriptase Inhibitors; Virus Replication; Zidovudine | 1990 |
Strength in numbers. Researchers begin combining compounds to fight AIDS.
Topics: Acquired Immunodeficiency Syndrome; CD4 Antigens; Didanosine; Drug Therapy, Combination; Humans; Interferons; Zalcitabine; Zidovudine | 1990 |
Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors.
Topics: ADP Ribose Transferases; Bacterial Toxins; CD4 Antigens; Cells, Cultured; Didanosine; Drug Synergism; Exotoxins; HIV; HIV Infections; Humans; Immunotoxins; In Vitro Techniques; Pseudomonas aeruginosa Exotoxin A; Reverse Transcriptase Inhibitors; T-Lymphocytes; Virulence Factors; Virus Replication; Zidovudine | 1990 |
Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization.
Topics: Cloning, Molecular; Didanosine; HIV-1; Humans; In Vitro Techniques; Leukocytes, Mononuclear; Microbial Sensitivity Tests; Nucleic Acid Hybridization; Reverse Transcriptase Inhibitors; RNA Probes; RNA-Directed DNA Polymerase; RNA, Viral; Sequence Homology, Nucleic Acid; Zidovudine | 1991 |
Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells.
Topics: Bone Marrow; Bone Marrow Cells; Bone Marrow Diseases; Cell Division; Colony-Forming Units Assay; Didanosine; Drug Synergism; Erythroid Precursor Cells; HIV; Humans; In Vitro Techniques; RNA-Directed DNA Polymerase; Stem Cells; Zidovudine | 1991 |
Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.
Topics: Base Sequence; Cells, Cultured; Codon; Didanosine; DNA, Viral; Drug Resistance, Microbial; Drug Synergism; Genotype; HIV-1; Humans; Interferon Type I; Leukocytes, Mononuclear; Molecular Sequence Data; Mutation; Recombinant Proteins; RNA-Directed DNA Polymerase; Virus Replication; Zidovudine | 1991 |
Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
Topics: Acquired Immunodeficiency Syndrome; Base Sequence; Didanosine; DNA, Viral; Drug Resistance, Microbial; Genotype; HIV-1; Humans; Molecular Sequence Data; Mutation; Oligodeoxyribonucleotides; RNA-Directed DNA Polymerase; Zidovudine | 1991 |
[Inhibitors of HIV-1 reverse transcriptase and protease as chemotherapeutics for AIDS].
Topics: Acquired Immunodeficiency Syndrome; Animals; Antiviral Agents; Didanosine; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Reverse Transcriptase Inhibitors; Thymine; Zalcitabine; Zidovudine | 1991 |
[Combination therapies with anti-retroviral agents in HIV and AIDS infections].
Topics: Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Interferons; Zalcitabine; Zidovudine | 1991 |
In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.
Topics: Base Sequence; Cell Line; Cloning, Molecular; Didanosine; DNA, Viral; Drug Resistance, Microbial; HIV-1; Humans; Immunoblotting; Kinetics; Molecular Sequence Data; Mutation; Phenotype; Polymerase Chain Reaction; Viral Proteins; Virus Replication; Zidovudine | 1992 |
In vitro inhibition studies of the glucuronidation of 3'-azido-3'-deoxythymidine catalysed by human liver UDP-glucuronosyl transferase.
Topics: Acquired Immunodeficiency Syndrome; Diazepam; Didanosine; Dose-Response Relationship, Drug; Flunitrazepam; Glucuronosyltransferase; Humans; Kinetics; Microsomes, Liver; Morphine; Naproxen; Zidovudine | 1992 |
From the National Institutes of Health.
Topics: Acquired Immunodeficiency Syndrome; Child; Didanosine; HIV Infections; Humans; National Institutes of Health (U.S.); United States; Zidovudine | 1992 |
DdI for AIDS patients intolerant to AZT.
Topics: Acquired Immunodeficiency Syndrome; Contraindications; Didanosine; Drug Storage; Female; Humans; Infant; Pregnancy; Zidovudine | 1991 |
Evaluation of HIV P24 antigen, beta 2-microglobulin, neopterin, soluble CD4, soluble CD8, and soluble interleukin-2 receptor levels in patients with AIDS or AIDS-related complex treated with 2',3'-dideoxyinosine (ddI).
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; beta 2-Microglobulin; Biopterins; CD4 Antigens; CD8 Antigens; Didanosine; Drug Tolerance; HIV Core Protein p24; Humans; Neopterin; Receptors, Interleukin-2; Solubility; Zidovudine | 1991 |
Second AIDS drug approved for those who can't tolerate AZT.
Topics: Acquired Immunodeficiency Syndrome; Adult; Child; Didanosine; Drug Tolerance; Humans; Zidovudine | 1991 |
Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity.
Topics: Antiviral Agents; Cell Line; Cytarabine; Didanosine; Dideoxynucleosides; DNA, Mitochondrial; HIV; Humans; Lymphocyte Activation; Nucleosides; Stavudine; T-Lymphocytes; Zalcitabine; Zidovudine | 1991 |
Human immunodeficiency virus infection of human lymph nodes in the SCID-hu mouse.
Topics: Animals; Antiviral Agents; Didanosine; DNA, Viral; HIV; HIV Infections; Humans; Immunohistochemistry; Immunologic Deficiency Syndromes; Lymph Nodes; Macrophages; Mice; Nucleic Acid Hybridization; Polymerase Chain Reaction; T-Lymphocytes; Transplantation, Heterologous; Zidovudine | 1991 |
Inhibition of immune functions by antiviral drugs.
Topics: Acyclovir; Antiviral Agents; Cell Cycle; Cells, Cultured; Concanavalin A; Didanosine; DNA; Ganciclovir; Humans; Immunity; In Vitro Techniques; Lymphocyte Activation; Lymphocytes; Proteins; Ribavirin; Zidovudine | 1991 |
[Anti-retroviral therapy of HIV-infection. With preliminary results of the Swiss postmarketing surveillance of zidovudine].
Topics: Didanosine; Hematologic Diseases; HIV Infections; Humans; Opportunistic Infections; Product Surveillance, Postmarketing; Switzerland; Zidovudine | 1991 |
Availability of dideoxyinosine.
Topics: Clinical Protocols; Didanosine; Drugs, Investigational; HIV Infections; Humans; Zidovudine | 1991 |
Antiretroviral treatment for children with human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Child; Didanosine; Drug Evaluation; Drug Tolerance; Humans; National Institutes of Health (U.S.); Research Design; Risk Factors; United States; Zidovudine | 1991 |
The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes.
Topics: Acetaminophen; Adolescent; Adult; Chromatography, High Pressure Liquid; Didanosine; Drug Interactions; Female; Glucuronosyltransferase; Humans; Male; Microsomes, Liver; Middle Aged; Salicylates; Sulfanilamide; Sulfanilamides; Zidovudine | 1991 |
[Antiretroviral therapy in Switzerland 1991].
Topics: Acquired Immunodeficiency Syndrome; Didanosine; HIV; Humans; RNA, Viral; Virus Replication; Zidovudine | 1991 |
In vitro inhibition of hepatitis B virus replication by 2',3'-dideoxyguanosine, 2',3'-dideoxyinosine, and 3'-azido-2',3'-dideoxythymidine in 2.2.15 (PR) cells.
Topics: Blotting, Southern; Cell Line; Didanosine; Dideoxynucleosides; DNA Replication; DNA, Viral; Hepatitis B virus; Humans; RNA, Viral; Time Factors; Virus Replication; Zidovudine | 1991 |
Determination of 3'-azido-3'-deoxythymidine, 2',3'-dideoxycytidine, 3'-fluoro-3'-deoxythymidine and 2',3'-dideoxyinosine in biological samples by high-performance liquid chromatography.
Topics: Animals; Antiviral Agents; Chromatography, High Pressure Liquid; Didanosine; Dideoxynucleosides; Humans; Liver; Rats; Zalcitabine; Zidovudine | 1990 |
Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex.
Topics: Acquired Immunodeficiency Syndrome; AIDS Dementia Complex; AIDS-Related Complex; CD4-Positive T-Lymphocytes; Didanosine; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Leukocyte Count; Male; T-Lymphocytes, Regulatory; Zidovudine | 1990 |
Clinical response to dideoxyinosine in patients with HIV infection resistant to zidovudine.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Drug Resistance, Microbial; HIV; Humans; Zidovudine | 1990 |
Methodological issues in AIDS clinical trials. Active control equivalence trials.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Humans; Placebos; Randomized Controlled Trials as Topic; Research Design; Zidovudine | 1990 |
Drugs for HIV infection.
Topics: Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1990 |
Clinical trials of combination therapies for HIV infection. Rationale for development of multidrug therapy.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1990 |
Testing of nucleoside analogues in cats infected with feline leukemia virus: a model.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antibodies, Viral; Antiviral Agents; Cats; Cell Line; Didanosine; Dideoxyadenosine; Dideoxynucleosides; Disease Models, Animal; Drug Evaluation, Preclinical; Immunologic Deficiency Syndromes; Leukemia Virus, Feline; Leukemia, Experimental; Nucleosides; Specific Pathogen-Free Organisms; Virus Replication; Zalcitabine; Zidovudine | 1989 |
[Antiretroviral treatment against HIV].
Topics: Antiviral Agents; Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1995 |
HIV-1, the brain, and combination therapy.
Topics: Adult; AIDS Dementia Complex; Antiviral Agents; Child; Didanosine; Drug Combinations; HIV-1; Humans; Lamivudine; Neuroprotective Agents; Stavudine; Zalcitabine; Zidovudine | 1995 |
Influence of human granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein (PIXY321) on the hematopoietic toxicity associated with anti-viral drugs (zidovudine and didanosine) in vitro using normal human marrow cells.
Topics: Antiviral Agents; Bone Marrow; Cells, Cultured; Didanosine; Dose-Response Relationship, Drug; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Hematopoietic Stem Cells; Humans; In Vitro Techniques; Interleukin-3; Recombinant Fusion Proteins; Zidovudine | 1995 |
Transmembrane P-glycoprotein (P-gp/P-170) in HIV infection: analysis of lymphocyte surface expression and drug-unrelated function.
Topics: Adult; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Didanosine; Female; HIV Seropositivity; Humans; Immunophenotyping; Interleukin-2; Lymphocyte Activation; Lymphocytes; Male; Phytohemagglutinins; Zalcitabine; Zidovudine | 1995 |
Combined drugs may be better than zidovudine alone for immunocompromised adults infected with HIV-1.
Topics: Adult; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Immunocompromised Host; Treatment Outcome; Zalcitabine; Zidovudine | 1995 |
[AIDS therapy with reverse transcriptase inhibitors].
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Drug Therapy, Combination; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1993 |
[Perinatally acquired human immunodeficiency virus infection].
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Female; gamma-Globulins; Humans; Infant; Male; Pregnancy; Pregnancy Complications, Infectious; Zidovudine | 1993 |
[HIV drug resistance and its genetic basis].
Topics: Amino Acid Sequence; Codon; Didanosine; Drug Resistance, Microbial; HIV; Molecular Sequence Data; Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zidovudine | 1993 |
Differential antiviral activity of two TIBO derivatives against the human immunodeficiency and murine leukemia viruses alone and in combination with other anti-HIV agents.
Topics: Animals; Antiviral Agents; Benzodiazepines; Cell Line; Didanosine; Drug Synergism; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Imidazoles; Mice; Rauscher Virus; Reverse Transcriptase Inhibitors; Virus Replication; Zidovudine | 1993 |
A cost analysis of approved antiretroviral strategies in persons with advanced human immunodeficiency virus disease and zidovudine intolerance.
Topics: Acquired Immunodeficiency Syndrome; Agranulocytosis; Algorithms; Anemia; Costs and Cost Analysis; Decision Support Techniques; Didanosine; Erythrocyte Transfusion; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; HIV Infections; Humans; Pancreatitis; Quality of Life; Zidovudine | 1994 |
Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
Topics: Amino Acid Sequence; Base Sequence; Cloning, Molecular; Codon; Didanosine; DNA Primers; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 1994 |
Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor.
Topics: Antiviral Agents; Benzodiazepines; Didanosine; Drug Synergism; Gene Products, tat; HeLa Cells; HIV; HIV Protease Inhibitors; Humans; Isoquinolines; Nevirapine; Pyridines; Pyrroles; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; tat Gene Products, Human Immunodeficiency Virus; Zalcitabine; Zidovudine | 1994 |
Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.
Topics: CD4-Positive T-Lymphocytes; Codon; Didanosine; Drug Resistance, Microbial; Genes, Viral; HIV; HIV Infections; Humans; Leukocyte Count; Mutation; Retrospective Studies; RNA-Directed DNA Polymerase; RNA, Viral; Zidovudine | 1994 |
Safety profile of didanosine among patients with advanced HIV disease who are intolerant to or deteriorate despite zidovudine therapy: results of the Canadian Open ddI Treatment Program.
Topics: Adult; Amylases; Cause of Death; Cohort Studies; Didanosine; Drug Evaluation; Female; Follow-Up Studies; HIV Infections; Humans; Male; Pancreatitis; Peripheral Nervous System Diseases; Prospective Studies; Risk Factors; Safety; Survival Analysis; Treatment Failure; Zidovudine | 1994 |
[Anti-HIV-therapy. Monotherapy with drugs delaying the course of the disease has limited effect].
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV Infections; Humans; Palliative Care; Zalcitabine; Zidovudine | 1994 |
Differential antiviral activities and intracellular metabolism of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine in human cells.
Topics: Antiviral Agents; Cells, Cultured; Chromatography, High Pressure Liquid; Didanosine; Humans; Leukemia Virus, Feline; Phosphorylation; Reverse Transcriptase Inhibitors; Virus Replication; Zidovudine | 1994 |
Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.
Topics: Base Sequence; Biological Evolution; Didanosine; DNA Primers; DNA, Viral; Drug Resistance, Microbial; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Leukocytes, Mononuclear; Molecular Sequence Data; Mutation; Phenotype; Polymerase Chain Reaction; RNA-Directed DNA Polymerase; Zidovudine | 1995 |
New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs.
Topics: Antiviral Agents; Benzodiazepines; Didanosine; Drug Synergism; HIV Reverse Transcriptase; HIV-1; Imidazoles; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Virus Replication; Zidovudine | 1994 |
Comparison of selective polymerase chain reaction primers and differential probe hybridization of polymerase chain reaction products for determination of relative amounts of codon 215 mutant and wild-type HIV-1 populations.
Topics: Base Sequence; Codon; Didanosine; DNA Primers; DNA Probes; DNA, Single-Stranded; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Nucleic Acid Hybridization; Point Mutation; Polymerase Chain Reaction; RNA-Directed DNA Polymerase; RNA, Viral; Zidovudine | 1995 |
The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
Topics: Antiviral Agents; Cells, Cultured; Cytotoxicity Tests, Immunologic; Didanosine; Drug Interactions; HIV Reverse Transcriptase; HIV-1; Humans; Indolizines; Isoquinolines; Leukocytes, Mononuclear; Molecular Structure; Nevirapine; Pyridines; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; Uracil; Zalcitabine; Zidovudine | 1995 |
In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the Inter-Company Collaboration Protocol.
Topics: Antiviral Agents; Cell Line, Transformed; Cytopathogenic Effect, Viral; Didanosine; Drug Synergism; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nevirapine; Pyridines; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Other AIDS drug regimens beat AZT alone, reduce clinical progression and mortality.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1995 |
Combination superior to zidovudine in Delta trial.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1995 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiprotozoal Agents; Antiviral Agents; Atovaquone; Candidiasis, Oral; Clindamycin; Clotrimazole; Cryptosporidiosis; Cytomegalovirus Infections; Dapsone; Didanosine; Drug Combinations; Drug Therapy, Combination; Fluconazole; Flucytosine; Folic Acid Antagonists; Foscarnet; Glucuronates; Herpes Simplex; Herpes Zoster; Humans; Isoniazid; Itraconazole; Ketoconazole; Lamivudine; Mycobacterium avium-intracellulare Infection; Naphthoquinones; Nystatin; Pentamidine; Pneumocystis Infections; Pneumonia, Pneumocystis; Prednisone; Primaquine; Reverse Transcriptase Inhibitors; Stavudine; Syphilis; Toxoplasmosis; Trimetrexate; Tuberculosis; Zalcitabine; Zidovudine | 1995 |
AZT combination trial shows positive results.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1995 |
Confirmation for combination AIDS therapy.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Controlled Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Multicenter Studies as Topic; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1995 |
Study shows two drugs are best for HIV infection.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1995 |
Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Base Sequence; Didanosine; Drug Resistance; Female; HIV Reverse Transcriptase; HIV-1; Humans; Male; Molecular Sequence Data; Mutation; RNA-Directed DNA Polymerase; Zidovudine | 1995 |
Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Cardiomyopathies; CD4 Lymphocyte Count; Child, Preschool; Didanosine; Dose-Response Relationship, Drug; Echocardiography; Female; Heart; HIV; Humans; Infant; Infant, Newborn; Male; Medical Records; Retrospective Studies; Severity of Illness Index; Zalcitabine; Zidovudine | 1995 |
Perspectives in drug therapy of HIV infection.
Topics: Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Time Factors; Zidovudine | 1995 |
Zidovudine regimen in pediatric AIDS trial halted, other regimens shown superior.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Didanosine; Disease Progression; Drug Therapy, Combination; Humans; Infant; Zidovudine | 1995 |
Increased human immunodeficiency virus (HIV) type 1 DNA content and quinolinic acid concentration in brain tissues from patients with HIV encephalopathy.
Topics: Adolescent; Adult; AIDS Dementia Complex; AIDS-Related Opportunistic Infections; Base Sequence; Brain; Brain Chemistry; Cells, Cultured; Cerebellum; Child; Child, Preschool; Didanosine; DNA Primers; DNA, Viral; Genes, pol; HIV-1; Humans; Infant; Macrophages; Middle Aged; Molecular Sequence Data; Mutation; Organ Specificity; Polymerase Chain Reaction; Quinolinic Acid; Tumor Necrosis Factor-alpha; Zidovudine | 1995 |
Chemotherapeutic options in HIV infection.
Topics: Analysis of Variance; Antiviral Agents; Biotransformation; Cell Line; Cells, Cultured; Chromatography, High Pressure Liquid; Didanosine; Drug Interactions; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lymphocytes; Microbial Sensitivity Tests; Tumor Cells, Cultured; Zidovudine | 1994 |
Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus.
Topics: Adenosine Kinase; Cells, Cultured; Didanosine; DNA Replication; Drug Synergism; HIV-1; Humans; Hydroxyurea; Phosphorylation; Proviruses; Uridine Kinase; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
Topics: Acquired Immunodeficiency Syndrome; Biological Evolution; Didanosine; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nevirapine; Polymerase Chain Reaction; Pyridines; Pyridones; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Selection, Genetic; Virus Replication; Zidovudine | 1993 |
Triple whammy. Will an AIDS therapy live up to its advance billing?
Topics: Acquired Immunodeficiency Syndrome; Cells, Cultured; Didanosine; Drug Therapy, Combination; HIV; Humans; Nevirapine; Pyridines; Pyridones; Reverse Transcriptase Inhibitors; Virus Replication; Zidovudine | 1993 |
Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.
Topics: Antiviral Agents; Cells, Cultured; Didanosine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Piperazines; Reverse Transcriptase Inhibitors; Virus Replication; Zidovudine | 1993 |
AIDS drugs. Harvard group makes a splash--twice.
Topics: Antiviral Agents; Didanosine; HIV; Mutation; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; Virus Replication; Zidovudine | 1993 |
Resisting the temptation.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Combinations; HIV; Humans; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Virus Replication; Zidovudine | 1993 |
HIV and multidrug resistance.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Reverse Transcriptase Inhibitors; Zidovudine | 1993 |
Effect of resistance on combination chemotherapy for human immunodeficiency virus infection.
Topics: Antiviral Agents; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; RNA-Directed DNA Polymerase; Virus Replication; Zidovudine | 1993 |
Evaluation of the combination effect of different antiviral compounds against HIV in vitro.
Topics: Antiviral Agents; Benzodiazepines; Didanosine; Dideoxynucleosides; Drug Combinations; Drug Evaluation; Drug Synergism; HIV; Humans; Imidazoles; Microbial Sensitivity Tests; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 1993 |
pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Didanosine; Drug Resistance, Microbial; Genes, pol; Glutamine; HIV Reverse Transcriptase; HIV-1; Humans; Leucine; Microbial Sensitivity Tests; Mutation; Phenotype; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tyrosine; Valine; Zidovudine | 1993 |
[A new AIDS drug in evaluation].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Delavirdine; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Indoles; Piperazines; Reverse Transcriptase Inhibitors; Zidovudine | 1993 |
Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
Topics: Base Sequence; Didanosine; DNA, Viral; Drug Resistance, Microbial; HeLa Cells; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutagenesis, Site-Directed; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zidovudine | 1993 |
Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor.
Topics: Antiviral Agents; Base Sequence; Benzimidazoles; Cell Line; Didanosine; DNA, Single-Stranded; Drug Synergism; HIV Reverse Transcriptase; HIV-1; Humans; Leukemia Virus, Murine; Molecular Sequence Data; Molecular Structure; Reverse Transcriptase Inhibitors; Thiazoles; Zidovudine | 1993 |
Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay.
Topics: Acyclovir; CD4 Lymphocyte Count; Didanosine; Disease Progression; DNA, Single-Stranded; Drug Therapy, Combination; Gene Amplification; Genes, pol; HIV Seropositivity; HIV-1; Humans; Longitudinal Studies; Nucleic Acid Hybridization; Oligonucleotide Probes; Reproducibility of Results; RNA, Viral; Sensitivity and Specificity; Zidovudine | 1995 |
Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds.
Topics: Amino Acid Sequence; Didanosine; DNA, Viral; Female; Genes, pol; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Male; Molecular Sequence Data; Mutagenesis; RNA, Viral; Sequence Analysis, DNA; Transcription, Genetic; Viremia; Zidovudine | 1995 |
Identification of drug-related genotypic changes in HIV-1 from serum using the selective polymerase chain reaction.
Topics: Antiviral Agents; Base Sequence; Didanosine; DNA Primers; DNA, Viral; Efficiency; Evaluation Studies as Topic; Genes, pol; Genotype; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Proviruses; Reproducibility of Results; RNA, Viral; Sensitivity and Specificity; Templates, Genetic; Virion; Zalcitabine; Zidovudine | 1994 |
Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine.
Topics: Base Sequence; Didanosine; DNA Ligases; DNA Primers; DNA Probes; DNA, Viral; Drug Resistance, Microbial; Evaluation Studies as Topic; Genes, pol; HIV Infections; HIV-1; Humans; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Sensitivity and Specificity; Time Factors; Virology; Zidovudine | 1995 |
Treatment of children with HIV infection. PENTA (Paediatric European Network for Treatment of AIDS)
Topics: Child; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zidovudine | 1995 |
Effects of the Th1 and Th2 stimulatory cytokines interleukin-12 and interleukin-4 on human immunodeficiency virus replication.
Topics: Antibodies, Monoclonal; Cells, Cultured; Cytopathogenic Effect, Viral; Didanosine; HIV Core Protein p24; HIV-1; Humans; Interleukin-12; Interleukin-4; Interleukins; Leukocytes, Mononuclear; Lymphocyte Activation; Macrophages; Monocytes; Muromonab-CD3; Phytohemagglutinins; T-Lymphocytes, Helper-Inducer; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Effect of zidovudine on transplacental pharmacokinetics of ddI in the pigtailed macaque (Macaca nemestrina).
Topics: Animals; Didanosine; Drug Interactions; Female; Macaca nemestrina; Maternal-Fetal Exchange; Metabolic Clearance Rate; Placenta; Pregnancy; Zidovudine | 1995 |
Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy.
Topics: Base Sequence; Didanosine; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV; HIV Infections; Humans; Molecular Sequence Data; RNA, Viral; Zidovudine | 1995 |
Study of AZT effectiveness in treating HIV-infected children halted.
Topics: Adolescent; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Infant; Treatment Outcome; Zidovudine | 1995 |
The effect of zidovudine and 2'3'-dideoxyinosine on human trophoblast in culture.
Topics: Analysis of Variance; Cells, Cultured; Chorionic Gonadotropin; Didanosine; Energy Metabolism; Female; Humans; Pregnancy; Pregnancy Proteins; Pregnancy Trimester, First; Pregnancy Trimester, Third; Progesterone; Trophoblasts; Zidovudine | 1995 |
[Use of an apoptosis test in the biological follow up of patients infected with HIV].
Topics: Apoptosis; CD4 Lymphocyte Count; Cells, Cultured; Didanosine; HIV Infections; Humans; Lymphocytes; Zidovudine | 1993 |
Synergistic effect of recombinant CD4-immunoglobulin in combination with azidothymidine, dideoxyinosine and 0.5 beta-monoclonal antibody on human immunodeficiency virus infection in vitro.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; CD4 Immunoadhesins; Cells, Cultured; Didanosine; Drug Synergism; Drug Therapy, Combination; HIV Infections; Humans; Lymphocytes; Zidovudine | 1994 |
Community treatment of HIV-1: initial stage and asymptotic dynamics.
Topics: Community Health Services; Didanosine; HIV Infections; HIV-1; Humans; Male; Mathematics; Models, Biological; Zidovudine | 1995 |
Stabilities of quantitative plasma culture for human immunodeficiency virus, RNA, and p24 antigen from samples collected in VACUTAINER CPT and standard VACUTAINER tubes.
Topics: Anticoagulants; Blood Specimen Collection; CD4 Lymphocyte Count; Culture Media; Didanosine; DNA, Viral; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Evaluation Studies as Topic; False Negative Reactions; Gels; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Polyesters; Polymerase Chain Reaction; Predictive Value of Tests; RNA, Viral; Severity of Illness Index; Specimen Handling; Viremia; Virus Cultivation; Zidovudine | 1994 |
Increased hematopoietic toxicity following administration of interferon-a with combination dideoxynucleoside therapy (zidovudine plus ddI) administered in normal mice.
Topics: Animals; Bone Marrow; Didanosine; Dose-Response Relationship, Drug; Drug Synergism; Female; Interferon-alpha; Mice; Mice, Inbred C57BL; Spleen; Zidovudine | 1995 |
Transfer of dideoxyinosine across the human isolated placenta.
Topics: Antipyrine; Biological Transport; Chromatography, High Pressure Liquid; Didanosine; Female; Glucose; Humans; Hydrogen-Ion Concentration; Hypoxanthine; Hypoxanthines; In Vitro Techniques; Inosine; Maternal-Fetal Exchange; Perfusion; Placenta; Pregnancy; Uric Acid; Zidovudine | 1994 |
Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells.
Topics: Analysis of Variance; B-Lymphocytes; Cell Line; Cells, Cultured; Didanosine; Drug Interactions; Humans; Leukocytes, Mononuclear; Lymphocyte Activation; Phosphorylation; Phytohemagglutinins; Thymidine; Zalcitabine; Zidovudine | 1994 |
A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments.
Topics: Didanosine; Dose-Response Relationship, Drug; Drug Antagonism; Drug Combinations; Drug Evaluation, Preclinical; Drug Interactions; Drug Synergism; HIV-1; Humans; Models, Theoretical; Zidovudine | 1994 |
Early and prolonged decrease of viremia in HIV-1-infected patients treated with didanosine.
Topics: AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Didanosine; DNA, Viral; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Polymerase Chain Reaction; Proviruses; RNA, Viral; Viremia; Virion; Zidovudine | 1995 |
Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations.
Topics: Acquired Immunodeficiency Syndrome; Cells, Cultured; Didanosine; Dideoxynucleosides; Drug Synergism; HIV-1; HIV-2; Humans; Leukocytes, Mononuclear; Zidovudine | 1994 |
In vivo inhibition of syncytium-inducing variants of HIV in patients treated with didanosine.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Giant Cells; HIV Infections; HIV-1; Humans; Phenotype; Prospective Studies; Zidovudine | 1995 |
In-vitro activity of zidovudine, zalcitabine, and didanosine against mycoplasmas.
Topics: Didanosine; In Vitro Techniques; Microbial Sensitivity Tests; Mycoplasma; Zalcitabine; Zidovudine | 1993 |
Transfusion of blood components to persons infected with human immunodeficiency virus type 1: relationship to opportunistic infection.
Topics: AIDS-Related Opportunistic Infections; Blood Component Transfusion; Blood Group Antigens; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Cell Count; Cytomegalovirus Infections; Didanosine; Erythrocyte Transfusion; Female; HIV-1; Humans; Isoantibodies; Male; Mycobacterium avium-intracellulare Infection; Retrospective Studies; Risk Factors; Zalcitabine; Zidovudine | 1994 |
Antiretroviral therapy in HIV-infected adults. Which regimens are recommended?
Topics: Adult; CD4-Positive T-Lymphocytes; Didanosine; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; HIV Infections; Humans; Leukocyte Count; Zalcitabine; Zidovudine | 1994 |
Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine.
Topics: Adult; CD4-Positive T-Lymphocytes; Didanosine; DNA, Viral; HIV Core Protein p24; HIV Infections; HIV Seropositivity; Humans; Leukocyte Count; Middle Aged; Polymerase Chain Reaction; Proviruses; RNA, Viral; Time Factors; Zidovudine | 1994 |
Dynamics of molecular parameters of human immunodeficiency virus type 1 activity in vivo.
Topics: Acquired Immunodeficiency Syndrome; Adult; CD4-Positive T-Lymphocytes; Didanosine; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Polymerase Chain Reaction; Proviruses; RNA, Viral; Time Factors; Transcription, Genetic; Zidovudine | 1994 |
Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds.
Topics: Cell Division; Cytopathogenic Effect, Viral; Didanosine; Drug Synergism; HIV-1; Humans; Interphase; Lymphocytes; Virus Replication; Zalcitabine; Zidovudine | 1994 |
Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection.
Topics: CD4-Positive T-Lymphocytes; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Genes, pol; HIV; HIV Infections; Humans; Leukocyte Count; Models, Biological; Mutation; Population Dynamics; Species Specificity; Virus Replication; Zidovudine | 1994 |
Preferential incorporation of nucleoside analogs after template switching during human immunodeficiency virus reverse transcription.
Topics: Antiviral Agents; Base Sequence; CD4-Positive T-Lymphocytes; Cell Line; Didanosine; Dideoxynucleotides; DNA, Viral; HIV-1; Humans; Molecular Sequence Data; Nucleosides; Polymerase Chain Reaction; RNA, Transfer, Lys; Templates, Genetic; Thymine Nucleotides; Transcription, Genetic; Zidovudine | 1994 |
Lower socioeconomic status and shorter survival following HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; British Columbia; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Health Services; HIV Infections; HIV Seropositivity; Homosexuality, Male; Humans; Income; Male; Pneumonia, Pneumocystis; Regression Analysis; Socioeconomic Factors; Survival Rate; Zalcitabine; Zidovudine | 1994 |
[HIV infection--current possibilities in antiviral therapy].
Topics: Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Pancreatitis; Zalcitabine; Zidovudine | 1994 |
Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides.
Topics: Antiviral Agents; Cells, Cultured; Didanosine; Dideoxynucleosides; Drug Synergism; HIV-1; Humans; Hydroxyurea; Virus Replication; Zalcitabine; Zidovudine | 1994 |
Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes.
Topics: Antiviral Agents; Asparagine; Aspartic Acid; Cell Survival; Cells, Cultured; Didanosine; Drug Synergism; HIV Infections; Humans; Hydroxyurea; In Vitro Techniques; Lymphocyte Activation; Lymphocytes; Virus Replication; Zalcitabine; Zidovudine | 1994 |
Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication.
Topics: Acquired Immunodeficiency Syndrome; Cell Survival; Didanosine; DNA Replication; DNA, Viral; Dose-Response Relationship, Drug; Drug Synergism; HIV Core Protein p24; HIV-1; Humans; Hydroxyurea; Leukocytes, Mononuclear; Lymphocyte Activation; Macrophage Activation; Macrophages; Virus Replication; Zidovudine | 1994 |
MT-2 cell tropism of human immunodeficiency virus type 1 isolates as a marker for response to treatment and development of drug resistance.
Topics: Adult; Biomarkers; CD4 Lymphocyte Count; Cell Line; Didanosine; Disease Progression; Drug Resistance, Microbial; Female; HIV Infections; HIV-1; Humans; Male; Prognosis; Virus Replication; Zidovudine | 1994 |
Generation of multiple drug resistance by sequential in vitro passage of the human immunodeficiency virus type 1.
Topics: Antiviral Agents; Cell Line; Cloning, Molecular; Didanosine; Drug Interactions; Drug Resistance, Microbial; HIV-1; Humans; Interferon-alpha; Neutralization Tests; Phenotype; Serial Passage; Stavudine; Zalcitabine; Zidovudine | 1994 |
[Current developments in antiviral chemotherapy. Part 4: Foscarnet, zidovudine, didanosine].
Topics: AIDS-Related Opportunistic Infections; Didanosine; Dose-Response Relationship, Drug; Drug Administration Schedule; Foscarnet; Herpesviridae Infections; HIV Infections; Humans; Zidovudine | 1994 |
Hyperosmolar nonketotic diabetic syndrome following treatment of human immunodeficiency virus infection with didanosine.
Topics: Adult; Blood Glucose; Didanosine; Female; HIV Infections; HIV Seropositivity; Humans; Hyperglycemia; Hyperglycemic Hyperosmolar Nonketotic Coma; Monitoring, Physiologic; Pregnancy; Pregnancy Complications, Infectious; Pregnancy in Diabetics; Zidovudine | 1994 |
[The anti-viral agents used in the treatment of AIDS].
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Humans; Zalcitabine; Zidovudine | 1994 |
Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine.
Topics: Animals; Antiviral Agents; Cats; Cells, Cultured; Didanosine; Drug Resistance, Microbial; Foscarnet; Immunodeficiency Virus, Feline; Mutation; Phenotype; Zalcitabine; Zidovudine | 1994 |
Influence of interleukin-3 (IL-3) on the hematopoietic toxicity associated with combination anti-viral drugs (zidovudine and DDI) in vitro using retrovirus-infected bone marrow cells.
Topics: Animals; Antiviral Agents; Bone Marrow; Bone Marrow Cells; Didanosine; Drug Interactions; Female; Hematopoiesis; Hematopoietic Stem Cells; Immunoglobulin M; Interleukin-3; Mice; Mice, Inbred C57BL; Retroviridae Infections; Stem Cells; Zidovudine | 1994 |
Effect of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine on establishment of human immunodeficiency virus type 1 infection in cultured CD8+ lymphocytes.
Topics: Antibodies, Monoclonal; Base Sequence; CD8 Antigens; Cells, Cultured; Didanosine; DNA Probes; DNA, Viral; Flow Cytometry; HIV Infections; HIV-1; Humans; Lymphocytes; Molecular Sequence Data; Zidovudine | 1994 |
In vitro susceptibility of clinical isolates of HIV-1 to XM323, a non-peptidyl HIV protease inhibitor.
Topics: Antiviral Agents; Azepines; Cells, Cultured; Didanosine; Giant Cells; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Species Specificity; Zalcitabine; Zidovudine | 1994 |
[Investigation of AZT susceptibility of sequential HIV-1 isolates from patients treated with ddI after long-term therapy with AZT].
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Didanosine; Female; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Zidovudine | 1994 |
Use of didanosine in zidovudine-intolerant patients infected with human immunodeficiency virus.
Topics: CD4-Positive T-Lymphocytes; Didanosine; HIV Core Protein p24; HIV Infections; Humans; Leukocyte Count; Male; Zidovudine | 1993 |
Didanosine and ACTG 116A.
Topics: Didanosine; HIV Infections; Humans; Zidovudine | 1993 |
Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy.
Topics: CD4-Positive T-Lymphocytes; Codon; Didanosine; Drug Therapy, Combination; Gene Amplification; Genes, Viral; HIV; HIV Infections; Humans; Leukocyte Count; RNA, Viral; Zidovudine | 1993 |
Quantitation of unintegrated HIV-1 DNA in asymptomatic patients in the presence or absence of antiretroviral therapy.
Topics: Adult; Antiviral Agents; Biomarkers; CD4-Positive T-Lymphocytes; Didanosine; DNA, Viral; Female; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Leukocyte Count; Male; Middle Aged; Zidovudine | 1993 |
Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Complex; Base Sequence; CD4-Positive T-Lymphocytes; Didanosine; DNA, Viral; Drug Resistance, Microbial; Female; Genes, pol; HIV Core Protein p24; HIV-1; Humans; Leukocyte Count; Male; Microbial Sensitivity Tests; Middle Aged; Molecular Sequence Data; Time Factors; Zidovudine | 1993 |
The Concorde trial.
Topics: Didanosine; HIV Infections; Humans; Time Factors; Zidovudine | 1993 |
Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy.
Topics: CD4-Positive T-Lymphocytes; Didanosine; HIV Infections; Humans; Interleukin-6; Leukocyte Count; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Risk Factors; Zidovudine | 1993 |
What to do when zidovudine fails.
Topics: Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1994 |
Prophylactic zalcitabine and interferon-alpha for a large-bore needlestick exposure to human immunodeficiency virus.
Topics: Adult; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Interferon alpha-2; Interferon-alpha; Needlestick Injuries; Recombinant Proteins; Zalcitabine; Zidovudine | 1994 |
Relationship between anti-p24 antibody levels and p24 antigenemia in HIV-infected patients.
Topics: Antigen-Antibody Complex; Didanosine; HIV Antibodies; HIV Core Protein p24; HIV Infections; Humans; Prognosis; Viremia; Zidovudine | 1993 |
Intermittent therapy.
Topics: Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1994 |
Efflux of zidovudine and 2',3'-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina.
Topics: Animals; Antipyrine; Chromatography, High Pressure Liquid; Didanosine; Drug Interactions; Female; Macaca nemestrina; Male; Zidovudine | 1994 |
Pharmacotherapy of HIV. APhA Editorial Board on Pharmaceutical Care for Patients with HIV Infection.
Topics: Adult; CD4 Antigens; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Male; Pharmaceutical Services; Zalcitabine; Zidovudine | 1994 |
Comparative embryonic cytotoxicity of antiretroviral nucleosides.
Topics: Animals; Antiviral Agents; Culture Techniques; Didanosine; Embryo, Mammalian; HIV; Mice; Nucleosides; Stavudine; Zalcitabine; Zidovudine | 1994 |
Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells.
Topics: Cells, Cultured; Deoxycytidine Kinase; Didanosine; Dideoxynucleosides; HIV-1; Humans; Monocytes; Phosphorylation; Phytohemagglutinins; Thymidine Kinase; Zidovudine | 1994 |
The drugs 2',3'-dideoxyinosine (ddI) and 2',3'-dideoxycytidine (ddC) are safe alternatives in people with AIDS with zidovudine-induced myopathy.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Humans; Male; Muscular Diseases; Zalcitabine; Zidovudine | 1994 |
Decreased anti-human immunodeficiency virus type-1 activities of 2',3'-dideoxynucleoside analogs in MOLT-4 cell sublines resistant to 2',3'-dideoxynucleoside analogs.
Topics: Cell Line; Culture Media; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Microscopy, Electron; Time Factors; Zalcitabine; Zidovudine | 1993 |
Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Didanosine; Drug Resistance, Microbial; HIV Seropositivity; HIV-1; Humans; Leukocytes, Mononuclear; Microbial Sensitivity Tests; Time Factors; Zalcitabine; Zidovudine | 1994 |
Inactivation of HIV infectivity by the chlorite-oxygen reaction product tetrachlorodecaoxygen.
Topics: Antiviral Agents; Cells, Cultured; Chlorine; Didanosine; Drug Interactions; HIV Envelope Protein gp120; HIV-1; HIV-2; Humans; Oxides; Tumor Cells, Cultured; Virus Replication; Zidovudine | 1993 |
Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs.
Topics: Acquired Immunodeficiency Syndrome; Amino Acid Sequence; Base Sequence; Consensus Sequence; Didanosine; Genes, pol; Genotype; HIV-1; Humans; Leukocytes, Mononuclear; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Point Mutation; Polymerase Chain Reaction; Sequence Homology, Amino Acid; Time Factors; Viral Plaque Assay; Zalcitabine; Zidovudine | 1993 |
Regulation of megakaryocyte colony forming cell numbers and ploidy by dideoxynucleosides in immunodeficient mice.
Topics: Animals; Bone Marrow; Colony-Forming Units Assay; Didanosine; Female; Hematocrit; Hematopoietic Stem Cells; Leukemia Virus, Murine; Megakaryocytes; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Platelet Count; Ploidies; Spleen; Zalcitabine; Zidovudine | 1993 |
[Treatment--medical management of HIV carrier].
Topics: Accidents, Occupational; Adjuvants, Immunologic; AIDS-Related Opportunistic Infections; Animals; Carrier State; Didanosine; Female; HIV Infections; Humans; Immunologic Factors; Male; Needles; Pneumonia, Pneumocystis; Zidovudine | 1993 |
[BRM and drug combination therapy of HIV carriers].
Topics: Carrier State; Cytokines; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Immunologic Factors; Male; Zidovudine | 1993 |
[Early treatment in HIV infection].
Topics: Acquired Immunodeficiency Syndrome; Carrier State; CD4 Antigens; Didanosine; HIV Infections; Humans; Zidovudine | 1993 |
[Treatment by antiviral drugs of HIV-infected patients].
Topics: Acyclovir; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Interferon-alpha; Zalcitabine; Zidovudine | 1993 |
[AIDS: therapeutic changes in the second decade. Triple combination--HIV vaccination].
Topics: Acquired Immunodeficiency Syndrome; AIDS Vaccines; Antiviral Agents; Cross-Sectional Studies; Didanosine; Drug Therapy, Combination; Germany; Humans; Incidence; Nevirapine; Pyridines; Zidovudine | 1993 |
Treating HIV infection: what pharmacists need to know.
Topics: Adult; AIDS-Related Opportunistic Infections; Didanosine; Education, Pharmacy, Continuing; Female; HIV Infections; Humans; Male; Middle Aged; Pharmacists; Risk Factors; Zidovudine | 1993 |
HIV-related thrombocytopenia.
Topics: Didanosine; HIV Infections; Humans; Recurrence; Thrombocytopenia; Zidovudine | 1993 |
Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.
Topics: Acquired Immunodeficiency Syndrome; Amino Acid Sequence; Base Sequence; Didanosine; Dose-Response Relationship, Drug; Genetic Variation; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Homology, Amino Acid; Zalcitabine; Zidovudine | 1993 |
Population-based estimates of antiretroviral therapy and anti-Pneumocystis prophylaxis in San Francisco: 1991.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antiviral Agents; Cohort Studies; Dapsone; Didanosine; Drug Combinations; Follow-Up Studies; HIV Infections; Humans; Male; Pentamidine; Pneumonia, Pneumocystis; San Francisco; Sulfamethizole; Trimethoprim; Zalcitabine; Zidovudine | 1993 |
Antiretroviral therapy.
Topics: Didanosine; Dideoxynucleosides; HIV Infections; Humans; Zalcitabine; Zidovudine | 1993 |
The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; AIDS-Related Complex; Body Weight; Diarrhea; Didanosine; Female; HIV Core Protein p24; Humans; Leukocyte Count; Lymphocyte Subsets; Male; Middle Aged; Pancreatitis; Peripheral Nervous System Diseases; Quality of Life; Risk Factors; Zidovudine | 1993 |
Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.
Topics: 5'-Nucleotidase; Acquired Immunodeficiency Syndrome; Adenosine Kinase; AIDS-Related Complex; Chromatography, High Pressure Liquid; Deoxycytidine Kinase; Deoxyribonucleotides; Didanosine; HIV-1; Humans; Kinetics; Microbial Sensitivity Tests; Monocytes; Phosphorylation; Thymidine Kinase; Uridine Kinase; Zalcitabine; Zidovudine | 1993 |
Mechanism of action of N-butyl deoxynojirimycin in inhibiting HIV-1 infection and activity in combination with nucleoside analogs.
Topics: 1-Deoxynojirimycin; Antiviral Agents; CD4 Antigens; Cell Line; Didanosine; Drug Interactions; HIV Envelope Protein gp120; HIV-1; Humans; Nucleosides; Zalcitabine; Zidovudine | 1993 |
High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Child; Child, Preschool; Didanosine; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; HIV-1; Humans; Infant; Microbial Sensitivity Tests; Mutation; Polymerase Chain Reaction; Time Factors; Zalcitabine; Zidovudine | 1993 |
Antiretroviral therapy and medical management of the human immunodeficiency virus-infected child. Working Group on Antiretroviral Therapy: National Pediatric HIV Resource Center.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Child; Child, Preschool; Didanosine; HIV Infections; Humans; Immunoglobulins, Intravenous; Infant; Zalcitabine; Zidovudine | 1993 |
A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; AIDS-Related Complex; Antigens, CD; Biomarkers; Body Weight; CD4 Antigens; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Core Protein p24; Humans; Male; Middle Aged; Pilot Projects; T-Lymphocyte Subsets; Time Factors; Zalcitabine; Zidovudine | 1993 |
Preliminary study analysis suggests similar efficacy for didanosine and zalcitabine.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Humans; Treatment Outcome; Zalcitabine; Zidovudine | 1993 |
Antiretroviral treatment reverses HIV-induced reduction in the expression of surface antigens on alveolar macrophages in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Antigens, Surface; Didanosine; HLA-DR Antigens; Humans; Macrophages, Alveolar; Zidovudine | 1993 |
Didanosine-associated eosinophilia with acute thrombocytopenia.
Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Adult; Didanosine; Eosinophilia; Humans; Male; Sarcoma, Kaposi; Thrombocytopenia; Zidovudine | 1993 |
[Antiretroviral therapy].
Topics: Clinical Trials as Topic; Didanosine; HIV Infections; Humans; Zidovudine | 1993 |
Comparison of dideoxynucleoside drugs (DDI and zidovudine) and induction of hematopoietic toxicity using normal human bone marrow cells in vitro.
Topics: Bone Marrow; Bone Marrow Cells; Colony-Forming Units Assay; Didanosine; Dose-Response Relationship, Drug; Drug Interactions; Erythropoietin; Hematopoiesis; Hematopoietic Stem Cells; Humans; In Vitro Techniques; Zidovudine | 1993 |
Using convergent combination therapy, researchers stopped the human immunodeficiency virus (HIV) from reproducing in test tubes.
Topics: Didanosine; Drug Therapy, Combination; HIV Infections; Humans; In Vitro Techniques; Pyridones; Zidovudine | 1993 |
Parvovirus B19 infection in human immunodeficiency virus type 1-infected persons failing or intolerant to zidovudine therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Antibodies, Viral; Didanosine; Erythema Infectiosum; HIV Infections; Humans; Incidence; Male; Middle Aged; Parvovirus B19, Human; Zidovudine | 1993 |
Population pharmacokinetics of didanosine in patients with human immunodeficiency virus infection.
Topics: Antiviral Agents; Demography; Didanosine; HIV Infections; Humans; Zidovudine | 1996 |
Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 1. Stability studies for hairless rat skin permeation.
Topics: Administration, Cutaneous; Animals; Anti-Infective Agents, Local; Antiviral Agents; Chromatography, High Pressure Liquid; Didanosine; Dideoxynucleosides; Enzyme Inhibitors; Female; Half-Life; HIV-1; In Vitro Techniques; Rats; Rats, Nude; Skin Absorption; Zalcitabine; Zidovudine | 1995 |
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.
Topics: Animals; Antiviral Agents; Base Sequence; Cell Line; Didanosine; DNA Primers; DNA, Viral; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HeLa Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutagenesis, Site-Directed; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Virus Replication; Zidovudine | 1996 |
Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA.
Topics: Antiviral Agents; Base Sequence; Cells, Cultured; Didanosine; Dideoxynucleotides; DNA, Viral; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Nucleic Acid Conformation; Nucleosides; Nucleotides; Phytohemagglutinins; RNA, Viral; Thymine Nucleotides; Transcription, Genetic; Zalcitabine; Zidovudine | 1996 |
Development of a human thymic organ culture model for the study of HIV pathogenesis.
Topics: Animals; Antiviral Agents; Apoptosis; Cats; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Didanosine; Drug Evaluation, Preclinical; Fetus; HIV Infections; HIV-1; Humans; Mice; Models, Biological; Organ Culture Techniques; Thymus Gland; Time Factors; Virus Replication; Zidovudine | 1995 |
Inhibitory effect of 3'-azido-3'-deoxythymidine on proliferative responsiveness of CD8+ lymphocytes to interleukin-2.
Topics: Antiviral Agents; CD8-Positive T-Lymphocytes; Cell Division; Didanosine; Humans; Interleukin-2; Lamivudine; Lymphocyte Activation; Zalcitabine; Zidovudine | 1994 |
Intracellular activation and cytotoxicity of three different combinations of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.
Topics: Antiviral Agents; Cell Division; Cell Line; Didanosine; Dideoxynucleotides; Drug Interactions; Humans; Reverse Transcriptase Inhibitors; Thymine Nucleotides; Zidovudine | 1995 |
Uptake and distribution of 2',3'-dideoxyinosine and its derivatives in a human monocytoid cell line.
Topics: Biological Transport; Biotransformation; Cell Division; Deoxyadenine Nucleotides; Didanosine; Dideoxynucleotides; DNA Damage; DNA Replication; DNA, Neoplasm; Humans; Lymphoma, Large B-Cell, Diffuse; Monocytes; RNA, Neoplasm; Tumor Cells, Cultured; Zidovudine | 1995 |
In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI.
Topics: Antiviral Agents; Cells, Cultured; Didanosine; Drug Interactions; HIV Protease Inhibitors; HIV-1; Humans; Leukocytes, Mononuclear; Molecular Structure; Oligopeptides; Phytohemagglutinins; Zidovudine | 1995 |
Managing HIV disease after Delta.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Combinations; HIV Infections; Humans; Randomized Controlled Trials as Topic; Zalcitabine; Zidovudine | 1996 |
The mutation frequency of feline immunodeficiency virus enhanced by 3'-azido-3'-deoxythymidine.
Topics: Animals; Antiviral Agents; Bromodeoxyuridine; Cats; Cell Line; Didanosine; Dose-Response Relationship, Drug; Gene Frequency; Immunodeficiency Virus, Feline; Kidney; Mutation; Virus Cultivation; Zalcitabine; Zidovudine | 1996 |
Factors associated with changes in the use of antiretroviral therapy by a cohort of homosexual men infected with human immunodeficiency virus type 1.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Drug Therapy, Combination; Drug Utilization; Follow-Up Studies; Hemoglobins; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Multicenter Studies as Topic; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1995 |
In vitro inhibition of the replication of human immunodeficiency virus type 1 by beta-mercaptoethylamine (cysteamine).
Topics: Antiviral Agents; Cell Death; Cells, Cultured; Cysteamine; Didanosine; DNA, Viral; Drug Therapy, Combination; HIV Core Protein p24; HIV-1; Humans; Macrophages; Monocytes; Polymerase Chain Reaction; Zidovudine | 1996 |
[Pancreatic disease in patients with HIV treated with didanosine (DDI)].
Topics: Acute Disease; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Pancreatic Diseases; Pancreatitis; Zidovudine | 1996 |
Determination intestinal metabolism and permeability for several compounds in rats. Implications on regional bioavailability in humans.
Topics: Animals; Biological Availability; Captopril; Didanosine; Humans; Intestine, Small; Male; Mannitol; Ofloxacin; Permeability; Rats; Rats, Sprague-Dawley; Zidovudine | 1996 |
Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 2. The effect of vehicle and enhancer on skin permeation.
Topics: Animals; Antiviral Agents; Didanosine; Drug Delivery Systems; Female; Rats; Skin; Zalcitabine; Zidovudine | 1996 |
Adverse events from drug therapy for human immunodeficiency virus disease.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Dapsone; Didanosine; Female; HIV Infections; Humans; Male; Pneumonia, Pneumocystis; Risk Factors; Trimethoprim, Sulfamethoxazole Drug Combination; Urban Health; Zalcitabine; Zidovudine | 1996 |
Didanosine (DDI) alone is now considered the first-line therapy for symptomatic children infected with the human immunodeficiency virus (HIV)
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Clinical Trials as Topic; Didanosine; HIV Infections; Humans; Infant; Zidovudine | 1996 |
[Anti-retroviral monotherapy with nucleoside analogues].
Topics: Antiviral Agents; Didanosine; HIV Infections; Humans; Zalcitabine; Zidovudine | 1995 |
Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma.
Topics: Antiviral Agents; Biopsy; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Kinetics; Lamivudine; Lymph Nodes; RNA, Viral; Viremia; Zalcitabine; Zidovudine | 1996 |
Zidovudine resistance reverse transcriptase mutations during didanosine monotherapy.
Topics: Didanosine; Drug Resistance, Microbial; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Sequence Analysis; Zidovudine | 1996 |
The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials.
Topics: Advisory Committees; Anti-Infective Agents; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Confidentiality; Conflict of Interest; Didanosine; Drug Evaluation; Federal Government; HIV Infections; Humans; National Institutes of Health (U.S.); Organizational Objectives; Professional Staff Committees; Pyrimethamine; Reverse Transcriptase Inhibitors; Risk Assessment; Toxoplasmosis, Cerebral; Treatment Outcome; United States; Zalcitabine; Zidovudine | 1995 |
MDL 74,968, a new acyclonucleotide analog: activity against human immunodeficiency virus in vitro and in the hu-PBL-SCID.beige mouse model of infection.
Topics: Adenine; Animals; Antiviral Agents; Cell Line; Cells, Cultured; Didanosine; DNA, Viral; Guanine; HIV Infections; HIV-1; HIV-2; Humans; Male; Mice; Mice, SCID; Monocytes; Organophosphonates; Spleen; T-Lymphocytes; Zidovudine | 1996 |
Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.
Topics: Antiviral Agents; Cells, Cultured; Didanosine; Drug Combinations; Drug Resistance, Microbial; Drug Synergism; Foscarnet; HIV-1; Humans; Microbial Sensitivity Tests; Monocytes; Zalcitabine; Zidovudine | 1996 |
Combination antiretroviral chemotherapy: a potential strategy in AIDS-related malignancy.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cell Division; Didanosine; HIV Infections; HL-60 Cells; Humans; Zalcitabine; Zidovudine | 1996 |
Combination drug treatment benefits patients with HIV.
Topics: Antiviral Agents; Didanosine; Drug Combinations; HIV Infections; Humans; Zalcitabine; Zidovudine | 1996 |
Acquisition of syncytium-inducing HIV-1 strains during therapy with zidovudine alone or combined with alpha interferon or didanosine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; Giant Cells; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Phenotype; Prospective Studies; Zidovudine | 1996 |
[Prescription of antiretroviral and prophylactic drugs in HIV diseases: reality of medical practices].
Topics: Anti-Infective Agents; Antiviral Agents; CD4 Lymphocyte Count; Dapsone; Didanosine; Drug Utilization; France; HIV Infections; Hospital Information Systems; Hospital Records; Humans; Pentamidine; Trimethoprim, Sulfamethoxazole Drug Combination; Zalcitabine; Zidovudine | 1995 |
Protection of human immunodeficiency virus encephalitis by a switch from zidovudine to didanosine.
Topics: Didanosine; Encephalitis, Viral; HIV Infections; Humans; Retrospective Studies; Zidovudine | 1996 |
Antiviral activities of nucleotide heterodimers against human immunodeficiency virus type 1 in vitro.
Topics: Anti-HIV Agents; Cell Line, Transformed; Cytopathogenic Effect, Viral; Didanosine; HIV-1; Humans; Ribavirin; Uracil; Zidovudine | 1996 |
Comparison of virus burden in blood and sequential lymph node biopsy specimens from children infected with human immunodeficiency virus.
Topics: Antiviral Agents; Biopsy; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; DNA, Viral; Drug Therapy, Combination; Female; HIV Core Protein p24; HIV Infections; HIV-1; Humans; In Situ Hybridization; Infant; Lymph Nodes; Male; Nevirapine; Pyridines; Viremia; Zidovudine | 1996 |
Therapy of HIV infections: problems and prospects.
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Stavudine; Urban Health; Zalcitabine; Zidovudine | 1996 |
Kinetics of viral clearance in plasma, peripheral blood mononuclear cells and lymph nodes.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Lymph Nodes; Male; Plasma; RNA, Viral; Time Factors; Zidovudine | 1996 |
AZT-related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro RT inhibition assay.
Topics: Base Sequence; Didanosine; Drug Resistance, Microbial; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutagenesis, Site-Directed; Polymerase Chain Reaction; Proviruses; Reverse Transcriptase Inhibitors; Zidovudine | 1996 |
Therapy for human immunodeficiency virus infection -- what have we learned?
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1996 |
Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Codon; Didanosine; Drug Therapy, Combination; HIV Reverse Transcriptase; Humans; Male; Middle Aged; Mutation; Phenotype; RNA, Viral; Zidovudine | 1996 |
Didanosine (ddl) and stavudine (d4T): absence of peripheral neurotoxicity in rabbits.
Topics: Animals; Antiviral Agents; Didanosine; Male; Microscopy, Electron; Neural Conduction; Neurons; Peripheral Nerves; Rabbits; Sciatic Nerve; Spinal Nerves; Stavudine; Zidovudine | 1995 |
Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.
Topics: Amino Acid Sequence; Animals; Antiviral Agents; Base Sequence; Cats; Cell Line; Didanosine; Drug Resistance, Microbial; Immunodeficiency Virus, Feline; Molecular Sequence Data; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 1996 |
Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry.
Topics: Animals; Antiviral Agents; Benzylamines; CD4-CD8 Ratio; Chromatography, High Pressure Liquid; Cyclams; Didanosine; Drug Implants; Heterocyclic Compounds; HIV Infections; HIV-1; Injections, Subcutaneous; Mice; Mice, Inbred BALB C; Mice, SCID; Rats; Spectrophotometry, Ultraviolet; Virus Replication; Zidovudine | 1996 |
Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds.
Topics: Animals; Antiviral Agents; Didanosine; DNA, Viral; Enzyme-Linked Immunosorbent Assay; Fetal Tissue Transplantation; Flow Cytometry; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Liver Transplantation; Lymphocyte Count; Mice; Mice, SCID; Neutrophils; Nevirapine; Polymerase Chain Reaction; Pyridines; Rats; T-Lymphocytes; Thymus Gland; Transplantation, Heterologous; Zidovudine | 1996 |
Intestinal absorption and first-pass elimination of 2', 3'-dideoxynucleosides following oral administration in rats.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Area Under Curve; Biological Availability; Didanosine; Dideoxynucleosides; Intestinal Absorption; Intestinal Mucosa; Male; Rats; Rats, Wistar; Stavudine; Zidovudine | 1996 |
Inhibition of the in vitro infectivity and cytopathic effect of human foamy virus by dideoxynucleosides.
Topics: Blotting, Southern; Cytopathogenic Effect, Viral; Didanosine; Dideoxynucleosides; DNA, Viral; Humans; Microscopy, Electron; Spumavirus; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1996 |
Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine.
Topics: Adult; Anti-HIV Agents; Antibodies, Bacterial; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Disease Progression; DNA, Viral; HIV Infections; HIV-1; Humans; Immunoglobulin G; Influenza Vaccines; Lymphocyte Activation; Middle Aged; Pneumococcal Infections; Polysaccharides, Bacterial; Proviruses; Receptors, Interleukin-2; RNA, Viral; Time Factors; Vaccination; Vaccines; Viral Load; Zidovudine | 1996 |
Efficacy of a combined zidovudine plus didanosine therapy in one case of HIV-related thrombocytopenia non-responder to zidovudine alone or to anti-Rho immunoglobulin administration.
Topics: Acute-Phase Proteins; Adult; Anti-HIV Agents; Didanosine; Drug Resistance; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Immunoglobulins, Intravenous; Male; Thrombocytopenia; Zidovudine | 1996 |
[Nevirapine: a new principle of action against HIV].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Child; Clinical Trials as Topic; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Infant, Newborn; Male; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Pyridines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Time Factors; Zidovudine | 1996 |
Stavudine selectively induces apoptosis in HIV type 1-infected cells.
Topics: Anti-HIV Agents; Apoptosis; Cell Line; Didanosine; DNA Fragmentation; Down-Regulation; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Inhibitors; Stavudine; T-Lymphocytes; Thymidine; Zalcitabine; Zidovudine | 1997 |
The Delta trial.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Zalcitabine; Zidovudine | 1997 |
Focusing on the second phase of plasma HIV-1 RNA clearance.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Virus Replication; Zidovudine | 1997 |
Treatment of late-state HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Combinations; HIV Infections; Humans; Randomized Controlled Trials as Topic; Reproducibility of Results; Reverse Transcriptase Inhibitors; Treatment Outcome; Zalcitabine; Zidovudine | 1997 |
Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
Topics: Adolescent; AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; RNA, Viral; Time Factors; Viral Load; Viremia; Zidovudine | 1997 |
The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Alcohol Drinking; Amylases; Anti-HIV Agents; Appetite Stimulants; CD4 Lymphocyte Count; Didanosine; Dronabinol; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Seropositivity; Humans; Liver Function Tests; Male; Marijuana Smoking; Middle Aged; Pancreatitis, Alcoholic; Zalcitabine; Zidovudine | 1997 |
HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
Topics: Adult; Anti-HIV Agents; Delavirdine; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Male; Mutation; Phenotype; Piperazines; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 1997 |
Resolution of HIV-associated cystic benign lymphoepithelial lesion of the parotid gland in a patient undergoing chemotherapy for non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cyclophosphamide; Cysts; Didanosine; Doxorubicin; Fatal Outcome; HIV Infections; Humans; Hyperplasia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Parotid Diseases; Prednisone; Vincristine; Zidovudine | 1996 |
Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells.
Topics: Animals; Didanosine; Dideoxynucleosides; DNA Replication; DNA, Mitochondrial; Nerve Growth Factors; Neurites; PC12 Cells; Phosphorylation; Rats; Stavudine; Zalcitabine; Zidovudine | 1997 |
Shedding of HIV-1 in semen during primary infection.
Topics: Anti-HIV Agents; Didanosine; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; RNA, Viral; Semen; Virus Shedding; Zidovudine | 1997 |
Analysis of repeated virological measurements based on cell dilution assays.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Models, Statistical; Survival Analysis; Treatment Outcome; Viral Load; Zidovudine | 1997 |
In vivo evidence for carrier-mediated efflux transport of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system.
Topics: Animals; Anti-HIV Agents; Biological Transport; Blood-Brain Barrier; Brain; Didanosine; Dose-Response Relationship, Drug; Inulin; Male; Probenecid; Rats; Rats, Wistar; Zidovudine | 1997 |
Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine.
Topics: Anti-HIV Agents; Cell Line; Delavirdine; Didanosine; DNA, Viral; HIV-1; Humans; Indoles; Piperazines; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Zidovudine | 1997 |
Hearing loss and antiretroviral therapy in patients infected with HIV-1.
Topics: Adult; Anti-HIV Agents; Didanosine; Female; Hearing Disorders; HIV Infections; HIV-1; Humans; Male; Middle Aged; Stavudine; Zidovudine | 1997 |
Pharmacokinetics of oral ganciclovir capsules in HIV-infected persons.
Topics: Anti-HIV Agents; Antiviral Agents; Area Under Curve; Biological Availability; Clinical Trials as Topic; Didanosine; Drug Interactions; Drug Therapy, Combination; Ganciclovir; HIV Infections; Humans; Zidovudine | 1996 |
Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; DNA, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Lymph Nodes; Male; Viral Load; Zidovudine | 1997 |
HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study.
Topics: Adult; Anti-HIV Agents; Antibodies, Anticardiolipin; Case-Control Studies; Didanosine; Echocardiography, Doppler; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; Humans; Hypertension, Pulmonary; Immunoglobulin M; Male; Prospective Studies; Survival Rate; Zidovudine | 1997 |
2.5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Indinavir; Leukoencephalopathy, Progressive Multifocal; Male; Time Factors; Zidovudine | 1997 |
Treatment options for human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Child; Didanosine; Drug Approval; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Lamivudine; Male; Saquinavir; Stavudine; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1996 |
Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors.
Topics: Antiviral Agents; Cell Line; Cells, Cultured; Didanosine; Drug Interactions; Drug Resistance, Microbial; Drug Resistance, Multiple; Genotype; HIV-1; Humans; Lamivudine; Mutation; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; Virus Replication; Zidovudine | 1996 |
[Therapeutic strategies against HIV: status in 1994 and future prospectives].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Forecasting; HIV Infections; Humans; Male; Zalcitabine; Zidovudine | 1994 |
Phenotypic variations and switches in HIV isolated from the blood and the gastrointestinal tissues of patients with HIV-1 infection. HIV/GI Research Study Group.
Topics: Biopsy; Didanosine; Digestive System; Female; Giant Cells; HIV; HIV Enteropathy; HIV Infections; Humans; Male; Mutation; Phenotype; Prospective Studies; Stavudine; Viral Load; Zidovudine | 1997 |
Determination of HIV-1 susceptibility to reverse transcriptase (RT) inhibitors by a quantitative cell-free RT assay.
Topics: Cell-Free System; Didanosine; Drug Resistance; HIV Reverse Transcriptase; HIV-1; Humans; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Zidovudine | 1996 |
Use of the Wei-Lin-Weissfeld method for the analysis of a recurring and a terminating event.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV-1; Humans; Models, Statistical; Proportional Hazards Models; Randomized Controlled Trials as Topic; Recurrence; Time Factors; Zidovudine | 1997 |
Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells.
Topics: Anti-HIV Agents; Biopsy; Cell Differentiation; Cell Division; Cells, Cultured; Didanosine; DNA, Mitochondrial; Dose-Response Relationship, Drug; Electron Transport Complex II; Electron Transport Complex IV; Humans; Kinetics; Lactates; Lipid Metabolism; Mitochondria, Muscle; Multienzyme Complexes; Muscle, Skeletal; NAD(P)H Dehydrogenase (Quinone); Nucleic Acid Synthesis Inhibitors; Oxidoreductases; Succinate Dehydrogenase; Zalcitabine; Zidovudine | 1997 |
Correlation between plasma HIV-1 RNA levels and the rate of immunologic decline.
Topics: Anti-HIV Agents; beta 2-Microglobulin; CD4 Lymphocyte Count; Didanosine; Disease Progression; DNA, Viral; Drug Therapy, Combination; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Longitudinal Studies; RNA, Viral; Stavudine; Viral Load; Viremia; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe.
Topics: Adult; Amino Acid Sequence; Base Sequence; Didanosine; DNA, Viral; Female; Genes, env; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Nevirapine; Nucleic Acid Heteroduplexes; Phylogeny; Pyridines; Reverse Transcriptase Inhibitors; Sequence Homology, Amino Acid; Zidovudine; Zimbabwe | 1997 |
Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; DNA, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Lymph Nodes; Male; Polymerase Chain Reaction; RNA, Viral; Saquinavir; Viral Load; Viremia; Zidovudine | 1997 |
Stable neurological function in subjects treated with 2'3'-dideoxyinosine.
Topics: Adult; AIDS Dementia Complex; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Follow-Up Studies; HIV Infections; Humans; Neuropsychological Tests; Zidovudine | 1997 |
The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine.
Topics: Adult; Aged; Anti-HIV Agents; beta 2-Microglobulin; Biopterins; Didanosine; HIV Infections; HIV-1; Humans; Middle Aged; Neopterin; RNA, Viral; Viral Load; Zidovudine | 1997 |
Successful treatment of HIV-1-related, zidovudine resistant, thrombocytopenia with didanosine.
Topics: Adult; CD4 Lymphocyte Count; Didanosine; HIV Infections; Humans; Male; Platelet Count; Thrombocytopenia; Zidovudine | 1997 |
Downregulation of increased CD95 (APO-1/Fas) ligand in T cells from human immunodeficiency virus-type 1-infected children after antiretroviral therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Didanosine; Drug Therapy, Combination; Fas Ligand Protein; fas Receptor; Gene Expression Regulation; HIV Infections; HIV-1; Humans; Lamivudine; Membrane Glycoproteins; Reverse Transcriptase Inhibitors; RNA, Messenger; T-Lymphocytes; Time Factors; Transcription, Genetic; Zalcitabine; Zidovudine | 1997 |
Cure or control of HIV/AIDS?
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Models, Biological; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1997 |
Monitoring antiretroviral activity using ICDp24 and CD4 counts in HIV infection.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Follow-Up Studies; HIV Core Protein p24; HIV Infections; Humans; Zidovudine | 1997 |
[Anti-retrovirals].
Topics: Anti-HIV Agents; Didanosine; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1997 |
Human immunodeficiency virus type 1 dynamics in different lymphoid tissue compartments.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Lymphoid Tissue; Male; RNA, Viral; Zidovudine | 1997 |
[Once-daily administration of didanosine in combination with anti-retroviral zidovudine in previously untreated patients].
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Male; Middle Aged; RNA, Viral; Zidovudine | 1997 |
Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid.
Topics: Animals; Anti-HIV Agents; Blood-Brain Barrier; Brain; Didanosine; Male; Models, Biological; Rats; Rats, Wistar; Zidovudine | 1997 |
Transport properties of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine in the rat choroid plexus.
Topics: 4-Chloromercuribenzenesulfonate; Animals; Anti-HIV Agents; Biological Transport, Active; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chloromercuribenzoates; Choroid Plexus; Didanosine; Dose-Response Relationship, Drug; In Vitro Techniques; Male; p-Chloromercuribenzoic Acid; Penicillin G; Rats; Rats, Wistar; Rotenone; Sulfhydryl Reagents; Tritium; Uncoupling Agents; Zidovudine | 1997 |
Transient renewal of thymopoiesis in HIV-infected human thymic implants following antiviral therapy.
Topics: Animals; Antigens, CD; Antigens, CD34; Antiviral Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; Flow Cytometry; Hematopoietic Stem Cells; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lymphocyte Depletion; Methylurea Compounds; Mice; Mice, SCID; Polymerase Chain Reaction; Proviruses; Pyridines; T-Lymphocytes; Thymus Gland; Transplantation, Heterologous; Valine; Zidovudine | 1997 |
Lamivudine (3TC) phosphorylation and drug interactions in vitro.
Topics: Anti-HIV Agents; Cells, Cultured; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Interactions; Humans; Kinetics; Lamivudine; Lymphocyte Activation; Lymphocytes; Mitogens; Models, Chemical; Monocytes; Phosphorylation; Stavudine; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1997 |
Comparative metabolism of the antiviral dimer 3'-azido-3'-deoxythymidine-P-2',3'-dideoxyinosine and the monomers zidovudine and didanosine by rat, monkey, and human hepatocytes.
Topics: Animals; Anti-HIV Agents; Cell Survival; Cells, Cultured; Didanosine; Dideoxynucleotides; Haplorhini; Humans; Liver; Rats; Rats, Sprague-Dawley; Species Specificity; Zidovudine | 1997 |
[Initial administration of a protease inhibitor delays the progression of AIDS by half time].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Disease Progression; HIV Infections; HIV Protease Inhibitors; Humans; Time Factors; Zalcitabine; Zidovudine | 1997 |
Human immunodeficiency virus infection impairs hemopoiesis in long-term bone marrow cultures: nonreversal by nucleoside analogues.
Topics: Anti-HIV Agents; Antigens, CD34; Apoptosis; Bone Marrow Cells; Cell Death; Cells, Cultured; Didanosine; Hematopoiesis; Hematopoietic Stem Cells; HIV; HIV Core Protein p24; Humans; Stromal Cells; Zidovudine | 1997 |
Drugs for HIV infection.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.
Topics: Animals; Anti-HIV Agents; CD4 Lymphocyte Count; Cell Fusion; Didanosine; Giant Cells; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mice; Ritonavir; RNA, Viral; Zidovudine | 1997 |
Antiretroviral therapy and HIV-related retinal microangiopathy.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Didanosine; Female; Humans; Male; Middle Aged; Retinal Diseases; Retinal Vessels; Reverse Transcriptase Inhibitors; Zidovudine | 1997 |
Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates.
Topics: Anti-HIV Agents; Cell Line, Transformed; Cells, Cultured; Didanosine; Foscarnet; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Zidovudine | 1998 |
Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine.
Topics: Anti-HIV Agents; Codon; Didanosine; Drug Resistance, Microbial; Genes, pol; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Oligonucleotide Probes; Polymerase Chain Reaction; RNA, Viral; Sensitivity and Specificity; Sequence Analysis, DNA; Zidovudine | 1998 |
Effect of combined zidovudine and didanosine therapy in early asymptomatic primary HIV-1 infection.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Polymerase Chain Reaction; Treatment Outcome; Zidovudine | 1998 |
Changes in CD8 cell subpopulations induced by antiretroviral therapy in human immunodeficiency virus infected patients.
Topics: Adult; Anti-HIV Agents; CD8-Positive T-Lymphocytes; Cell Count; Didanosine; Drug Therapy, Combination; Flow Cytometry; HIV Seropositivity; HIV-1; Humans; Male; Phenotype; RNA, Viral; Viremia; Zidovudine | 1997 |
HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination.
Topics: Animals; Anti-HIV Agents; Cell Line, Transformed; COS Cells; Didanosine; Drug Resistance, Microbial; Drug Resistance, Multiple; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis; Oligopeptides; Polymerase Chain Reaction; Recombination, Genetic; Reverse Transcriptase Inhibitors; Transfection; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro.
Topics: Anti-HIV Agents; Cell Count; Cell Survival; Didanosine; Drug Interactions; Humans; Indinavir; Lamivudine; Leukocytes, Mononuclear; Nucleosides; Phosphorylation; Protease Inhibitors; Ritonavir; Saquinavir; Stavudine; Trypan Blue; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 1998 |
Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Dideoxynucleosides; Disease Progression; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Stavudine; Survival Analysis; Zalcitabine; Zidovudine | 1998 |
Visceral leishmaniasis in patients infected with the human immunodeficiency virus.
Topics: AIDS-Related Opportunistic Infections; Allopurinol; Amebicides; Amphotericin B; Analysis of Variance; Anti-HIV Agents; Antimetabolites; Antimony; Antiprotozoal Agents; Blood; Bone Marrow; CD4-Positive T-Lymphocytes; Cerebrospinal Fluid; Didanosine; Digestive System; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatic Encephalopathy; HIV; Humans; Intestinal Mucosa; Leishmaniasis, Visceral; Lymphocyte Count; Male; Myocarditis; Neutrophils; Pancreatitis; Pentamidine; Renal Insufficiency; Spain; Zidovudine | 1997 |
Brain lactate and N-acetylaspartate in pediatric AIDS encephalopathy.
Topics: AIDS Dementia Complex; Anti-HIV Agents; Aspartic Acid; Brain; Child; Child, Preschool; Creatine; Didanosine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lactic Acid; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Neurologic Examination; Zidovudine | 1998 |
Combination therapy for HIV: the effect on inpatient activity, morbidity and mortality of a cohort of patients.
Topics: Anti-HIV Agents; Cohort Studies; Cost Savings; Costs and Cost Analysis; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Prospective Studies; Zalcitabine; Zidovudine | 1998 |
1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity.
Topics: Anti-HIV Agents; Cells, Cultured; Didanosine; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Nevirapine; Structure-Activity Relationship; Zidovudine | 1998 |
Resolution of Mycobacterium avium complex bacteremia following highly active antiretroviral therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Bacteremia; Didanosine; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Indinavir; Male; Mycobacterium avium-intracellulare Infection; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
[Combined antiretroviral therapy for prevention of vertical HIV-1 transmission].
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Zidovudine | 1998 |
Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance.
Topics: Animals; Anti-HIV Agents; Cells, Cultured; COS Cells; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Resistance, Multiple; Evolution, Molecular; Genes, pol; HIV-1; Humans; Lymphocytes; Microbial Sensitivity Tests; Mutation; Virus Replication; Zalcitabine; Zidovudine | 1998 |
Virus burden in lymph nodes and blood of subjects with primary human immunodeficiency virus type 1 infection on bitherapy.
Topics: Adenoids; Adult; Anti-HIV Agents; CD4-CD8 Ratio; Dendritic Cells; Didanosine; DNA, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lymph Nodes; Male; Middle Aged; Palatine Tonsil; Proviruses; Reverse Transcriptase Inhibitors; Viral Load; Virus Replication; Zidovudine | 1998 |
Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Didanosine; Dideoxynucleosides; Disease Progression; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Point Mutation; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1998 |
Human immunodeficiency virus proviral DNA from peripheral blood and lymph nodes demonstrates concordant resistance mutations to zidovudine (codon 215) and didanosine (codon 74). Division of AIDS Treatment Research Initiative 003 Study Group.
Topics: Adult; Anti-HIV Agents; Codon; Didanosine; DNA, Viral; Drug Resistance, Microbial; Drug Resistance, Multiple; Female; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Lymph Nodes; Male; Point Mutation; Proviruses; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
Induction-maintenance antiretroviral therapy: proof of concept.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 1998 |
Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; Herpesvirus 8, Human; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sarcoma, Kaposi; Stavudine; Treatment Outcome; Viral Load; Viremia; Zalcitabine; Zidovudine | 1998 |
The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
Topics: Anti-HIV Agents; Cohort Studies; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Methionine; Point Mutation; Reverse Transcriptase Inhibitors; Stavudine; Valine; Zalcitabine; Zidovudine | 1998 |
Researchers report sustained suppression of HIV with nevirapine--didanosine--zidovudine.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
A mixed model for repeated dilution assays.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Models, Statistical; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reproducibility of Results; Viral Load; Zalcitabine; Zidovudine | 1998 |
Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
Topics: Anti-HIV Agents; Cell Line; Deamination; Deoxycytidine Kinase; Didanosine; DNA Polymerase gamma; DNA-Directed DNA Polymerase; DNA, Mitochondrial; DNA, Viral; Drug Interactions; HIV Reverse Transcriptase; HIV-1; Phosphorylation; Stavudine; Virus Replication; Zalcitabine; Zidovudine | 1998 |
Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Prevalence; Reverse Transcriptase Inhibitors; Spain; Zalcitabine; Zidovudine | 1998 |
Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Retrospective Studies; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
Risk of HIV dementia and opportunistic brain disease in AIDS and zidovudine therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Brain Diseases; Didanosine; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Retrospective Studies; Risk; Stavudine; Treatment Outcome; Zalcitabine; Zidovudine | 1998 |
Therapeutic and other interventions to reduce the risk of mother-to-child transmission of HIV-1 in Europe. The European Collaborative Study.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Cesarean Section; Cohort Studies; Didanosine; Europe; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Prospective Studies; Risk Factors; Zidovudine | 1998 |
Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations.
Topics: Anti-HIV Agents; Codon; Didanosine; DNA Probes; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Polymerase Chain Reaction; Sequence Analysis, DNA; Zalcitabine; Zidovudine | 1998 |
Analysis of antiretroviral nucleosides by electrospray ionization mass spectrometry and collision induced dissociation.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Gas Chromatography-Mass Spectrometry; Lamivudine; Models, Chemical; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Secondary Ion; Zalcitabine; Zidovudine | 1998 |
Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Immunophenotyping; Lymphocyte Activation; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 1998 |
Rebound of plasma HIV viral load following prolonged suppression with combination therapy.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Male; Nevirapine; Reverse Transcriptase Inhibitors; Time Factors; Viral Load; Zidovudine | 1998 |
Visceral leishmaniasis: a lingual presentation in a patient with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antimony; Antiprotozoal Agents; Didanosine; HIV Infections; Humans; Laryngitis; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Spain; Tongue Diseases; Zidovudine | 1998 |
A semiparametric Bayesian approach to the random effects model.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Bayes Theorem; Biometry; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Longitudinal Studies; Models, Statistical; Randomized Controlled Trials as Topic; Zidovudine | 1998 |
The sequential occurrence of pol 215 and pol 41 zidovudine resistance mutations is associated in an additive fashion with low CD4 cell counts and high plasma and cellular HIV viral load.
Topics: Adult; Anti-HIV Agents; Biomarkers; CD4 Lymphocyte Count; Cross-Sectional Studies; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Longitudinal Studies; Male; Mutation; RNA, Viral; Viral Load; Zalcitabine; Zidovudine | 1998 |
[Infection with Mycobacterium genavense in 2 HIV-seropositive patients in Amsterdam].
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Humans; Male; Mycobacterium Infections; Zidovudine | 1998 |
Taste and smell complaints in HIV-infected patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Clarithromycin; Didanosine; Female; HIV Infections; Humans; Indinavir; Lamivudine; Male; Middle Aged; Quality of Life; Ritonavir; Smell; Surveys and Questionnaires; Taste; Trimethoprim, Sulfamethoxazole Drug Combination; Zidovudine | 1998 |
[Weak antiviral effect of changing two nucleoside analogues combined with antiretroviral agents. 3TC and d4T after ZDU and ddi or ddc].
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Retrospective Studies; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1998 |
Resting energy expenditure and body composition in children with HIV infection.
Topics: Adipose Tissue; Anthropometry; Anti-HIV Agents; Arm; Body Composition; Body Water; Child; Child Development; Child, Preschool; Didanosine; Energy Intake; Energy Metabolism; Female; Growth Disorders; HIV Infections; Humans; Male; Muscle Development; Muscle, Skeletal; Skinfold Thickness; Zidovudine | 1998 |
Advanced testicular germ cell tumor in a hemophilic patient with human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; CD4 Lymphocyte Count; Cisplatin; Combined Modality Therapy; Didanosine; Drug Therapy, Combination; Etoposide; Factor VIII; Germinoma; Hemophilia A; Humans; Male; Orchiectomy; Saquinavir; Testicular Neoplasms; Zidovudine | 1998 |
High incidence of nevirapine-associated rash in HIV-infected Chinese.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; China; Didanosine; Drug Eruptions; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 1998 |
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.
Topics: Amino Acid Sequence; Anti-HIV Agents; Base Sequence; Cells, Cultured; Didanosine; Drug Resistance, Multiple; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis, Site-Directed; Mutation; Nucleosides; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1998 |
Estimates of the virological benefit of antiretroviral therapy are both assay- and analysis-dependent.
Topics: Analysis of Variance; Anti-HIV Agents; Data Interpretation, Statistical; Didanosine; HIV Infections; HIV-1; Humans; Nevirapine; RNA, Viral; Statistics, Nonparametric; Time Factors; Viral Load; Zidovudine | 1998 |
Zidovudine toxicity in uninfected healthcare workers. Italian Registry of Antiretroviral Prophylaxis.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Health Personnel; HIV Infections; Humans; Italy; Occupational Exposure; Registries; Retrospective Studies; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1997 |
[Observing in HIV infections].
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Patient Compliance; Physician-Patient Relations; Reverse Transcriptase Inhibitors; Time Factors; Zidovudine | 1998 |
Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Randomized Controlled Trials as Topic; Zidovudine | 1999 |
Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Randomized Controlled Trials as Topic; Viral Load; Zidovudine | 1999 |
Normal T-cell telomerase activity and upregulation in human immunodeficiency virus-1 infection.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cohort Studies; Didanosine; Drug Therapy, Combination; Enzyme Induction; HIV Infections; HIV-1; Humans; Lymphoid Tissue; Reverse Transcriptase Inhibitors; Telomerase; Telomere; Up-Regulation; Zalcitabine; Zidovudine | 1999 |
Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Didanosine; DNA, Viral; Drug Therapy, Combination; Female; HIV Infections; Humans; Injections, Subcutaneous; Interleukin-2; Leukocyte Common Antigens; Male; Pilot Projects; Receptors, Interleukin-2; Zidovudine | 1999 |
Dynamics of provirus load and lymphocyte subsets after interleukin 2 treatment in HIV-infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Female; HIV; Humans; Interleukin-2; Male; Polymerase Chain Reaction; Proviruses; Recombinant Proteins; T-Lymphocyte Subsets; Viral Load; Zidovudine | 1999 |
Antiretroviral drugs: new agents, new combinations line up against HIV.
Topics: Antiviral Agents; Australia; Didanosine; Drug Therapy, Combination; Europe; HIV; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Thiazoles; United States; Valine; Zalcitabine; Zidovudine | 1996 |
Patients with HIV-1 RNA below 1000 copies/ml after 48 weeks on dual nucleoside combination therapy. Delta Coordinating Committee.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1999 |
Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.
Topics: Adult; Aging; Anti-HIV Agents; Didanosine; Follow-Up Studies; HIV Infections; HIV-1; Humans; Immunologic Memory; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Time Factors; Zidovudine | 1999 |
Management of liver failure in a haemophilic patient co-infected with human immunodeficiency and hepatitis C viruses.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Clarithromycin; Didanosine; Hemophilia A; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver Failure, Acute; Male; Middle Aged; Zidovudine | 1999 |
Data and safety monitoring in the Concorde and Alpha trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Biomarkers; Didanosine; Double-Blind Method; Humans; Randomized Controlled Trials as Topic; Survival Analysis; Zidovudine | 1999 |
Data and safety monitoring in the Delta trial.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Therapy, Combination; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Survival Analysis; Zalcitabine; Zidovudine | 1999 |
Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay.
Topics: Adaptation, Biological; Animals; Anti-HIV Agents; COS Cells; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Resistance, Multiple; Genetic Variation; HeLa Cells; HIV-1; Humans; Reverse Transcriptase Inhibitors; Tumor Cells, Cultured; Virus Replication; Zidovudine | 1999 |
Relevance of AIDS treatment with two nucleoside analogues alone.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Humans; Survival Rate; Zalcitabine; Zidovudine | 1999 |
Intracellular activation of 2',3'-dideoxyinosine and drug interactions in vitro.
Topics: Anti-HIV Agents; Deoxyadenine Nucleotides; Didanosine; Dideoxynucleotides; Drug Interactions; Guanosine; Humans; Hydroxyurea; Inosine; Intracellular Fluid; Lamivudine; Pentoxifylline; Stavudine; U937 Cells; Zidovudine | 1999 |
Reconstitution of human thymic implants is limited by human immunodeficiency virus breakthrough during antiretroviral therapy.
Topics: Animals; Anti-HIV Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Disease Models, Animal; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Kinetics; Lymphocyte Depletion; Mice; Mice, SCID; Reverse Transcriptase Inhibitors; Thymus Gland; Zidovudine | 1999 |
Changing cost of English HIV service provision 1996-1997. NPMS Steering Group. National Prospective Monitoring System.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Costs; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Hospital Costs; Humans; Nevirapine; RNA-Directed DNA Polymerase; United Kingdom; Zalcitabine; Zidovudine | 1999 |
Severe lactic acidosis induced by nucleoside analogues in an HIV-infected man.
Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Antimetabolites; Didanosine; Humans; Male; Zidovudine | 1999 |
Beneficial effect of highly active antiretroviral therapy (HAART) in reducing both HIV viral load and monoclonal gammopathy.
Topics: Adult; Anti-HIV Agents; B-Lymphocytes; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lymphocyte Activation; Male; Paraproteinemias; Ritonavir; Viral Load; Zidovudine | 1999 |
Efficacy of antiretroviral agents against murine replication-competent retrovirus infection in human cells.
Topics: Cell Line; Didanosine; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Humans; Indinavir; Leukemia Virus, Murine; Reverse Transcriptase Inhibitors; Virus Replication; Zidovudine | 1999 |
Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; Humans; Mutation; Reverse Transcriptase Inhibitors; Stavudine; Viral Load; Zidovudine | 1999 |
Inhibition of telomerase activity and cell proliferation by a reverse transcriptase inhibitor in gynaecological cancer cell lines.
Topics: Blotting, Southern; Cell Division; Cystadenocarcinoma; Didanosine; Dideoxynucleotides; Endometrial Neoplasms; Female; HIV Reverse Transcriptase; Humans; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Telomerase; Thymine Nucleotides; Tumor Cells, Cultured; Uterine Neoplasms; Zidovudine | 1999 |
Zidovudine (AZT) induced alterations in mitochondrial biogenesis in rat striated muscles.
Topics: Animals; Blood Pressure; Didanosine; DNA-Binding Proteins; Electron Transport Complex IV; Male; Mitochondria, Muscle; NF-E2-Related Factor 1; Nuclear Respiratory Factor 1; Nuclear Respiratory Factors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Trans-Activators; Xenopus Proteins; Zidovudine | 1999 |
Reaction times are faster in HIV-seropositive patients on antiretroviral therapy: A preliminary report.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; CD4-CD8 Ratio; Choice Behavior; Cognition; Cross-Sectional Studies; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Pilot Projects; Psychiatric Status Rating Scales; Psychomotor Performance; Reaction Time; Statistics, Nonparametric; Zalcitabine; Zidovudine | 1999 |
Highly active anti-retroviral therapy (HAART) is associated with a lower level of CD4+ T cell apoptosis in HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1999 |
Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Disease Progression; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Incidence; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir; Stavudine; Switzerland; Treatment Failure; Viral Load; Zalcitabine; Zidovudine | 1999 |
Evaluation of antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice.
Topics: AIDS Dementia Complex; Animals; Cells, Cultured; Didanosine; Dideoxynucleosides; Disease Models, Animal; HIV-1; Humans; Lamivudine; Male; Mice; Mice, SCID; Monocytes; Reverse Transcriptase Inhibitors; Stavudine; Virus Replication; Zidovudine | 2000 |
Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance; Genes, pol; Genotype; HIV-1; Humans; Lamivudine; Point Mutation; RNA, Viral; Zalcitabine; Zidovudine | 1999 |
A combination of nucleoside analogues and a protease inhibitor reduces HIV-1 RNA levels in semen: implications for sexual transmission of HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Didanosine; Drug Therapy, Combination; HIV Protease Inhibitors; HIV-1; Humans; Male; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Semen; Sexually Transmitted Diseases; Zidovudine | 1999 |
Different outcome in the first two patients with an HIV-1 multinucleoside drug-resistant T69SSS insertion in Spain.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Didanosine; Drug Resistance, Multiple; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mutation; Spain; Zalcitabine; Zidovudine | 1999 |
Drugs for HIV infection.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Costs; Drug Therapy, Combination; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 2000 |
Functional reconstitution of thymopoiesis after human immunodeficiency virus infection.
Topics: Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Disease Models, Animal; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Mice; Mice, SCID; Receptors, Antigen, T-Cell, alpha-beta; Reverse Transcriptase Inhibitors; Thymus Gland; Zidovudine | 2000 |
Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality.
Topics: Acute Disease; Anti-HIV Agents; Clone Cells; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Gene Rearrangement, beta-Chain T-Cell Antigen Receptor; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Lamivudine; Lymphocyte Activation; Polymerase Chain Reaction; RNA-Directed DNA Polymerase; Saquinavir; T-Lymphocytes, Cytotoxic; Viremia; Zidovudine | 2000 |
Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Follow-Up Studies; Genotype; HIV Infections; HIV-1; Humans; Mutation; Phenotype; Polymerase Chain Reaction; RNA-Directed DNA Polymerase; RNA, Viral; Stavudine; Viral Load; Zidovudine | 2000 |
Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Cohort Studies; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Organ Size; Reverse Transcriptase Inhibitors; Stavudine; Thymus Gland; Viral Load; Zidovudine | 2000 |
HIV-associated bacteremia: how it has changed in the highly active antiretroviral therapy (HAART) era.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Bacteremia; Community-Acquired Infections; Cross Infection; Didanosine; Drug Therapy, Combination; Female; Humans; Incidence; Male; Prospective Studies; Risk Factors; Viral Load; Zalcitabine; Zidovudine | 2000 |
Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy.
Topics: CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Polymerase Chain Reaction; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zalcitabine; Zidovudine | 2000 |
Decreased HIV-associated T cell apoptosis by HIV protease inhibitors.
Topics: Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Didanosine; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Jurkat Cells; Nelfinavir; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; T-Lymphocytes; Viral Load; Zidovudine | 2000 |
Convergent evolution of reverse transcriptase (RT) genes of human immunodeficiency virus type 1 subtypes E and B following nucleoside analogue RT inhibitor therapies.
Topics: Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; Base Sequence; Didanosine; DNA, Viral; Drug Resistance, Microbial; Evolution, Molecular; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Molecular Sequence Data; Protein Structure, Secondary; Reverse Transcriptase Inhibitors; Zidovudine | 2000 |
Does brain penetration of anti-HIV drugs matter?
Topics: AIDS Dementia Complex; Anti-HIV Agents; Brain; Didanosine; HIV-1; Humans; Zidovudine | 2000 |
Cutaneous side effects induced by indinavir.
Topics: Adult; Alopecia; Didanosine; Drug Eruptions; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lipodystrophy; Male; Middle Aged; Pruritus; Pyoderma Gangrenosum; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Scalp Dermatoses; Skin; Stavudine; Zalcitabine; Zidovudine | 2000 |
GEE with Gaussian estimation of the correlations when data are incomplete.
Topics: Anti-HIV Agents; Biometry; Computer Simulation; Controlled Clinical Trials as Topic; Didanosine; HIV Infections; Humans; Longitudinal Studies; Models, Statistical; Normal Distribution; Zidovudine | 2000 |
Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Cohort Studies; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; HIV Wasting Syndrome; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Factors; Stavudine; Time Factors; Zidovudine | 2000 |
Assessment of developmental toxicity of antiretroviral drugs using a rat whole embryo culture system.
Topics: Abnormalities, Drug-Induced; Animals; Anti-HIV Agents; Crown-Rump Length; Didanosine; Drug Therapy, Combination; Embryo, Mammalian; Female; HIV Protease Inhibitors; Indinavir; Organ Culture Techniques; Pregnancy; Rats; Rats, Sprague-Dawley; Zalcitabine; Zidovudine | 2000 |
Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Topics: Anti-HIV Agents; Cells, Cultured; Deoxycytidine; Didanosine; Drug Combinations; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Molecular Structure; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; T-Lymphocytes; Thionucleosides; Zidovudine | 2000 |
[Perinatal co-infection with hepatitis B and HIV viruses--reciprocal effect of the disease and the treatment].
Topics: Anti-HIV Agents; Didanosine; Female; Hepatitis B; HIV Infections; Humans; Infant; Ritonavir; Zidovudine | 1999 |
Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virologic failure.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Amino Acid Sequence; Cohort Studies; Consensus Sequence; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Italy; Male; Middle Aged; Molecular Sequence Data; Multicenter Studies as Topic; Mutagenesis, Insertional; Mutation; Prevalence; Protease Inhibitors; Reverse Transcriptase Inhibitors; Zidovudine | 2000 |
[Cost effectiveness analysis of highly active antiretroviral therapy in HIV asymptomatic patients].
Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Didanosine; Drug Therapy, Combination; Female; HIV Seropositivity; Humans; Indinavir; Lamivudine; Male; Middle Aged; Nevirapine; Sickness Impact Profile; Spain; Stavudine; Viral Load; Zidovudine | 2000 |
Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1.
Topics: Amino Acid Sequence; Anti-HIV Agents; Didanosine; Drug Resistance; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutagenesis, Site-Directed; Virus Replication; Zalcitabine; Zidovudine | 2000 |
Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells.
Topics: Anti-HIV Agents; Cell Survival; Cells, Cultured; Didanosine; DNA; Drug Synergism; Humans; Hypoxanthine Phosphoribosyltransferase; Mutagenesis; Reverse Transcriptase Inhibitors; Zidovudine | 2000 |
Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy.
Topics: Adult; Amino Acid Sequence; Consensus Sequence; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genes, Viral; Genotype; HIV Infections; HIV-2; Humans; Lamivudine; Male; Molecular Sequence Data; Phenotype; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zidovudine | 2000 |
Monotherapy in an era of combination therapy: is there a benefit? Experience in HIV-1-infected symptomatic South African children.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; Follow-Up Studies; Health Care Rationing; HIV Infections; HIV-1; Hospitalization; Humans; Infant; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; South Africa; Treatment Outcome; Zidovudine | 2000 |
Antiretroviral agents inhibit infection of human cells by porcine endogenous retroviruses.
Topics: Amino Acid Sequence; Animals; Anti-HIV Agents; Cells, Cultured; Didanosine; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Retroviridae; Sequence Homology, Amino Acid; Swine Diseases; Virus Replication; Zidovudine | 2000 |
Evidence for late stage compartmentalization of HIV-1 resistance mutations between lymph node and peripheral blood mononuclear cells.
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Evolution, Molecular; Genes, env; Genes, pol; Genetic Variation; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Lymph Nodes; Male; Mutation; Peptide Fragments; Time Factors; Zidovudine | 2000 |
A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
Topics: Anti-HIV Agents; Codon; Didanosine; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Genotype; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Nucleic Acid Hybridization; Point Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 2000 |
Suppression of maternal virus load with zidovudine, didanosine, and indinavir combination therapy prevents mother-to-fetus HIV transmission in macaques.
Topics: Animals; Didanosine; Drug Therapy, Combination; Female; Fetus; HIV Antibodies; HIV Infections; HIV Protease Inhibitors; HIV-2; Indinavir; Infectious Disease Transmission, Vertical; Macaca nemestrina; Pregnancy; Reverse Transcriptase Inhibitors; T-Lymphocyte Subsets; Viral Load; Zidovudine | 2000 |
Sustained responses to dual nucleoside therapy in women.
Topics: Adult; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Middle Aged; Reverse Transcriptase Inhibitors; Stavudine; Viral Load; Zidovudine | 2000 |
Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol.
Topics: Cell Division; Didanosine; Dose-Response Relationship, Drug; Drug Resistance; Drug Synergism; HIV-1; Humans; Hydroxyurea; Leukocytes, Mononuclear; Macrophages; Nucleosides; Resveratrol; Stilbenes; Virus Replication; Zalcitabine; Zidovudine | 2000 |
Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Didanosine; Hemophilia A; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Middle Aged; Pilot Projects; Treatment Outcome; Zidovudine | 2000 |
Phenotypic resistance pattern of HIV-1 isolates with zidovudine and/or multidrug resistance mutations after didanosine-stavudine combination therapy.
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Phenotype; Reverse Transcriptase Inhibitors; Stavudine; Viral Load; Zidovudine | 2000 |
Protease inhibitor therapy in HIV-infected children.
Topics: Adolescent; Age Factors; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lamivudine; Male; Nelfinavir; Patient Compliance; Retrospective Studies; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2000 |
Detection of resistant mutations in the reverse transcriptase of HIV-1-infected children.
Topics: CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Infant; Male; Mutation; Reverse Transcriptase Inhibitors; Ritonavir; Viremia; Zidovudine | 2000 |
Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Contact Tracing; Counseling; Didanosine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Patient Compliance; Reverse Transcriptase Inhibitors; Risk Factors; Risk-Taking; Sexually Transmitted Diseases, Viral; Substance Abuse, Intravenous; Time Factors; Zidovudine | 2001 |
Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Time Factors; Viral Load; Zidovudine | 2001 |
Leukocytopenia due to zidovudine- and nevirapine-containing regimens in elderly patients with HIV infection.
Topics: Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Drug Therapy, Combination; Fatal Outcome; Granulocyte Colony-Stimulating Factor; HIV Infections; HIV-1; Humans; Leukopenia; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Zidovudine | 2000 |
[Bilateral hip necrosis, corticoids, and human immunodeficiency virus protease inhibitors].
Topics: Aged; Antiretroviral Therapy, Highly Active; Dexamethasone; Didanosine; Femur Head Necrosis; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Prednisone; Zidovudine | 2001 |
Vertical HIV-1 transmission: prophylaxis and paediatric follow-up.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; Follow-Up Studies; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Ritonavir; Viral Load; Zidovudine | 2001 |
Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.
Topics: Adult; Amylases; Anti-HIV Agents; Didanosine; Female; HIV Infections; HIV-1; Humans; Hydroxyurea; Incidence; Lipase; Longitudinal Studies; Male; Pancreatitis; Reverse Transcriptase Inhibitors; Stavudine; United States; Zidovudine | 2001 |
Predictive value of codon 215 reverse transcriptase mutation on the efficacy of didanosine in HIV-infected, zidovudine-experienced patients.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Codon; Didanosine; Female; HIV Infections; HIV Reverse Transcriptase; Humans; Male; Mutation; Retrospective Studies; Survival Rate; Zidovudine | 1996 |
A bend in the road--implications of ACTG 175 and Delta trials.
Topics: Anti-HIV Agents; Australia; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Europe; HIV Infections; HIV-1; Humans; Survival Analysis; United States; Zalcitabine; Zidovudine | 1996 |
Zidovudine plus didanosine in primary HIV-1 infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4-CD8 Ratio; Didanosine; Drug Therapy, Combination; Female; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Zidovudine | 1997 |
Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia.
Topics: Acute Disease; Aged; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Didanosine; Fatal Outcome; Fatty Liver; HIV Infections; HIV-1; Humans; Hypertension, Portal; Male; Mitochondria, Liver; Stavudine; Zidovudine | 2001 |
Trial data available.
Topics: Didanosine; HIV Seropositivity; Humans; Zidovudine | 1995 |
Anti-HIV therapy lowers risk of AIDS, death in patients with intermediate-stage HIV disease.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Survival Rate; Zalcitabine; Zidovudine | 1995 |
Triple therapy in previously untreated patients reduces viral load below limit of detection.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Pyridines; Viral Load; Zidovudine | 1996 |
Crixivan reduces viral load.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Viral Load; Zalcitabine; Zidovudine | 1996 |
Research study of combination AIDS therapies underway.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Lamivudine; Zidovudine | 1996 |
FDA clearance for ritonavir in children with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Didanosine; Drug Approval; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Ritonavir; United States; United States Food and Drug Administration; Zidovudine | 1997 |
Two studies suggest nevirapine benefit for children.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 1997 |
Viramune triple therapy shows suppression of HIV after 1 year, 7 months.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Zidovudine | 1997 |
AZT studies reinforce benefits of combination.
Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Synergism; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Lymphocyte Count; Zalcitabine; Zidovudine | 1995 |
Nevirapine triple combo results released.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Erythema; HIV Infections; HIV-1; Humans; Nevirapine; Pyridines; Virus Replication; Zidovudine | 1995 |
Treatment briefs.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Industry; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Nerve Growth Factors; Nervous System Diseases; Pyridines; Recombinant Proteins; Stavudine; Zalcitabine; Zidovudine | 1995 |
Results of pediatric study present new questions.
Topics: Adolescent; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Pregnancy; Pregnancy Complications, Infectious; Quality of Health Care; Zidovudine | 1995 |
CTG studies yield results. AIDS Clinical Trials Group.
Topics: Acyclovir; Child; Clinical Trials as Topic; Cytomegalovirus Infections; Didanosine; Drug Therapy, Combination; Fluconazole; HIV Infections; Humans; Mycoses; Pneumonia, Pneumocystis; Valacyclovir; Valine; Zidovudine | 1995 |
What we know about anti-HIV drugs.
Topics: Antiviral Agents; Didanosine; DNA, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; RNA, Viral; Stavudine; Zalcitabine; Zidovudine | 1995 |
Combination treatment and single drugs: interview with Margaret Poscher, M.D. Interview by John S. James.
Topics: Acyclovir; Administration, Oral; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Ganciclovir; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |
Combination treatment and single drugs: interview with Margaret Poscher, M.D. Interview by John S. James.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Approval; Drug Combinations; Drug Therapy, Combination; Health Services Accessibility; Humans; Insurance, Health; Lamivudine; Managed Care Programs; United States; Zalcitabine; Zidovudine | 1995 |
Inmate not entitled to choose his own course of HIV medicines.
Topics: Acyclovir; Didanosine; Drug Therapy, Combination; HIV Seropositivity; Humans; Informed Consent; Male; New York; Patient Participation; Prisoners; Refusal to Treat; Zidovudine | 1995 |
Antiretroviral drug resistance.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; RNA, Viral; Stavudine; Viremia; Zalcitabine; Zidovudine | 1995 |
Update on clinical trials of combination therapies for HIV infection.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Lamivudine; RNA-Directed DNA Polymerase; Stavudine; Zalcitabine; Zidovudine | 1995 |
Researchers are rethinking role of AZT in drug therapy.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; HIV Infections; Humans; United States; Zidovudine | 1995 |
Update on HIV protease inhibitors.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Design; Drug Therapy, Combination; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Phosphorylation; Pyridines; Quinolines; Ritonavir; Saquinavir; Substrate Specificity; Thiazoles; Valine; Zalcitabine; Zidovudine | 1995 |
Protease inhibitors and prevention of cross resistance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Carbamates; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nelfinavir; Pyridines; Quinolines; Saquinavir; Sulfonamides; Zalcitabine; Zidovudine | 1995 |
AZT delta study: major European/Australian study finds combinations better than AZT alone.
Topics: Acquired Immunodeficiency Syndrome; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1995 |
ACTG 175 and Delta.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Evaluation Studies as Topic; Humans; Treatment Outcome; Zalcitabine; Zidovudine | 1995 |
Making sense of 175 and Delta.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; Evaluation Studies as Topic; Humans; Zalcitabine; Zidovudine | 1995 |
New trials reach same conclusion: two drugs are better than AZT alone.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Data Interpretation, Statistical; Didanosine; Drug Therapy, Combination; Humans; Treatment Outcome; Zalcitabine; Zidovudine | 1995 |
Study results at a glance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1995 |
Closing the circle on HIV--or not.
Topics: Antiviral Agents; Biomarkers; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-2; Nelfinavir; Prognosis; RNA, Viral; Zalcitabine; Zidovudine | 1995 |
Can the conundrums of ACTG 175 be solved? An interview with Martin S. Hirsch, MD.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Treatment Outcome; Zidovudine | 1995 |
Review of viral load and combination therapy data from 35th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Mutation; RNA, Viral; Zidovudine | 1995 |
FDA triple header. Food and Drug Administration.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Mutation; Quinolines; Salvage Therapy; Saquinavir; Stavudine; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1995 |
Combination therapy increases survival.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |
To treat or not to treat--approaches to antiretroviral therapy. Interview by Anthony J. Japour.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Didanosine; Drug Therapy, Combination; HIV; Humans; Lamivudine; Practice Patterns, Physicians'; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
Benefits of combination therapy confirmed.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Treatment Failure; Zalcitabine; Zidovudine | 1995 |
Merck protease inhibitor: more news from Retroviruses Conference.
Topics: CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Pyridines; Zalcitabine; Zidovudine | 1996 |
AZT, ddI, and ddC combinations at FDA advisory hearing. Food and Drug Administration.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1996 |
Europe out of step with the US.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Costs; Europe; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Quinolines; Ritonavir; Saquinavir; Thiazoles; United States; Valine; Zalcitabine; Zidovudine | 1996 |
ACTG 175: new insights into treating patients with intermediate-stage HIV disease.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Humans; Zalcitabine; Zidovudine | 1995 |
Back to the nukes.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1996 |
Pediatric treatment update.
Topics: Adolescent; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Infant; Zidovudine | 1996 |
Update on other antivirals.
Topics: Adenine; Antiviral Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Organophosphonates; Stavudine; Zalcitabine; Zidovudine | 1996 |
Nipping HIV in the bud.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Virus Replication; Zalcitabine; Zidovudine | 1996 |
Antiviral roundup.
Topics: CD4 Lymphocyte Count; Cohort Studies; Delavirdine; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Mutation; Piperazines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Stavudine; Zidovudine | 1996 |
Top AIDS researchers' strategy for antiretroviral treatment.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Patient Compliance; Practice Guidelines as Topic; RNA, Viral; Stavudine; Zalcitabine; Zidovudine | 1996 |
Nevirapine: new drug, new class, new questions.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Didanosine; Drug Approval; Drug Therapy, Combination; HIV; HIV Infections; Humans; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration; Zidovudine | 1996 |
3TC: combination trial stopped early as clinical benefit shown.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Disease Progression; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Placebos; Treatment Failure; Zalcitabine; Zidovudine | 1996 |
ACTG 152: new insights into pediatric antiretroviral therapy.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Infant; Zidovudine | 1996 |
Outdated yet out-of-reach: AIDS society treatment guidelines at the International Conference.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Decision Making; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Lamivudine; Practice Guidelines as Topic; Zalcitabine; Zidovudine | 1996 |
Nevirapine approved by FDA. Food and Drug Administration.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Approval; Drug Therapy, Combination; Female; HIV Infections; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pyridines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration; Viral Load; Zidovudine | 1996 |
A patient's guide to protease inhibitors.
Topics: Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Eating; Guidelines as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Ritonavir; Saquinavir; Stavudine; Zidovudine | 1996 |
ddI and d4T plus protease inhibitors.
Topics: Anti-HIV Agents; Didanosine; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1996 |
FDA advisory committee deadlocks on delavirdine. Food and Drug Administration.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Delavirdine; Didanosine; Disease Progression; Drug Approval; Drug Industry; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indoles; Piperazines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration; Viral Load; Zidovudine | 1996 |
Dethroning AZT.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Lamivudine; Oxazines; Stavudine; Viral Load; Zidovudine | 1997 |
NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Chemokines; Clinical Trials as Topic; Clone Cells; Dendritic Cells; Didanosine; Disease Progression; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-10; Killer Cells, Natural; Lamivudine; Male; Nevirapine; Pyridines; Receptors, Cytokine; Reverse Transcriptase Inhibitors; Ritonavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Delavirdine (Rescriptor) approved.
Topics: Anti-HIV Agents; Delavirdine; Didanosine; Drug Approval; Drug Costs; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Indoles; Piperazines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration; Zidovudine | 1997 |
Immune modulation with IL-2 and IL-12.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cytokines; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Interleukin-12; Interleukin-2; Zidovudine | 1997 |
Combo therapy for children and adolescents.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Clinical Trials as Topic; Didanosine; Disease Progression; Drug Therapy, Combination; HIV Infections; Humans; Infant; Lamivudine; Zidovudine | 1997 |
Update on nevirapine: quest for a niche.
Topics: Adult; Anti-HIV Agents; Child; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Infant, Newborn; Nevirapine; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1997 |
Reevaluating initial therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Polymerase Chain Reaction; Stavudine; Viral Load; Zidovudine | 1998 |
Vertical transmission research at the Retrovirus Conference.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Maternal-Fetal Exchange; Pregnancy; Pregnancy Complications, Infectious; Viral Load; Zidovudine | 1998 |
Viral load--how low is best?
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 1998 |
Hydroxyurea, a potential new anti-HIV agent.
Topics: Didanosine; DNA Replication; Drug Therapy, Combination; HIV; HIV Infections; Humans; Hydroxyurea; Leukocytes, Mononuclear; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Antiretroviral therapy for adults and children.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Didanosine; Female; HIV Infections; Humans; Pregnancy; Pregnancy Complications, Infectious; Primary Health Care; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1995 |
[A rare etiology of hepatic steatosis associated with lactic acidosis: the toxicity of antiviral nucleoside analogues].
Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Antimetabolites; Didanosine; Fatal Outcome; Fatty Liver; Female; HIV Seropositivity; Humans; Lamivudine; Microscopy, Electron; Mitochondria, Liver; Stavudine; Zidovudine | 2001 |
Choosing which nuke to use first.
Topics: Didanosine; Dideoxynucleosides; Drug Administration Schedule; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2001 |
[Symptomatic hyperlactemia in patients infected with the human immunodeficiency virus treated with nucleoside analogs].
Topics: Adult; Anti-HIV Agents; Didanosine; Female; HIV Infections; HIV Reverse Transcriptase; Humans; Lactic Acid; Lamivudine; Male; Reverse Transcriptase Inhibitors; Zidovudine | 2001 |
Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.
Topics: Animals; Anti-HIV Agents; Biological Availability; Cell Line; Didanosine; Drug Synergism; HIV Reverse Transcriptase; HIV-1; Humans; Mice; Models, Molecular; Pyridines; Quinoxalines; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship; Thiourea; Zidovudine | 2001 |
HIV-1 multi-dideoxynucleoside resistance mutation (Q151M): prevalence, associated resistance mutations and response to antiretroviral salvage treatment.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Reverse Transcriptase Inhibitors; Salvage Therapy; Treatment Failure; Viral Load; Zidovudine | 2001 |
Differential susceptibility of retroviruses to nucleoside analogues.
Topics: Animals; Antiviral Agents; Cell Line; Cricetinae; Didanosine; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; Lamivudine; Mink; Nucleosides; Retroviridae; Reverse Transcriptase Inhibitors; Stavudine; Substrate Specificity; Zalcitabine; Zidovudine | 2001 |
Immunological and virological effects of long term IL-2 therapy in HIV-1-infected patients.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Didanosine; DNA, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Immunologic Memory; Interleukin-2; Reverse Transcriptase Inhibitors; Time Factors; Zidovudine | 2001 |
Innovative AIDS drug plan may be undermining testing.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Federal Government; Government; Human Experimentation; Humans; Patient Care; Pharmaceutical Preparations; Public Policy; Research; Research Design; Therapeutic Human Experimentation; United States; Zidovudine | 1989 |
Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study.
Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Cohort Studies; Didanosine; Female; HIV Infections; Humans; Male; Prevalence; Reverse Transcriptase Inhibitors; Risk Factors; Stavudine; Switzerland; Zidovudine | 2001 |
Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons.
Topics: Anti-HIV Agents; Base Sequence; Didanosine; Dideoxynucleosides; DNA, Viral; Drug Resistance, Viral; Evolution, Molecular; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutagenesis; Recombination, Genetic; Reverse Transcriptase Inhibitors; Stavudine; Virus Replication; Zalcitabine; Zidovudine | 2001 |
Drugs for HIV infection.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dose-Response Relationship, Drug; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Saquinavir; Stavudine; Zidovudine | 2001 |
Prevalence and genetic heterogeneity of the reverse transcriptase T69S-S-X insertion in pretreated HIV-infected patients.
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Genetic Heterogeneity; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutagenesis; Prevalence; Reverse Transcriptase Inhibitors; Spain; Zidovudine | 2001 |
Lymphocytes proliferate in blood and lymph nodes following interleukin-2 therapy in addition to highly active antiretroviral therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apoptosis; B-Lymphocytes; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Cell Division; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunotherapy; Interleukin-2; Lymph Nodes; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; T-Lymphocytes; Zidovudine | 2002 |
Acanthosis nigricans: a new manifestation of insulin resistance in patients receiving treatment with protease inhibitors.
Topics: Acanthosis Nigricans; Adult; Diabetes Mellitus; Didanosine; HIV Infections; HIV Protease Inhibitors; Humans; Insulin Resistance; Male; Ritonavir; Zidovudine | 2002 |
Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries.
Topics: Anti-HIV Agents; Developing Countries; Didanosine; Drug Resistance, Viral; Gabon; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Population Surveillance; Practice Guidelines as Topic; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2002 |
Viral and immunologic follow up of 4 to 9 years of AIDS treatments by quadruple combinations of virostatics including integrase inhibitors applied in short sequences differing by drug rotation.
Topics: Acquired Immunodeficiency Syndrome; Acriflavine; Adult; Anti-HIV Agents; Antiviral Agents; CD4-CD8 Ratio; Didanosine; Drug Therapy, Combination; Ellipticines; Female; Follow-Up Studies; HIV-1; Humans; Integrase Inhibitors; Male; Middle Aged; Protease Inhibitors; Stavudine; Vitamin B 12; Zalcitabine; Zidovudine | 2002 |
Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors.
Topics: Adenine; Anti-HIV Agents; Antigens, CD34; Cell Line; Didanosine; Dideoxynucleosides; Epithelial Cells; Hematopoietic Stem Cells; Humans; Kidney Tubules, Proximal; Liver; Muscle, Skeletal; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 2002 |
The dangers of inferring treatment effects from observational data: a case study in HIV infection.
Topics: Adult; Anti-HIV Agents; Data Interpretation, Statistical; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Observation; Randomized Controlled Trials as Topic; Selection Bias; Zalcitabine; Zidovudine | 2002 |
[Drug combination therapy for children infected with HIV/AIDS--own experience].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lamivudine; Male; Nelfinavir; Poland; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2001 |
An ancient prevertebrate Na+-nucleoside cotransporter (hfCNT) from the Pacific hagfish (Eptatretus stouti).
Topics: Amino Acid Sequence; Animals; Anti-HIV Agents; Chimera; Cloning, Molecular; Didanosine; DNA, Complementary; Hagfishes; Kinetics; Molecular Sequence Data; Oocytes; Protein Isoforms; Recombinant Proteins; Symporters; Xenopus; Zalcitabine; Zidovudine | 2002 |
Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.
Topics: Base Sequence; Codon; Czech Republic; Didanosine; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Probe Techniques; Molecular Sequence Data; Mutation; Phylogeny; Prevalence; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Zalcitabine; Zidovudine | 2001 |
Molecular analysis of mutations at the HPRT and TK loci of human lymphoblastoid cells after combined treatments with 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosinedagger.
Topics: Anti-HIV Agents; B-Lymphocytes; Blotting, Southern; Cell Line; Didanosine; DNA; DNA Mutational Analysis; Drug Synergism; Gene Deletion; Genes, Reporter; Humans; Hypoxanthine Phosphoribosyltransferase; Mutagenicity Tests; Mutation; Point Mutation; Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Zidovudine | 2002 |
[Mononucleosis syndrome with viro-immunologic parameters similar to those of a primary HIV-1 infection after interruption of highly effective anti-retroviral treatment].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; Depression; Didanosine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Mononucleosis; Male; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Treatment Refusal; Trimethoprim, Sulfamethoxazole Drug Combination; Viral Load; Viremia; Zalcitabine; Zidovudine | 2002 |
When will once (-a day) be enough?
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Didanosine; Emtricitabine; Humans; Hydroxyurea; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Zidovudine | 2000 |
[Cytomegalovirus retinitis after highly active antiretroviral therapy: a case report].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Cytomegalovirus Retinitis; Didanosine; Ganciclovir; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Retinal Hemorrhage; Reverse Transcriptase Inhibitors; Risk; Saquinavir; Stavudine; Substance Abuse, Intravenous; Zidovudine | 2002 |
Macrophage protection by addition of glutathione (GSH)-loaded erythrocytes to AZT and DDI in a murine AIDS model.
Topics: Animals; Anti-HIV Agents; Didanosine; DNA, Viral; Drug Therapy, Combination; Erythrocytes; Female; Glutathione; Hypergammaglobulinemia; Lymphatic Diseases; Lymphocytes; Macrophages; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Reverse Transcriptase Inhibitors; Splenomegaly; Zidovudine | 2002 |
Determinations of zidovudine/didanosine/nevirapine and zidovudine/didanosine/ritonavir in human serum by micellar electrokinetic chromatography.
Topics: Anti-HIV Agents; Chromatography, Micellar Electrokinetic Capillary; Didanosine; Humans; Nevirapine; Ritonavir; Zidovudine | 2002 |
Repeated cycles of alternate administration of fludarabine and Zidovudine plus Didanosine inhibits murine AIDS and reduces proviral DNA content in lymph nodes to undetectable levels.
Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; Didanosine; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Female; Leukemia Virus, Murine; Lymph Nodes; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Proviruses; Reverse Transcriptase Inhibitors; Treatment Outcome; Vidarabine; Zidovudine | 2002 |
Multiple relapses of human cytomegalovirus retinitis during HAART in an AIDS patient with reconstitution of CD4+ T cell count in the absence of HCMV-specific CD4+ T cell response.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cytomegalovirus Retinitis; Didanosine; Follow-Up Studies; Ganciclovir; HIV Protease Inhibitors; Humans; Lamivudine; Lymphocyte Activation; Male; Nevirapine; Recurrence; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2003 |
New questions about an old combination--ddI + d4T.
Topics: Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2003 |
Acute hepatic failure and lactate acidosis associated with antiretroviral treatment for HIV.
Topics: Acidosis, Lactic; Acute Disease; Adult; Anti-HIV Agents; Biopsy; Critical Care; Didanosine; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Liver; Liver Failure; Pancreatitis; Reverse Transcriptase Inhibitors; Stavudine; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography; Zidovudine | 2003 |
Effects of hypokalemia and hypomagnesemia on zidovudine (AZT) and didanosine (ddI) nephrotoxicity in rats.
Topics: Acute Kidney Injury; Animals; Anti-HIV Agents; Didanosine; Diet; Disease Models, Animal; HIV Infections; Hypokalemia; Magnesium; Male; Rats; Rats, Wistar; Risk Factors; Zidovudine | 2003 |
HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
Topics: Adenine; Anti-HIV Agents; Cell Line; Cytidine Triphosphate; Didanosine; Drug Resistance, Multiple, Viral; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Species Specificity; Tenofovir; Transfection; Zalcitabine; Zidovudine | 2003 |
Pathways for the emergence of multi-dideoxynucleoside-resistant HIV-1 variants.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Reverse Transcriptase Inhibitors; Virus Replication; Zidovudine | 2003 |
[Observational study on the efficacy of the application of two classical regimens of triple antiretroviral therapy].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Didanosine; Drug Evaluation; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Time Factors; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Semiparametric regression analysis of longitudinal data with informative drop-outs.
Topics: Child; Clinical Trials as Topic; Computer Simulation; Didanosine; HIV Infections; Humans; Longitudinal Studies; Models, Statistical; Numerical Analysis, Computer-Assisted; Patient Dropouts; Regression Analysis; Time Factors; Zidovudine | 2003 |
Incorporating prior beliefs about selection bias into the analysis of randomized trials with missing outcomes.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Bayes Theorem; CD4 Lymphocyte Count; Data Interpretation, Statistical; Didanosine; Double-Blind Method; Drug Therapy, Combination; Humans; Models, Statistical; Randomized Controlled Trials as Topic; Selection Bias; Statistics, Nonparametric; Treatment Outcome; Zidovudine | 2003 |
Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis.
Topics: Acidosis, Lactic; Adult; Alanine Transaminase; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lactates; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Stavudine; Time Factors; Zidovudine | 2003 |
HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cell Line; Didanosine; Disease Progression; Evolution, Molecular; Genetic Variation; HIV Infections; HIV-1; Humans; Male; Phenotype; Receptors, CCR5; Receptors, CXCR4; Receptors, HIV; Recombinant Fusion Proteins; Virus Replication; Zidovudine | 2003 |
Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors.
Topics: Analysis of Variance; Anti-HIV Agents; Didanosine; DNA, Mitochondrial; Drug Combinations; HIV Infections; Humans; Mitochondrial Diseases; Reverse Transcriptase Inhibitors; Self-Sustained Sequence Replication; Sensitivity and Specificity; Zalcitabine; Zidovudine | 2004 |
Genetic damage detected in CD-1 mouse pups exposed perinatally to 3'-azido-3'-deoxythymidine and dideoxyinosine via maternal dosing, nursing, and direct gavage.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythrocytes; Female; Lactation; Male; Mice; Mice, Inbred Strains; Micronuclei, Chromosome-Defective; Micronucleus Tests; Mutagens; Pregnancy; Prenatal Exposure Delayed Effects; Time Factors; Zidovudine | 2004 |
Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Lamivudine; Male; Middle Aged; Prospective Studies; Ritonavir; Stavudine; Zidovudine | 2003 |
Pseudo-likelihood estimation for a marginal multivariate survival model.
Topics: Acquired Immunodeficiency Syndrome; Adoption; Antiviral Agents; Didanosine; Drug Therapy, Combination; Genetics, Population; Humans; Likelihood Functions; Models, Statistical; Multivariate Analysis; Survival Analysis; Zidovudine | 2004 |
Interval-censored survival time data: confidence intervals for the non-parametric survivor function.
Topics: Antiviral Agents; Computer Simulation; Confidence Intervals; Data Interpretation, Statistical; Didanosine; HIV Infections; Humans; RNA, Viral; Survival Analysis; Zidovudine | 2004 |
Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in mice treated neonatally with zidovudine and didanosine.
Topics: Animals; Animals, Newborn; Anti-HIV Agents; Bone Marrow Cells; Didanosine; Drug Interactions; Female; Hypoxanthine Phosphoribosyltransferase; Loss of Heterozygosity; Lymphocytes; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Micronucleus Tests; Mutagens; Thymidine Kinase; Zidovudine | 2004 |
Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Australia; Cohort Studies; Didanosine; Drug Administration Schedule; Europe; Female; HIV Infections; Humans; Lamivudine; Male; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Stavudine; Time Factors; Viral Load; Zidovudine | 2004 |
Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.
Topics: Adenine; Algorithms; Anti-HIV Agents; Databases, Genetic; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV; HIV Infections; Humans; Mutation; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Thymidine; Zalcitabine; Zidovudine | 2004 |
Genetic damage detected in CD-1 mouse pups exposed perinatally to 3'-azido-3'-deoxythymidine or dideoxyinosine via maternal dosing, nursing, and direct gavage: II. Effects of the individual agents compared to combination treatment.
Topics: Analysis of Variance; Animals; Animals, Newborn; Anti-HIV Agents; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythrocytes; Female; Male; Mice; Mice, Inbred Strains; Micronuclei, Chromosome-Defective; Micronucleus Tests; Pregnancy; Prenatal Exposure Delayed Effects; Zidovudine | 2004 |
Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals.
Topics: Alanine; Antiretroviral Therapy, Highly Active; Didanosine; Female; HIV Infections; HIV Seronegativity; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lactic Acid; Logistic Models; Male; Mitochondria; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Reverse Transcriptase Inhibitors; Zidovudine | 2004 |
Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Controlled Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome; Zidovudine | 2004 |
The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro.
Topics: 3T3-L1 Cells; Adenine; Adipocytes; Animals; Apoptosis; Cell Differentiation; Didanosine; Dideoxynucleosides; HIV-1; HIV-Associated Lipodystrophy Syndrome; Lamivudine; Lipid Metabolism; Mice; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2004 |
Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Didanosine; Dideoxynucleosides; Drug Stability; HIV; HIV Infections; Humans; Lamivudine; Quality Control; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Stavudine; Zidovudine | 2005 |
Prolonged treatment interruption in chronic HIV infection: a new strategy?
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chronic Disease; Cohort Studies; Didanosine; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 2005 |
Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection.
Topics: Anti-HIV Agents; Biomarkers; CD4 Lymphocyte Count; Didanosine; Disease Progression; Dose-Response Relationship, Drug; Female; HIV Infections; Humans; Interferons; Interleukin-6; Male; Neopterin; Predictive Value of Tests; Risk Factors; Zidovudine | 2005 |
Changes in mitochondrial RNA production in cells treated with nucleoside analogues.
Topics: Antiviral Agents; Cell Line; Didanosine; DNA, Mitochondrial; Humans; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA; RNA, Mitochondrial; Stavudine; U937 Cells; Zidovudine | 2005 |
Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariates.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Humans; Likelihood Functions; Longitudinal Studies; Models, Statistical; Nevirapine; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Zalcitabine; Zidovudine | 2006 |
The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
Topics: Adenosine Triphosphate; Anti-HIV Agents; Base Sequence; Didanosine; DNA Primers; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutation; Reverse Transcriptase Inhibitors; Thymidine; Zidovudine | 2005 |
Human immunodeficiency virus infection: personal experience in changes in head and neck manifestations due to recent antiretroviral therapies.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Antigens; Didanosine; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Incidence; Lymphoma, Non-Hodgkin; Male; Prevalence; Pseudomonas Infections; Sarcoma, Kaposi; Zidovudine | 2005 |
The effect of long-term storage on measured plasma lactate concentrations and prospective lactate results from a multicenter trial of antiretroviral therapy.
Topics: Acidosis, Lactic; Anti-HIV Agents; Blood Preservation; Blood Specimen Collection; Didanosine; HIV Infections; Humans; Lactates; Lamivudine; Multicenter Studies as Topic; Oxalates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Sodium Fluoride; Specimen Handling; Stavudine; Time Factors; Zidovudine | 2005 |
Homo and heterodimers of ddI, d4T and AZT: influence of (5'-5') thiolcabonate-carbamate linkage on anti-HIV activity.
Topics: Anti-HIV Agents; Antiviral Agents; Carbamates; Didanosine; Dimerization; HIV; HIV Infections; Models, Chemical; Molecular Conformation; Mutation; Stavudine; Sulfhydryl Compounds; Zidovudine | 2005 |
Economic impact of antiretroviral therapy prescription decisions in the context of rapid scaling-up of access to treatment: lessons from Mexico.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Drug Prescriptions; Health Care Costs; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; Humans; Mexico; Oxazines; Patient Compliance; Practice Guidelines as Topic; Saquinavir; Zidovudine | 2006 |
In vitro mutagenicity studies of the antiretrovirals AZT, Didanosine, and 3TC and a plant antiviral extract Secomet-V derived from the Trifollium species.
Topics: Anti-HIV Agents; Antiviral Agents; Didanosine; Lamivudine; Mutagenicity Tests; Phytotherapy; Plant Extracts; Salmonella; Trifolium; Zidovudine | 2005 |
A simplified weight-based method for pediatric drug dosing for zidovudine and didanosine in resource-limited settings.
Topics: Adolescent; Anti-HIV Agents; Body Surface Area; Body Weight; Child; Child, Preschool; Didanosine; Dosage Forms; Female; HIV Infections; Humans; Infant; Male; Zidovudine | 2006 |
Nucleotide excision repair and template-independent addition by HIV-1 reverse transcriptase in the presence of nucleocapsid protein.
Topics: Didanosine; DNA Primers; DNA Repair; DNA Replication; DNA, Viral; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Nucleocapsid Proteins; Recombinant Proteins; Reverse Transcriptase Inhibitors; RNA, Viral; Templates, Genetic; Virus Replication; Zidovudine | 2006 |
[In vitro selection and phenotyping of HIV-1 mutants resistant to azidothymidine and didanosine].
Topics: Didanosine; Drug Resistance, Viral; HIV-1; Mutation; Reverse Transcriptase Inhibitors; Stavudine; Thymidine; Zidovudine | 2005 |
Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
Topics: Adenine; Cohort Studies; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; France; HIV Infections; HIV Reverse Transcriptase; HIV-1; Hospitals, University; Humans; Lamivudine; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Species Specificity; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2006 |
The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Arginine; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lysine; Organophosphonates; Phenotype; Point Mutation; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine; Zalcitabine; Zidovudine | 2006 |
In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells.
Topics: Adenine; Anti-HIV Agents; Cell Survival; Cells, Cultured; Didanosine; DNA, Mitochondrial; Drug Interactions; Electron Transport Complex IV; Humans; Kidney Tubules, Proximal; Lopinavir; Mitochondria; Organophosphonates; Pyrimidinones; Ritonavir; RNA; Tenofovir; Zidovudine | 2006 |
Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors.
Topics: Alendronate; Animals; Apoptosis; Cell Differentiation; Didanosine; Humans; Leukocytes, Mononuclear; Male; Mice; Mice, Inbred C57BL; Osteoclasts; Osteoprotegerin; RANK Ligand; Reverse Transcriptase Inhibitors; Zidovudine | 2006 |
[Sustained spontaneous remission of chronic hepatitis C coinfection in HIV].
Topics: Adult; Anti-HIV Agents; Didanosine; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Pregnancy; Pregnancy Complications, Infectious; Remission, Spontaneous; Viremia; Zidovudine | 2007 |
Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect?
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Didanosine; Female; HIV Infections; HIV-1; Humans; Hyperplasia; Liver; Liver Diseases; Liver Regeneration; Middle Aged; Nevirapine; Zidovudine | 2007 |
The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa.
Topics: Africa, Southern; Antiretroviral Therapy, Highly Active; Didanosine; Drug Resistance, Multiple, Viral; Evolution, Molecular; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Molecular Sequence Data; Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Thymidine; Treatment Failure; Zidovudine | 2007 |
Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir.
Topics: Adolescent; Adult; Confidence Intervals; Cross-Over Studies; Didanosine; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Quinolones; Stavudine; Zidovudine | 2007 |
Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.
Topics: Adenine; Adult; AIDS Dementia Complex; Alkynes; Anti-HIV Agents; Anticonvulsants; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cerebrospinal Fluid; Cyclopropanes; Didanosine; HIV-1; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Seizures; Stavudine; Tenofovir; Viral Load; Virus Replication; Zidovudine | 2008 |
Comparative analysis of genetic toxicity of AZT and ddI antiretrovirals in somatic cells of Drosophila melanogaster.
Topics: Animals; Anti-HIV Agents; Didanosine; Drosophila melanogaster; Female; Male; Mitosis; Mutagenicity Tests; Mutagens; Mutation; Recombination, Genetic; Reverse Transcriptase Inhibitors; Wings, Animal; Zidovudine | 2008 |
[Evaluation of antiretroviral therapy in HIV-infected adults in the Department of Haematology, University Hospital of Brazzavllle, Congo].
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Congo; Cyclopropanes; Didanosine; Drug Evaluation; Drug Therapy, Combination; Female; Hematology; HIV Infections; Hospital Departments; Hospitals, University; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Retrospective Studies; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2008 |
The nucleoside reverse transcriptase inhibitors didanosine, lamivudine, stavudine and zidovudine show little effect on the virulence of Candida albicans in vitro.
Topics: Antifungal Agents; Biofilms; Candida albicans; Cell Adhesion; Cell Line; Didanosine; Humans; Lamivudine; Microbial Sensitivity Tests; Reverse Transcriptase Inhibitors; Stavudine; Virulence; Zidovudine | 2008 |
[Screening of HIV-1 replication inhibitors by using pseudotyped virus system].
Topics: Anti-HIV Agents; Didanosine; DNA Replication; Drug Evaluation, Preclinical; Genes, Reporter; HIV-1; Humans; Lamivudine; Pseudocowpox Virus; Tumor Cells, Cultured; Virus Replication; Zidovudine | 2008 |
Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Female; HIV Infections; HIV-1; Humans; Hypertension, Portal; Lamivudine; Male; Middle Aged; Risk Factors; Thrombophilia; Viral Load; Zidovudine | 2008 |
Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cohort Studies; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lamivudine; Lopinavir; Male; Multivariate Analysis; Pyrimidinones; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; South Africa; Stavudine; Treatment Outcome; Zidovudine | 2008 |
Effect of macrophage depletion on viral DNA rebound following antiretroviral therapy in a murine model of AIDS (MAIDS).
Topics: Animals; Anti-HIV Agents; Clodronic Acid; Didanosine; DNA, Viral; Female; Immunologic Factors; Leukocyte Reduction Procedures; Macrophages; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Viral Load; Zidovudine | 2009 |
Improvement of sensitivity and selectivity of high-performance liquid chromatography for anti-retroviral drugs (non-reverse transcriptase inhibitors) by diamond-electrode electrochemical and fluorescence detection.
Topics: Anti-Retroviral Agents; Chromatography, High Pressure Liquid; Didanosine; Dideoxynucleosides; Electrochemical Techniques; Fluorescence; Humans; Lamivudine; Linear Models; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Water; Zidovudine | 2009 |
Emergence of primary NNRTI resistance mutations without antiretroviral selective pressure in a HAART-treated child.
Topics: Adult; Antiretroviral Therapy, Highly Active; Didanosine; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Mutation, Missense; Nelfinavir; Phylogeny; Point Mutation; Pregnancy; Pregnancy Complications, Infectious; Selection, Genetic; Zidovudine | 2009 |
Permeation of four oral drugs through human intestinal mucosa.
Topics: Administration, Oral; Adult; Didanosine; Diffusion; Drug Evaluation, Preclinical; Enalapril; Female; Humans; In Vitro Techniques; Intestinal Absorption; Intestinal Mucosa; Jejunum; Kinetics; Male; Middle Aged; Permeability; Propranolol; Reproducibility of Results; Solubility; Zidovudine | 2009 |
WR1065 mitigates AZT-ddI-induced mutagenesis and inhibits viral replication.
Topics: Adenoviridae; Cell Line; Cytoplasm; Didanosine; Dideoxynucleotides; Dose-Response Relationship, Drug; HIV Core Protein p24; HIV-1; Humans; Hypoxanthine Phosphoribosyltransferase; Influenza A virus; Influenza B virus; Intracellular Space; Lymphocytes; Mercaptoethylamines; Mutagenesis; Mutation; Phytohemagglutinins; Serotyping; Time Factors; Virus Replication; Zidovudine | 2009 |
Mitochondrial DNA depletion in rat liver induced by fosalvudine tidoxil, a novel nucleoside reverse transcriptase inhibitor prodrug.
Topics: Animals; Didanosine; DNA, Mitochondrial; Lipids; Liver; Male; Polymerase Chain Reaction; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Zidovudine | 2009 |
High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Female; HIV Infections; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir; South Africa; Survival Analysis; Treatment Outcome; Viral Load; Zidovudine | 2010 |
Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Ligase Chain Reaction; Mutation, Missense; Nevirapine; Postpartum Period; Pregnancy; RNA, Viral; Sequence Analysis, DNA; Viral Load; Young Adult; Zidovudine | 2010 |
Another milestone in minimizing risks to mothers exposed to single-dose nevirapine for prevention of vertical transmission of HIV-1 to infants: what next?
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Mutation, Missense; Nevirapine; Pregnancy; Zidovudine | 2010 |
A weighted combination of pseudo-likelihood estimators for longitudinal binary data subject to non-ignorable non-monotone missingness.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Computer Simulation; Didanosine; Double-Blind Method; Humans; Longitudinal Studies; Models, Statistical; Zidovudine | 2010 |
Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice.
Topics: Animals; Anti-Retroviral Agents; Apoptosis; Body Weight; Cell Membrane Permeability; Cell Proliferation; Didanosine; HIV Protease Inhibitors; Indinavir; Intestinal Absorption; Intestinal Mucosa; Male; Mice; Models, Animal; Necrosis; Nelfinavir; Reverse Transcriptase Inhibitors; Survival Rate; Water-Electrolyte Balance; Zidovudine | 2010 |
Progressive mitochondrial compromise in brains and livers of primates exposed in utero to nucleoside reverse transcriptase inhibitors (NRTIs).
Topics: Animals; Animals, Newborn; Cerebral Cortex; Didanosine; Disease Models, Animal; DNA, Mitochondrial; Drug Therapy, Combination; Erythrocebus patas; Female; Lamivudine; Maternal Exposure; Mitochondria, Liver; Oxidative Phosphorylation; Pregnancy; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2010 |
Genotypic and phenotypic cross-drug resistance of harboring drug-resistant HIV type 1 subtype B' strains from former blood donors in central Chinese provinces.
Topics: Adult; Anti-HIV Agents; Blood Donors; China; Didanosine; Drug Resistance, Multiple, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Phenotype; pol Gene Products, Human Immunodeficiency Virus; RNA, Viral; Sequence Analysis, RNA; Stavudine; Zidovudine | 2010 |
Combination anti-HIV therapy with the self-assemblies of an asymmetric bolaamphiphilic zidovudine/didanosine prodrug.
Topics: Animals; Anti-HIV Agents; Cell Line; Cell Survival; Chromatography, High Pressure Liquid; Didanosine; HIV Infections; Humans; Mice; Prodrugs; Zidovudine | 2011 |
Common inherited mitochondrial DNA mutations and nucleoside reverse transcriptase inhibitor-induced severe hyperlactataemia in HIV-infected adults: an exploratory study.
Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Black People; Case-Control Studies; Didanosine; DNA, Mitochondrial; Female; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Mitochondria; Mutation; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; Sequence Deletion; Stavudine; White People; Zidovudine | 2012 |
The combined use of known antiviral reverse transcriptase inhibitors AZT and DDI induce anticancer effects at low concentrations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Cell Line, Tumor; Didanosine; Fluorescent Antibody Technique; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Mice; Mice, Nude; Neoplasms, Experimental; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Telomere; Telomere Shortening; Xenograft Model Antitumor Assays; Zidovudine | 2012 |
Azidothymidine and other chain terminators are mutagenic for template-switch-generated genetic mutations.
Topics: Anti-HIV Agents; Base Sequence; Didanosine; DNA, Bacterial; Escherichia coli; Models, Genetic; Mutagens; Mutation; Stavudine; Templates, Genetic; Zidovudine | 2012 |
In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Didanosine; Dideoxynucleosides; DNA Primers; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Telomerase; Tenofovir; Zidovudine | 2012 |
Comparative analysis of genetic toxicity of antiretroviral combinations in somatic cells of Drosophila melanogaster.
Topics: Animals; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; DNA Damage; Dose-Response Relationship, Drug; Drosophila melanogaster; Drug Combinations; Female; Lamivudine; Male; Mitosis; Mutation; Recombinant Proteins; Wings, Animal; Zidovudine | 2013 |
Didanosine-associated retinal toxicity in adults infected with human immunodeficiency virus.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Corneal Dystrophies, Hereditary; Didanosine; Electroretinography; HIV Infections; Humans; Male; Middle Aged; Retina; Visual Acuity; Zidovudine | 2013 |
Vitamin D attenuates nucleoside reverse transcriptase inhibitor induced human skeletal muscle mitochondria DNA depletion.
Topics: Anti-HIV Agents; Calcitriol; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Female; HIV Reverse Transcriptase; Humans; Infant; Lamivudine; Mitochondria, Muscle; Muscle Fibers, Skeletal; Muscle, Skeletal; Myoblasts; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Stavudine; Vitamins; Zidovudine | 2013 |
Long-term exposure of mice to nucleoside analogues disrupts mitochondrial DNA maintenance in cortical neurons.
Topics: Animals; Antimetabolites; Cells, Cultured; Cerebral Cortex; Didanosine; DNA, Mitochondrial; Lamivudine; Liver; Mice; Mitochondria; Muscle, Skeletal; Neurons; Stavudine; Zidovudine | 2014 |
Tempol protects cardiomyocytes from nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity.
Topics: Animals; Cell Line; Cyclic N-Oxides; Didanosine; Microscopy, Electron; Mitochondria; Myocytes, Cardiac; Rats; Reverse Transcriptase Inhibitors; Spin Labels; Superoxides; Zidovudine | 2014 |
Caenorhabditis elegans as a Model System for Studying Drug Induced Mitochondrial Toxicity.
Topics: Animals; Anti-HIV Agents; Caenorhabditis elegans; Didanosine; Dideoxynucleosides; DNA-Directed DNA Polymerase; DNA, Mitochondrial; Drug Evaluation; Humans; Mitochondria; Mitochondrial Proteins; Models, Biological; Oxygen Consumption; Reverse Transcriptase Inhibitors; Stavudine; Ubiquinone; Zalcitabine; Zidovudine | 2015 |
Mitochondrial DNA D-loop AG/TC transition mutation in cortical neurons of mice after long-term exposure to nucleoside analogues.
Topics: Animals; Cerebral Cortex; Didanosine; DNA, Mitochondrial; Lamivudine; Laser Capture Microdissection; Mice; Mice, Inbred BALB C; Mutation; Neurons; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2015 |
Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Estonia; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Prevalence; Reverse Transcriptase Inhibitors; Zidovudine | 2016 |
Structural Insights into HIV Reverse Transcriptase Mutations Q151M and Q151M Complex That Confer Multinucleoside Drug Resistance.
Topics: Anti-HIV Agents; Crystallography, X-Ray; Didanosine; DNA-Binding Proteins; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Protein Conformation; Protein Structure, Quaternary; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 2017 |
A Lower Baseline CD4/CD8 T-Cell Ratio Is Independently Associated with Immunodiscordant Response to Antiretroviral Therapy in HIV-Infected Subjects.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; CD4-CD8 Ratio; CD8-Positive T-Lymphocytes; Cell Survival; Didanosine; Female; HIV Infections; Humans; Male; Middle Aged; Receptors, CXCR4; Stavudine; T-Lymphocytes, Regulatory; Viral Load; Zalcitabine; Zidovudine | 2017 |
Risk of cancer in children exposed to antiretroviral nucleoside analogues in utero: The french experience.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Didanosine; Female; HIV Infections; Humans; Incidence; Infant; Infant, Newborn; Male; Maternal Exposure; Maternal-Fetal Exchange; Neoplasms; Nucleosides; Pregnancy; Prenatal Exposure Delayed Effects; Prospective Studies; Reverse Transcriptase Inhibitors; Risk; Surveys and Questionnaires; Zidovudine | 2019 |
Evaluation of a Library of FDA-Approved Drugs for Their Ability To Potentiate Antibiotics against Multidrug-Resistant Gram-Negative Pathogens.
Topics: Anti-Bacterial Agents; Didanosine; Drug Resistance, Multiple, Bacterial; Ethanolamines; Floxuridine; Gram-Negative Bacteria; Microbial Sensitivity Tests; Mitoxantrone; Zidovudine | 2019 |
Sustainable Protocol for the Synthesis of 2',3'-Dideoxynucleoside and 2',3'-Didehydro-2',3'-dideoxynucleoside Derivatives.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Stavudine; Zalcitabine; Zidovudine | 2022 |
The antiretroviral agents azidothymidine, stavudine, and didanosine have the identical mutational fingerprint in the rpoB region of Escherichia coli.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Didanosine; DNA-Directed RNA Polymerases; Escherichia coli; Escherichia coli Proteins; HIV Reverse Transcriptase; Mutation; Stavudine; Zidovudine | 2022 |